

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83729 A2

(51) International Patent Classification⁷: **C12N 15/00**

(21) International Application Number: PCT/EP01/04863

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). **THE SCRIPPS RESEARCH INSTITUTE** [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(71) Applicants and

(72) Inventors: **NEMEROW, Glen, R.** [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). **VON SEGGERN, Daniel, J.** [US/US]; Apartment 30, 5175 Luigi Terrace, San Diego, CA 92122 (US). **FRIEDLANDER, Marty** [US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.



WO 01/83729 A2

VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

Work described herein was supported by NIH grants EY11431 and HL54352. The government has certain rights in such subject matter.

5 RELATED APPLICATIONS

This application claims the benefit of priority to U.S. application Serial No. 09/562,934, filed May 1, 2000, to Glen R. Nemerow, Daniel Von Seggern,; Martin Friedlander, entitled "VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY".

- 10** This application is related to copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000)), to Daniel Von Seggern, Glen R. Nemerow, Paul Hallenbeck, Susan Stevenson, Yelena Skripchenko, filed January 14, 2000, entitled "Adenovirus Vectors, Packaging Cell Lines, Compositions, and
- 15** Methods for Preparation and Use," which is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999. Where permitted, the contents and subject matter of each application and of the provisional application are incorporated in their entirety herein by reference.

20 FIELD OF INVENTION

- The present invention relates to gene therapy, especially to adenovirus vector-based gene therapy. In particular, adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene
- 25** therapy are provided.

BACKGROUND OF THE INVENTION

Retinal dystrophies

- The eye is susceptible to a number of hereditary and/or age related degenerative disorders. In the United States, common causes of irreversible
- 30** blindness or severe loss of vision are retinal dystrophies (see, *e.g.*, Cotlier *et al.* (1995) *Surv. Ophthalmology* 40:51-61; Bird (1995) *Am. J. Ophthal.* 119: 543-562; and Adler (1996) *Arch Ophthal* 114:79-83). The retina is the sensory

-2-

tunic of the eye, containing light sensitive receptors, a complex of neurons, and pigmented epithelium, arranged in discrete layers. In humans, the macula is the portion of the retina that lies directly behind the lens. Cones, the photoreceptor cells responsible for central vision, are heavily concentrated in the macula.

- 5 Central dystrophies, which affect the macula, include Best's disease, age-related macular degeneration, and Stargardt's macular dystrophy. The peripheral retina is composed mainly of rods, which are responsible for side and night vision. Peripheral degenerative retinal diseases include retinitis pigmentosa, choroidemia and Bietti's crystalline dystrophy.

- 10 Macular degenerations are a heterogenous group of diseases, characterized by progressive central vision loss and degeneration of the macula and underlying retinal pigmented epithelium. Age-related macular degeneration (ARMD) is the most common form of the disease, affecting an estimated 20% of persons over 75 years of age. ARMD is poorly understood in terms of etiology and pathogenesis. The very late onset of the disease has made genetic mapping particularly difficult. Certain macular degenerative conditions with a clear genetic basis, such as Stargardt's and Best's diseases, share many features with ARMD, but have been more amenable to molecular and genetic analysis.

- Hereditary peripheral retinopathies are also relatively common. Retinitis pigmentosa (RP), for example, affects approximately 1.5 million people worldwide. Substantial genetic heterogeneity has been observed in this condition, with over 20 chromosomal loci identified. A predisposition to retinitis pigmentosa can be inherited by autosomal dominant, autosomal recessive, X-linked or digenic mode. Mutations have been identified in seven genes, four of which encode proteins in the rod phototransduction cascade: rhodopsin, alpha and beta subunits of rod cGMP phosphodiesterase, and rod cGMP cation-gated channel protein .alpha. subunit. Mutations in the peripherin/RDS gene have been linked to retinitis pigmentosa and macular degeneration. A single peripherin/RDS mutation apparently caused retinitis pigmentosa, pattern dystrophy and fundus flavimaculatus, in different family members.

-3-

In spite of causal heterogeneity, there is significant clinical similarity among RP subtypes. Common signs and symptoms include early electroretinographic abnormalities, ophthalmoscopic findings, and protracted, contiguous expansion of the ring-like scotoma toward the macula, leading to progressively worsening tunnel vision. A recent hypothesis is that active photoreceptor cell death, which is characteristic of these genetically distinct disorders, is mediated by a common induction of apoptosis. It may be possible to treat these conditions by the administration of agents that block induction of apoptosis in photoreceptors, such as neurotrophic factors.

10 Adenovirus delivery vectors

Adenovirus, which is a DNA virus with a 36 kilobase (kb) genome, is very well-characterized and its genetics and genetic organization are understood. The genetic organization of adenoviruses permits substitution of large fragments of viral DNA with foreign DNA. In addition, recombinant adenoviruses are structurally stable and no rearranged viruses are observed after extensive amplification.

Adenoviruses have been employed as delivery vehicles for introducing desired genes into eukaryotic cells. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors followed by internalization. The adenovirus fiber protein is responsible for binding to cells. The fiber protein has two domains, a rod-like shaft portion and a globular head portion that contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses bind to and infect a broad range of cultured cell lines and primary tissues from different species.

The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described (see, *e.g.*, Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Virol.* 161: 549-554, 1987).

-4-

The 35,935 bp sequence of Ad5 DNA is also known and portions of many other adenovirus genomes have been sequenced. The upper packaging limit for adenovirus virions is about 105% of the wild-type genome length (see, *e.g.*, Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this
5 would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats permit single strands of viral DNA to circularize by base-pairing of their terminal sequences to form base-paired "panhandle" structures that are
10 required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and
15 contiguous packaging sequence) have been constructed.

Ad vectors have several distinct advantages as gene delivery vehicles. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to
20 accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins. Adenovirus (Ad)-based gene delivery vectors efficiently infect many different cells and tissues. This broad tropism, however, means that gene delivery cannot be directed to a specific target cell. A large fraction of intravenously administered adenovirus is
25 retained by the liver, which could lead to undesirable side-effects. Adenovirus may potentiate immune responses. For example, Adenovirus type 5 (Ad5) also transduces dendritic cells, which present antigens very efficiently, thereby possibly exacerbating the immune response against the vector. It has been proposed that vectors with different targeting efficiencies might eliminate these
30 problems, permitting a lower total particle dose and more specific targeting (see, *e.g.*, U.S. application Serial No. 09/482,682).

-5-

The wealth of information on adenovirus structure and mechanism of infection, its efficient infection of nondividing cells, and its large genetic capacity make adenovirus a popular gene therapy vector. The wide expression of receptors to which adenovirus binds makes targeting adenovirus vectors
5 difficult.

Hence there is a need to improve delivery and targeting of adenoviral vectors and also to provide treatments for ocular disorders. Therefore, it is an object herein to provide adenoviral vectors that specifically or selectively target cells in the eye. It is also an object herein to provide these vectors for treatment
10 of ocular disorders.

SUMMARY OF THE INVENTION

Degenerative ocular diseases, such as, but not limited to, retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, and others (see, *e.g.*, Table below), have a genetic basis. Genes expressed in
15 the photoreceptor cells at the back of the retina are implicated in these diseases. Provided herein are recombinant viral vectors for targeting therapeutic products to these cells.

Recombinant adenoviral vectors that include nucleic acid that permits specific binding to these photoreceptors are provided. In particular, the vector
20 particles contain a fiber protein of Ad37 or a modified form thereof. As shown herein, fiber protein from Ad37 permits efficient infection of photoreceptor cells. Fiber proteins from other adenovirus D serotypes may also be used. In addition, the portions of the fiber protein, particularly those that interact with other viral structural proteins, such as penton, may be modified to resemble the viral source
25 of the other structural proteins. As exemplified herein, the recombinant virus provided herein include Ad5 structural components. The N-terminus of the Ad37 fiber protein, which interacts with the penton protein, is modified to resemble the Ad5 fiber protein N-terminus to ensure production of viral particles.

The recombinant adenoviral vectors are intended for gene therapy of
30 diseases in which genes expressed in the photoreceptors are implicated. Such diseases include, but are not limited to, degenerative ocular diseases, such as retinitis pigmentosa and Stargardt's disease. These vectors are also useful for

-6-

targeting to other ocular cells, such as conjunctival cells, which also bear receptors to which fiber from Ad37 and related serotypes bind.

The vectors will deliver therapeutic agents to the targeted cells for treatment of a variety of disorders (see *e.g.*, Tables 3 and 4, below)). The therapeutic agents are intended for expression in the photoreceptors and for secretion from the photoreceptor cells, which are surrounded on one side by choroidal vasculature, and on the other side by retinal vasculature, thereby providing a means for delivery of products. In addition, expression of growth factors, such as VEGF and others, can be used to enhance blood flow to the retina and prevent or slow the degeneration.

Therapeutic agents encoded by the recombinant adenoviral vectors include, but are not limited to, nucleic acid molecules encoding genes that are defective in certain hereditary disorders, nucleic acid molecules that encode antiangiogenics and antitumor agents for treatment of retinal disorders, such as retinoblastomas; nucleic acid molecules encoding trophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF), growth factors and growth factor inhibitors, antiapoptotic factors, such as Bcl-2 (CNTF), antitumor agents, anti-angiogenics, and genes or portions thereof for gene replacement or repair of defective genes. Hence, methods for treatment of inherited and acquired retinal diseases, including diseases involving neovascular and vascular degeneration are provided.

Methods for treating diseases involving genes expressed in photoreceptor cells are provided herein. The methods provided herein are practiced by administration of the recombinant viral vectors by any means suitable for delivery to the photoreceptors. A preferred mode of administration is intraocular injection including intravitreal and subretinal injection. Other modes of administration include, but are not limited to, intrascleral, periorbital and intravenous administration. The vectors also can include photoreceptor-specific promoters thereby providing a means, not only for specific targeting of expression in these cells, but also for photoreceptor-restricted transgene expression.

-7-

DETAILED DESCRIPTION OF THE INVENTION**A. DEFINITIONS**

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to anywhere in the disclosure herein are incorporated by reference in their entirety.

As used herein, the amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art (see, Table 1).

As used herein, amino acid residue refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. § § 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table:

Table 1
Table of Correspondence

SYMBOL		AMINO ACID
1-Letter	3-Letter	
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine

-8-

5

10

15

20

SYMBOL		
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
Q	Gln	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan
R	Arg	arginine
D	Asp	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
X	Xaa	Unknown or other

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. § § 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or

-9-

more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224).

Such substitutions are preferably made in accordance with those set forth in TABLE 2 as follows:

TABLE 2		
	Original residue	Conservative substitution
15	Ala (A)	Gly; Ser
	Arg (R)	Lys
	Asn (N)	Gln; His
	Cys (C)	Ser
	Gln (Q)	Asn
20	Glu (E)	Asp
	Gly (G)	Ala; Pro
	His (H)	Asn; Gln
	Ile (I)	Leu; Val
	Leu (L)	Ile; Val
25	Lys (K)	Arg; Gln; Glu
	Met (M)	Leu; Tyr; Ile
	Phe (F)	Met; Leu; Tyr
	Ser (S)	Thr
	Thr (T)	Ser
30	Trp (W)	Tyr
	Tyr (Y)	Trp; Phe
	Val (V)	Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

As used herein, a complementing plasmid describes plasmid vectors that deliver nucleic acids into a packaging cell line for stable integration into a chromosome in the cellular genome.

As used herein, a delivery plasmid is a plasmid vector that carries or delivers nucleic acids encoding a therapeutic gene or gene that encodes a

-10-

therapeutic product or a precursor thereof or a regulatory gene or other factor that results in a therapeutic effect when delivered *in vivo* in or into a cell line, such as, but not limited to a packaging cell line, to propagate therapeutic viral vectors.

5 As used herein, a variety of vectors with different requirements are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors are generally identified herein as complementing plasmids. A further type of vector described herein carries or delivers nucleic
10 acid molecules in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is used to carry nucleic acid molecules encoding therapeutic proteins or polypeptides or regulatory proteins or are regulatory sequences to specific cells or cell types in a
15 subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or recombinant adenoviral vectors or viral Ad-derived . vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette for expressing the therapeutic gene.

 As used herein, a DNA or nucleic acid homolog refers to a nucleic acid
20 that includes a preselected conserved nucleotide sequence, such as a sequence encoding a therapeutic polypeptide. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a lesser percentage of homology or identity and conserved biological activity or function.

25 The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482
30 (1981)). Briefly, the GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default

-11-

parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE*
5 *AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for
end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that
10 are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to
15 determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics*
20 *and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).
25 While there exist a number of methods to measure identity between two polynucleotides or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge
30 Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred

-12-

computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

5 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the
10 reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and
15 reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or
20 deletions.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is
25 expressed and a therapeutic product encoded thereby is produced.

Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic
30 acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth

-13-

factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified
5 prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, heterologous DNA is DNA that encodes RNA and proteins that are not normally produced *in vivo* by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by
10 affecting transcription, translation, or other regulatable biochemical processes. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed is herein encompassed by heterologous DNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes
15 traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been
20 introduced.

Hence, herein heterologous DNA or foreign DNA, refers to a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in the corresponding wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or
25 from another Ad serotype.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

30 Typically, DNA encoding the desired heterologous DNA is cloned into a plasmid vector and introduced by routine methods, such as calcium-phosphate mediated DNA uptake (see, (1981) Somat. Cell. Mol. Genet. 7:603-616) or

-14-

microinjection, into producer cells, such as packaging cells. After amplification in producer cells, the vectors that contain the heterologous DNA are introduced into selected target cells.

As used herein, an expression or delivery vector refers to any plasmid or virus into which a foreign or heterologous DNA may be inserted for expression in a suitable host cell — *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors that allow cloning of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

As used herein, a gene is a nucleic acid molecule whose nucleotide sequence encodes RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by the fiber protein, such as by the C-terminus portion that comprises the knob.

As used herein, isolated with reference to a nucleic acid molecule or polypeptide or other biomolecule means that the nucleic acid or polypeptide has separated from the genetic environment from which the polypeptide or nucleic acid were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in

-15-

Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

Thus, by "isolated" is meant that the nucleic acid is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) immediately flank the gene encoding the nucleic acid of interest. Isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

Isolated or purified as it refers to preparations made from biological cells or hosts means any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "substantially pure" or "isolated" should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

As used herein, a packaging cell line is a cell line that provides a missing gene product or its equivalent.

As used herein, an adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of

-16-

particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

As used herein, "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may
5 also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, a plasmid refers to an autonomous self-replicating extrachromosomal circular nucleic acid molecule, typically DNA.

10 As used herein, a post-transcription regulatory element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA
15 sequence.

As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 fiber protein. This may be
20 accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

As used herein, promoters of interest herein may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters do not require the presence of
25 any additional molecule to regulate gene expression. a regulatable or inducible promoter may also be described as a promoter where the rate or extent of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include, but are not limited to various compounds or compositions, light, heat, stress and chemical energy sources. Inducible, suppressible and repressible
30 promoters are considered regulatable promoters. Preferred promoters herein, are promoters that are selectively expressed in ocular cells, particularly photoreceptor cells.

-17-

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

- 5 As used herein, recombinant refers to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

- As used herein, a transgene or therapeutic nucleic acid molecule includes DNA and RNA molecules encoding an RNA or polypeptide. Such molecules may
10 be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" that are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleic acid molecule," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

- 15 Therefore, therapeutic nucleotide nucleic acid molecules include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) all include nucleic acid molecules that function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic
20 nucleic acid molecule can include a sequence of nucleotides that encodes a functional protein intended for delivery into a cell which is unable to produce that functional protein.

 As used herein, the vitreous of the eye refers to material that fills the chamber behind the lens of the eye (i.e., vitreous humor or vitreous body).

- 25 As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region
30 includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or

-18-

may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

Thus, promoters are nucleic acid fragments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences that direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (see, *e.g.*, U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, *e.g.*, Palmiter et al. (1986) Ann. Rev. Genet. 20: 465-499).

As used herein, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control sequences on one segment control expression or replication or other such control of other segments. The two segments are not necessarily contiguous.

-19-

As used herein, exogenous encompasses any therapeutic composition that is administered by the therapeutic methods provided herein. Thus, exogenous may also be referred to herein as foreign, or non-native or other equivalent expression.

5 B. Ad37 fiber tropism

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* 10 (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr.Top.Microbiol.Immunol.* 15 199:163-200; Riurok *et al.* (1990) *J.Mol.Biol.* 215:589-596; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). Fiber proteins of most adenovirus subgroups have been shown to bind specifically or selectively to the 46 kDa coxsackievirus-adenovirus receptor (CAR), (Bergelson *et al.* (1997) *Science* 275:1320-1323; Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). CAR appears to be expressed in a variety of human tissues, including the lung, at various levels (Bergelson *et al.* 20 (1997) *Science* 275:1320-1323), but Ad37 binds poorly to lung epithelial cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). This suggests that the tropism of this serotype may be influenced by factors independent of CAR expression.

Structural and biochemical data also suggest that distinct receptor binding sites are located on different regions of the Ad5 and Ad37 fiber knobs.

25 Adopting the nomenclature of Xia *et al.* (Xia *et al.* (1994) *Structure* 2:1259-1270), the receptor binding site for Ad5 is located at the AB-loop on the side of the fiber knob (Bewley *et al.* (1999) *Science* 286:1579-1583; Roelvink *et al.* (1999) *Science* 286:1568-1571). It is known that a lysine residue at position 240 of the Ad37 fiber, located in the CD-loop, is important for receptor binding 30 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). The co-crystal structure of the Ad12 knob and the N-terminal domain of CAR (Bewley *et al.* (1999) *Science* 286:1579-1583) show that the CD-loop does not contact CAR. It thus appears

-20-

that different regions of the Ad5 and Ad37 fiber knobs recognize distinct cell receptors.

A 46 kDa receptor for coxsackieviruses and adenoviruses (CAR) mediates attachment for many adenovirus serotypes. The wide distribution of CAR fails to explain why certain adenovirus serotypes (i.e. Ad37) are highly associated with severe ocular infections such as epidemic keratoconjunctivitis (EKC). Ad37 does not use CAR, but instead uses a glycoprotein that contains sialic acid as its primary receptor (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). The modest number of Ad37 binding sites per cell (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) also suggests that Ad37 recognizes a specific glycoprotein as its primary receptor for binding to conjunctival cells.

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract. The tropism of Ad37 derives from the binding preference of its fiber protein, which binds to a receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.* (1999) *J. Virology* 73:2798-2802).

A protein receptor that is preferentially expressed on conjunctival cells to which Ad37 fiber binds is shown herein. The preferential expression of the Ad37 receptor protein on conjunctival cells suggests that this receptor likely influences Ad37 tropism and should play a key role in ocular pathogenesis. It is shown herein that Ad37 uses a distinct protein receptor that is selectively expressed on conjunctival cells. It is shown that Ad37 binds well to conjunctival cells (Chang C), but poorly to lung carcinoma cells (A549). To determine if infection correlated with cell binding, an Ad5 vector containing the Ad37 fiber protein was constructed. The 'pseudotyped' vector delivered transgenes to Chang C cells better than to A549 cells. Ad37 binding was abolished by protease treatment of Chang C cells, indicating the receptor is a membrane protein. Ad37 binding to conjunctival cells is shown herein to be calcium-dependent. It is also shown that Ad37 infection was not inhibited by a function-blocking anti-CAR monoclonal antibody, which is a feature distinct from Ad5 fiber interaction with CAR. Using a virus overlay protein blot assay (VOPBA), calcium-dependent Ad37 binding to a 50 KDa membrane protein on Chang C

-21-

cells, but not A549 cells was detected. Ad19p a closely related serotype that fails to bind to conjunctival cells, does not recognize the 50 kDa protein.

Together, these data indicate that the 50 kDa protein is a candidate receptor for Ad37 on conjunctival cells.

- 5 Significantly, it is also shown herein that, upon administration of the vector to the vitreous humor, the recombinant adenovirus with the Ad37 fiber preferentially and selectively binds to photoreceptor cells. Hence, a recombinant adenoviral delivery vehicle that has an Ad37 fiber protein can serve as a vector for delivery of therapeutic agents to the eye for treatment of ocular disorders,
10 including genetic and acquired disorders. The identification of the receptor for Ad37 and the resulting recognition of Ad37 tropism allows targeting of adenovirus vectors to specific human ocular cells.

- As noted, fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on a cell surface. Hexon, penton and fiber
15 capsomeres are the major components on the surface of the virion. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber includes three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that
20 forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus (see, *e.g.*, Hong and Engler,
25 *Virology* 185: 758-761, 1991). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery.

- As shown herein, alteration of fiber in recombinant Ad vectors such that the fiber is derived from Ad37 or another adenovirus serotype D, provides a means for selective delivery of a recombinant virus to particular cells in the eye,
30 including conjunctival cells, and most significantly photoreceptors, thereby providing a means for targeted delivery to photoreceptor cells.

-22-

Photoreceptor cells are implicated in a number of hereditary and acquired retinal degenerative disorders. In addition, photoreceptor cells are located such that products produced therein can be delivered to other areas of the eye by virtue of the blood flow in the vicinity of the photoreceptor cells and also by virtue of the proximity of the photoreceptors to the retinal pigmented epithelium (RPE) and other retinal cells.

Hence it is contemplated herein that the recombinant viral vector will include a packaged recombinant adenovirus genome containing at least the minimal elements for replication and packaging; heterologous DNA encoding a desired gene product, typically a therapeutic product or plurality of products, such as several trophic factors, whose combined activity is effective for treating a disorder, such as a retinal degenerative disorder; and the resulting virion particles will include a fiber that has a sufficient portion to confer specific targeting to photoreceptor cells when the recombinant viral particles are introduced into the aqueous humor of a mammalian, preferably a human, eye, or otherwise contacted with the photoreceptor cells. The fiber may be a chimeric protein that has been modified for effective interaction with other coat structural proteins, such as penton. In addition, the fiber may be modified to include other elements that alter its tropism to permit binding to other cells as well (see, *e.g.*, U.S. Patent Nos. 5,756,086 and 5,543,328, International PCT application No. WO 95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996).

C. Construction of the viral particles

1. Selection of viral genome and fiber protein

Methods for preparing recombinant adenoviral vectors for gene product delivery are well known. Preferred among those are the methods exemplified herein (see EXAMPLES) and also described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000, which claims priority to U.S. provisional application Serial No. 60/115,920, as does U.S. application Serial No. 09/482,682)).

-23-

As noted, any desired recombinant adenovirus is contemplated for use in the methods herein as long as the viral genome is packaged in a capsid that includes at least the portion of a fiber protein that provides selective binding to photoreceptor cells. This fiber protein is preferably from an adenovirus type D serotype and is preferably an Ad37 fiber. The fiber protein should retain the knob region at the C-terminus ("head domain") from the Ad virus of subgroup D that contains the type-specific antigen and is responsible for binding to the cell surface receptor. Hence the fiber protein can be a chimeric fiber protein as long as it retains a sufficient portion of the type D serotype to specifically or selectively bind to photoreceptor cells. Generally the portion retained will be all or a portion of the knob region. The precise amount of knob region required can be determined empirically by including portions thereof and identifying the minimum residues from an Ad type D serotype, preferably Ad37, to effect selective targeting of a virion packaged with such fiber to photoreceptors in the eye upon introduction of the packaged virion into the aqueous humor.

Recombinant adenovirus containing heterologous nucleic acids that encode a desired product, such a gene to correct a genetic defect, may be made by any methods known to those of skill in the art. The viruses must be packaged in a cell line that results in expression of fiber on the particles that specifically, electively or preferentially targets (binds and results in internalization) the viral particle to cells in the eye. The fiber protein from Ad37 and other Adenoviruses of serotype D that infect the eye effects such targeting. The resulting adenovirus particles that express such fiber is administered by intraocular injection, subretinal injection, particularly intravitreal injection, or any means that results in preferential accumulation in photoreceptor cells.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses and members of the Aviadenovirus genus, including bird viruses, such as CELO.

-24-

Thus it is contemplated that the methods herein can be applied to any recombinant viral vectors derived from any adenovirus species. One of skill in the art would have knowledge of the different adenoviruses (see, *e.g.*, Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) and can construct recombinant viruses containing portions of the genome of any such virus.

In the exemplified embodiment, viral particles with Ad37 fiber were prepared. Site-directed mutations were made to the Ad37 fiber gene to make the tail sequence more closely match that of Ad5 to facilitate Ad37 fiber binding to the Ad5 penton base. The plasmid for the expression of the Ad37 fiber protein, pDV80, contains the CMV promoter, the adenovirus type 5 tripartite leader (TPL), and the modified Ad37 fiber gene sequence. Genes of interest, such as nucleic acid encoding the β subunit of cGMP phosphodiesterase (β PDE), β -glucuronidase, rhodopsin, growth factors, anti-cancer agents, growth factor receptors and other anti-angiogenic agents, and anti-apoptotic agents, can be incorporated into these vectors using the methods known to those of skill in the art and exemplified herein.

Known adenovirus vectors, previously constructed for intraocular therapy (see, *e.g.*, Bennett *et al.* (1996) *Nature Medicine* 2:649-654, which provides an Ad virus encoding β PDE for treatment of retinitis pigmentosa; Cayouette *et al.* (1998) *Human Gene Therapy* 8:423-430, which provides an Ad vector that expresses CNTF for treatment of retinitis pigmentosa and other retinal degenerative diseases; and Li *et al.* (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:7700-7704, which provides an Ad virus vector that encodes a human β -glucuronidase for treatment of lysosomal storage disease caused by β -glucuronidase deficiency) can be modified by repackaging the recombinant genome using a packaging line that expresses an Ad37 fiber or other D serotype fiber.

For exemplification, nucleic acid encoding GFP was incorporated into these vectors as a means to visualize their localization. Other genes, such as genes that encode therapeutic products, may be included in place of or in addition to GFP.

-25-

Plasmid pDV80 was electroporated into E1-2a S8 cells and stable lines were selected. The fiber-deleted vectors Ad5. β gal. Δ F and Ad5.GFP. Δ F were grown in cells in a resulting cell line, designated 705, to produce virions, which express the Ad37 fiber (Ad5. β gal. Δ F/37F and Ad5.GFP. Δ F/37F) and CsCl-
5 purified. These virions selectively transduce photoreceptor cells when injected intraocularly into the vitreous humor.

2. Packaging

Recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b
10 regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of
15 complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1
20 gene region products to "support" the growth of E1-deleted virus in the cell line (see, *e.g.*, Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378).

Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

Copending U.S. application Serial No. 09/482,682 (also filed as
25 International PCT application No. PCT/US00/00265, filed January 14, 2000)) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the
30 chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to

-26-

be replicated and packaged. The packaging cell line express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The expression can be constitutive or under the control of a regulatable promoter. These cell lines are designed for expression of recombinant adenoviruses intended for delivery of therapeutic products.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For therapeutic applications, the delivery plasmid further includes a nucleotide sequence encoding a foreign polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, p Δ E1B β -gal and p Δ E1sp1B. In a similar or analogous manner, therapeutic genes may be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a chromosome(s) of the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

-27-

In a variation, the packaging cell line expresses fiber protein or chimeric variant thereof from an Ad virus of subgroup D, preferably Ad37, serotype or it can be any fiber protein but one that has been modified to include the portion of the Ad virus of subgroup D, such as Ad37, responsible for selective targeting to photoreceptors upon introduction into the vitreous humor of the eye of a mammal, preferably a human. The fiber protein can be further modified to include a non-native amino acid residue sequence that targets additional specific receptors. In all instances, the modification should not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. The structural protein is fiber can include amino acid residue sequences from more than one adenovirus serotype. The nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein, may be modified "internally" as well as at the termini.

Additional nucleic acid fragments can encode polypeptides that are added to the fiber protein. In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker.

Suitable ligands include, but are not limited to, ligands that specifically or selectively bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome.

The packaging cell line can be derived from a procaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

3. Components of the nucleic acid molecule included in the particle

-28-

A recombinant viral vector or therapeutic viral vector for use in the methods herein, typically includes a nucleic acid fragment that encodes a protein or polypeptide molecule, or a biologically active fragment thereof, or other regulatory sequence, that is intended for use in therapeutic applications.

5 The nucleic acid molecule to be packaged in the viral particle also may include an enhancer element and/or a promoter located 3' or 5' to and controlling the expression of the therapeutic product-encoding nucleic acid molecule if the product is a protein. Further, for purposes herein, the promoter and/or other transcriptional and translational regulatory sequences controlling
10 expression of the product is preferably one that is expressed specifically in the targeted cells, such as the a photoreceptor-specific promoter, such as a rhodopsin gene promoter.

 The nucleic acid molecule to be packaged in viral capsid includes at least 2 different operatively linked DNA segments. The DNA can be manipulated and
15 amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce such molecule, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous
20 replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and nucleic acid molecule to the vector, the attached segments are replicated along with the vector sequences.

 Thus, the recombinant DNA molecule (rDNA) is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in
25 nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. The nucleic acid molecule intended to be packaged is from about 20 base pairs to about 40,000 base pairs in length, preferably about 50 bp to about 38,000 bp in length. In various embodiments, the nucleic acid molecule is of sufficient length
30 to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, encoding nucleic acid molecules

-29-

from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic product-encoding nucleic acid molecules.

Preferably the molecule includes an adenovirus tripartite leader (TPL)

- 5 nucleic acid sequence operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron. The intron includes any sequence of
- 10 nucleotides that function in the packaging cell line to provide RNA processing signals, including splicing signals. Introns have been well characterized from a large number of structural genes, and include but are not limited to a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs (see,
- 15 *e.g.*, Petitclerc *et al.* (1995)*J. Biotechnol.*, 40:169; and Choi *et al.* (1991)*Mol. Cell. Biol.*, 11:3070).

- The nucleic acid molecule encoding the TPL includes either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from among the complete TPL exon 1, partial TPL
- 20 exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.
- 25 The use of a TPL with a partial exon 1 has been reported (International PCT application No. WO 98/13499).

- The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence. An intron may not be a part of the construct. For example, the intron can be positioned
- 30 between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment,

-30-

complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPL nucleotide sequence as described herein.

4. Complementing Plasmids

Also contemplated are the use of nucleic acid molecules, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product encoded by the nucleic acid molecule. Expression cassettes typically contain a promoter and a structural gene operatively linked to the promoter. The complementing plasmid can further include a sequence of nucleotides encoding TPL nucleotide to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

A complementing plasmid can include a promoter operatively linked to a sequence of nucleotides encoding an adenovirus structural polypeptide, such as, but are not limited to, penton base; hexon; fiber; polypeptide IIIa; polypeptide V;

-31-

polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid may also include a sequence of nucleotides encoding a first adenovirus regulatory polypeptide, a second regulatory polypeptide, and/or a third regulatory polypeptide, and any combination of the foregoing.

Plasmid pDV80 is a preferred plasmid herein. Other plasmids constructed in an analogous manner to encode modified fiber proteins and chimeric fiber proteins are also contemplated herein.

5. Nucleic Acid Molecule Synthesis

A nucleic acid molecule comprising synthetic oligonucleotides can be prepared using any suitable method, such as the phosphotriester or phosphodiester methods (see, *e.g.*, Narang (1979) *et al.*, *Meth. Enzymol.*, 68:90; U.S. Patent No. 4,356,270; and Brown *et al.*, (1979) *Meth. Enzymol.*, 68:109). For oligonucleotides, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants (see, *e.g.*, Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., New York ,1991).

-32-

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and ligation, as is well known.

D. Adenovirus Expression Vector Systems

The adenovirus vector genome that is encapsulated in the virus particle and that expresses exogenous genes in a gene therapy setting is a key component of the system. Thus, the components of a recombinant adenovirus vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known and described herein.

-33-

Although adenovirus include many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector). Thus, deletion of the appropriate genes from a recombinant Ad vector permits accommodation of even larger "foreign" DNA segments.

5 A preferred recombinant adenovirus vector genome is "helper independent" so that genome can replicate and be packaged without the help of a second, complementing helper virus. Complementation is provided by a packaging cell.

10 In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is
15 referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

 Thus, contemplated for use are helper-independent fiberless recombinant adenovirus vector genomes that include genes that (a) express all adenovirus
20 structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contain an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

25 The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

30 A vector herein includes a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, *e.g.*, a gene or polynucleotide, can be operatively linked to bring about replication of the

-34-

attached segment. For purposes herein, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule. As noted above, therapeutic nucleic acid molecules include those encoding proteins and also those that encode regulatory factors
5 that can lead to expression or inhibition or alteration of expression of a gene product in a targeted cell.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also
10 feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least a portion of a therapeutic nucleotide sequence
15 operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

The choice of viral vector into which a therapeutic nucleic acid molecule is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and
20 the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the use of *any* adenovirus serotype, including hybrids and derivatives thereof are contemplated.

25 A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the
30 nucleic acid material and any polypeptides that are to be inserted into the cell.

-35-

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector may also include a promoter, particularly a tissue or cell specific promoter, preferably one expressed in ocular cells, particularly photoreceptors.

5 Promoters contemplated for use herein include regulatable (inducible) as well as constitutive promoters, which may be used, either on separate vectors or on the same vector. Some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, *e.g.*, International PCT application No. WO
10 96/14061). Preferably the promoter selected is from a photoreceptor-specific gene, such as a rhodopsin gene or gene that encodes a protein that regulates rhodopsin expression.

E. Formulation and administration

Compositions containing therapeutically effective concentrations of
15 recombinant adenovirus delivery vectors are provided. These are for delivery of therapeutic gene products to cells, particularly cells express a particular 50 kDa receptor or other receptor with which the vectors interact. These cells include cells of the eye and genital tract. Of particular interest are photoreceptor cells of the eye. Administration is effected by any means through which contacting with
20 the photoreceptors is effected. Preferable modes of administration include, but are not limited to, subretinal injection, particularly intravitreal injection, to provide access to photoreceptor cells.

The recombinant viral compositions may also be formulated for
implantation into the anterior or posterior chamber of the eye, preferably the
25 vitreous cavity, in sustained released formulations, such as those adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be
30 prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

-36-

The vectors are formulated in an ophthalmologically acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml.

5 The composition can be provided in a sealed sterile vial containing an amount of a compound of formula I, that upon intraocular administration will deliver a sufficient amount of viral particles to the photoreceptors in a volume of about 50 to 150 μ l, containing at least about 10^7 , more preferably at least about 10^8 plaque forming units in such volume. Typically, the vials will, thus, contain about 0.150 ml of the composition.

10 To prepare compositions the viral particles are dialyzed into a suitable ophthalmologically acceptable carrier or viral particles, for example, may be concentrated and/or mixed therewith. The resulting mixture may be a solution, suspension or emulsion. In addition, the viral particles may be formulated as the sole pharmaceutically active ingredient in the composition or may be
15 combined with other active agents for the particular disorder treated.

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene
20 glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. Suitable ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic
25 solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM
30 sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium β -hydroxybutyrate and 5-5.5 mM glucose.

-37-

The compositions may be prepared with carriers that protect them from rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).

- 10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm *et al.* (1983) *Bioch. Bioph. Acta* 728:339-398; Assil *et al.* (1987) *Arch Ophthalmol.* 105:400; and U.S. Patent No. 4,522,811]. The viral particles
15 may be encapsulated into the aqueous phase of liposome systems.

- The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high
20 molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751
25 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%,
30 preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as

-38-

methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional active agents may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material.

5 Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other containers, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein.

10 Finally, the compounds may be packaged as articles of manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing the viral particles and a label that indicates the therapeutic use of the composition.

Also provided are kits for practice of the methods herein. The kits
15 contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles, such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

20 Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or
25 subtenon injection, or by topical application to the cornea, if a penetrating formulation is used.

Administration

The compositions containing the compounds are administered intraocularly or by other means, such as topically in the form of penetrating
30 eyedrops, whereby contact of the recombinant vectors with the aqueous humor is effected. Intraocular administration may be effected by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as

-39-

subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device.

Administration is preferably by intravitreal injection, preferably through self sealing 25-30 gauge needles or other suitably calibrated delivery device.

- 5 Injection into the eye may be through the pars plana via the self-sealing needle.

It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the recombinant viruses, and that the concentration ranges set

- 10 forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods

F. Diseases, Disorders and therapeutic products

1. Disease and disorders

Retinitis pigmentosa

- 15 Methods for specifically or selectively targeting recombinant adenovirus vectors for delivery of gene products, particularly therapeutic products are provided herein. These methods are particularly suitable for targeting cells that express receptors that are selectively recognized by Ad virus of subgroup D viruses, particularly Ad37. It is shown herein that these viruses selectively
- 20 recognize receptors on cells, such as conjunctival cells and photoreceptors, that are not recognized by other adenoviruses. Hence, methods for targeting to these cell types by providing vectors that are packaged in viral particles that contain a sufficient portion of a fiber protein from one of these Ad serotypes to bind to these receptors. These methods are useful for targeting to
- 25 photoreceptors and for treating ocular disorders, including, but are not limited to, inherited and acquired retinal, neovascular degenerative diseases (see table below).

- It is estimated that 1 in 3,500 individuals in the United States suffer from one of the pigmented retinopathies. This group of retinal diseases, commonly
- 30 called retinitis pigmentosa, is characterized by progressive loss of peripheral and night vision. Patients may be affected at almost any age and it is not uncommon to experience symptoms in early childhood in certain inherited forms.

-40-

It has been shown that there are a variety of mutations in genes expressed in the photoreceptors, including genes in the rhodopsin gene and pathway that appear to be responsible for these diseases. In addition to mutations in rhodopsin, changes in the retinal pigmented epithelial (RPE) cells, also undergo
5 degenerative changes and can form clumps of pigment that give rise to the characteristic pigmentary changes seen in patients with RP.

Angiogenesis and ocular diseases and disorders

The vast majority of diseases that cause catastrophic loss of vision do so as a result of ocular neovascularization; age related macular degeneration
10 (ARMD) affects 12-15 million American over the age of 65 and causes visual loss in 10-15% of them as a direct effect of choroidal (sub-retinal) neovascularization. The leading cause of visual loss for Americans under the age of 65 is diabetes; 16 million individuals in the United States are diabetic and 40,000 per year suffer from ocular complications of the disease, which often are
15 a result of retinal neovascularization. Laser photocoagulation has been effective in preventing severe visual loss in subgroups of high risk diabetic patients, but the overall 10 year incidence of retinopathy remains essentially unchanged. For patients with choroidal neovascularization due to ARMD or inflammatory eye disease, such as ocular histoplasmosis, photocoagulation, with few exceptions,
20 is ineffective in preventing visual loss. While recently developed, non-destructive photodynamic therapies hold promise for temporarily reducing individual loss in patients with previously untreatable choroidal neovascularization, only 61.4% of patients treated every 3-4 months had improved or stabilized vision compared to 45.9% of the placebo-treated group.

25 In the normal adult, angiogenesis is tightly regulated and limited to wound healing, pregnancy and uterine cycling. Angiogenesis is turned on by specific angiogenic molecules such as basic and acidic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor (TGF), tumor necrosis factor- α (TNF- α) and platelet derived growth factor
30 (PDGF). Angiogenesis can be suppressed by inhibitory molecules such as interferon- α , thrombospondin-1, angiostatin and endostatin. It is the balance of these naturally occurring stimulators and inhibitors that controls the normally

-41-

quiescent capillary vasculature. When this balance is upset, as in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate.

Angiogenesis plays a central role in a variety of diseases, including, but
5 are not limited to, cancer and ocular neovascularization. Sustained growth and metastasis of a variety of tumors has also been shown to be dependent on the growth of new host blood vessels into the tumor in response to tumor derived angiogenic factors. Proliferation of new blood vessels in response to a variety of stimuli occurs as the dominant finding in the majority of eye diseases that blind,
10 such as, but are not limited to, proliferative diabetic retinopathy (PDR), ARMD, rubeotic glaucoma, interstitial keratitis and retinopathy of prematurity. In these diseases, tissue damage can stimulate release of angiogenic factors resulting in capillary proliferation. VEGF plays a dominant role in iris neovascularization and neovascular retinopathies. While reports clearly show a correlation between
15 intraocular VEGF levels and ischemic retinopathic ocular neovascularization, FGF likely plays a role. Basic and acidic FGF are known to be present in the normal adult retina, even though detectable levels are not consistently correlated with neovascularization. This may be largely due to the fact that FGF binds very tightly to charged components of the extracellular matrix and may not be readily
20 available in a freely diffusible form that would be detected by standard assays of intraocular fluids.

A final common pathway in the angiogenic response involves integrin-mediated information exchange between a proliferating vascular endothelial cell and the extracellular matrix. This class of adhesion receptors, called integrins,
25 are expressed as heterodimers having an α and β subunit on all cells. One such integrin, $\alpha_v\beta_3$, is the most promiscuous member of this family and allows endothelial cells to interact with a wide variety of extracellular matrix components. Peptide and antibody antagonists of this integrin inhibit angiogenesis by selectively inducing apoptosis of the proliferating vascular
30 endothelial cells. Two cytokine-dependent pathways of angiogenesis exist and may be defined by their dependency on distinct vascular cell integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. Specifically, basic FGF- and VEGF-induced angiogenesis depend on integrin

-42-

$\alpha_v\beta_3$ and $\alpha_v\beta_5$, respectively, since antibody antagonists of each integrin selectively block one of these angiogenic pathways in the rabbit corneal and chick chorioallantoic membrane (CAM) models. Peptide antagonists that block all α_v integrins inhibit FGF- and VEGF-stimulated angiogenesis. While normal human ocular blood vessels do not display either integrin, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins are selectively displayed on blood vessels in tissues from patients with active neovascular eye disease. While only $\alpha_v\beta_3$ was consistently observed in tissue from patients with ARMD, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ were present in tissues from patients with PDR. Systemically administered peptide antagonists of integrins blocked new blood vessel formation in a mouse model of retinal vasculogenesis.

In addition to adhesion events described above, cell migration through the extracellular matrix also depends on proteolysis. Matrix metalloproteinases are a family of zinc-requiring matrix-degrading enzymes that include the collagenases, gelatinases and stromelysins, all of which have been implicated in invasive cell behavior. Invasive cell processes such as tumor metastasis and angiogenesis have been found to be associated with the expression of integrins and MMP-2, MMP-2 are all found throughout the eye where they may interact to maintain a quiescent vasculature until the balance is upset, resulting in pathological angiogenesis. A non-catalytic C-terminal hemopexin-like domain of MMP-2 (PEX) can block cell surface collagenolytic activity and inhibit angiogenesis in the CAM model by preventing localization of MMP-2 to the surface of invasive cells through interaction with the integrin $\alpha_v\beta_3$.

Hence, anti-angiogenic agents have a role in treating retinal degeneration to prevent the damaging effects of these trophic and growth factors. Angiogenic agents, also have a role in promoting desirable vascularization to retard retinal degeneration by enhancing blood flow to cells.

Members of adenovirus subgroup D, Ad8, 19A, and 37, are infectious agents that cause particularly severe cases of epidemic keratoconjunctivitis (EKC) (Arnberg *et al.* (1998) *Virology* 227:239-244; Curtis *et al.* (1998) *J. Med. Microbiol.* 47:91-94; Ritterband *et al.* (1998) *Rev. Med. Virol.* 8:187-201; and Takeuchi *et al.* (1999) *J. Clin. Microbiol.* 37:3392-3394). There is no effective treatment for this debilitating and contagious disease and EKC

-43-

continues to be a problem in ophthalmology clinics worldwide (Curtis *et al.* (1998) *J.Med.Microbiol.* 47:91-94, Lukashok *et al.* (1998) *Curr.Clin.Top.Infec.Dis.* 18:286-304). Hence the vectors herein may be used for treating the disease.

5

Table 3
Candidate targets for ocular disease therapy

CANDIDATE TARGETS FOR OCULAR DISEASE THERAPY	
Disease	Candidate target(s)
Retinitis pigmentosa	Rhodopsin gene, and genes that regulate expression thereof <i>rds/peripherin</i>
10 Stargardt's disease	rim protein (ARC protein)
Choroideremia	rab geranylgeranyl transferase CHM, TCD, CHML*
Gyrate Atrophy	ornithine aminotransferase
15 Macular dystrophy	<i>rds/peripherin</i>

15

* see, "MSR6-yeast homologue of the choroideraemia gene," *Nature Genetics* 3: 193-4 (1993)

TABLE 4

Other Diseases	
20	Exudative Choroidal Diseases
	ICSC, fluorescein angiogram
	ICSC with large serous detachment of RPE (retinal pigmented epithelium)
	ICSC with bullous retinal detachment
	Macular drusen, exudative, confluent
25	Drusen, sub-RPE choroidal neovascularization
	Drusen, notched serous detachment of RPE

-44-

Other Diseases	
	Drusen, notched serous and hemorrhagic detachment of RPE
	Drusen, serous and hemorrhagic detachment of RPE and retina
	Drusen, organized RPE detachment causing bullous retinal detachment
	Drusen, geographic atrophy of RPE
5	Drusen, exudative and cuticular, vitelliform macular detachment
	Drusen, cuticular, large vitelliform macular detachment
	North Carolina dystrophy with macular staphyloma
	North Carolina dystrophy with macular staphyloma
	Angioid streaks, pseudoxanthoma elasticum (PXE), CNVM
10	Angioid streaks, PXE, large notched retinal detachment
	Myopic degeneration, Foerster-Fuchs spot
	Presumed ocular histoplasmosis syndrome (POHS)
	Submacular bacterial abscess
	<i>Toxocara canis</i> , subretinal granuloma
15	Serpiginous (geographic) choroiditis
	Posterior scleritis
	Harada's disease
	Posterior sympathetic uveitis
	Benign reactive lymphoid hyperplasia of uveal tract
20	Choroidal ruptures and CNVM
	Cavernous hemangioma of choroid
	Choroidal osteoma
	Choroidal nevus, serous macular detachment
	Choroidal nevus with CNVM
25	Diffuse sclerochoroidal melanocytic nevus
	Choroidal melanoma with serous detachment of RPE
	Metastatic lung carcinoma to choroid
	Sub-RPE reticulum cell sarcoma

-45-

	Other Diseases
	RPE tear, idiopathic choroidal neovascularization
	Heredodystrophic Disorders Affecting RPE & Retina
5	Best's vitelliform macular dystrophy
	Best's vitelliform macular dystrophy with CNVM
	Best's vitelliform macular dystrophy, multiple lesions
	Adult-onset vitelliform foveomacular dystrophy
	Pattern dystrophy simulating fundus flavimaculatus
10	Stargardt's disease (fundus flavimaculatus)
	Asteroid macular dystrophy
	Sjögren-Larssen syndrome
	Oguchi's disease, light-adapted state
	Oguchi's disease, dark-adapted state
15	Fundus albipunctatus
	Retinitis pigmentosa, cystoid macular edema
	Crystalline tapetoretinal dystrophy
	Choroideremia
	Goldmann-Favre syndrome
20	Sex-linked juvenile retinoschisis
	Perivenous retinitis pigmentosa
	Retinal Vascular Disorders
	Retinal arteriovenous aneurysm
	Central retinal artery occlusion
25	Cilioretinal artery obstruction
	Ischemic retinopathy in systemic lupus erythematosus
	Ischemic retinopathy in scleroderma
	Hemorrhagic detachment of internal limiting membrane, hypertensive retinopathy
	Acquired retinal arterial macroaneurysm

-46-

Other Diseases	
	Cystoid macular edema, aphakic
	Cystoid macular edema, nicotinic acid maculopathy
	Congenital retinal telangiectasis
	Acquired bilateral juxtafoveal telangiectasis
5	Acquired bilateral juxtafoveal obliterative telangiectasis
	Diabetic optic neuropathy
	X-ray radiation exudative retinopathy
	Sickle cell SC disease, macular hemorrhage
	Retinal arterial aneurysms, arteritis, neuroretinitis
10	Branch retinal vein obstruction (BRVO)
	BRVO, exudative maculopathy
	BRVO, optic disc new vessels, photocoagulation
	Waldenström's macroglobulinemia
Inflammatory Diseases of the Retina and Choroid	
15	Luetic retinal vasculitis
	Focal <i>Candida</i> retinal abscess
	Toxoplasmosis, atrophic chorioretinal scar
	Toxoplasmosis retinitis and macular detachment
	Toxoplasmosis scar, CNVM, macular detachment
20	Diffuse unilateral subacute neuroretinitis, small worm
	Diffuse unilateral subacute neuroretinitis, large worm
	Cytomegalic inclusion disease, papillitis
	Acute posterior multifocal placoid pigment epitheliopathy
	Acute macular neuroretinitis
25	Sarcoid retinitis
	Sarcoid papillitis
	Behcet's disease
	Vitiliginous (bird-shot) chorioretinitis

-47-

	Other Diseases
	Multifocal choroiditis and panuveitis (pseudo-POHS)
	Retinal and Pigment Epithelial Hamartomas
	Congenital grouped albinotic RPE spots
	Congenital hyperplasia of RPE
5	Combined RPE and retinal hamartoma, juxtapapillary
	Combined RPE and retinal hamartoma, peripheral
	Cystic astrocytoma, juxtapapillary
	Astrocytoma, macula
	Astrocytoma, juxtapapillary
10	Cavernous hemangioma of retina
	Juxtapapillary sessile retinal capillary hemangioma
	Juxtapapillary endophytic retinal capillary hemangioma
	Other Tumors of the Choroid
	Choroidal metastasis
15	Choroidal osteoma
	Choroidal hemangioma
	Miscellaneous uveal tumors
	Intraocular Lymphoid Tumors
	The leukemias and lymphomas
20	Tumors of the Vitreous
	Non-Hodgkins ("reticulum cell") lymphoma
	Tumor involvement of the vitreous cavity
	Macular Disease
	Age-related macular degeneration -- atrophic form
25	Exudative age-related macular degeneration
	Choroidal neovascular membrane in degenerative myopia
	Central serous retinopathy
	Macular hole

	Other Diseases
	Macular dystrophies
	Retinal Vascular Disease
	Etiologic mechanisms in diabetic retinopathy
	Background diabetic retinopathy
5	Proliferative diabetic retinopathy
	Retinal arterial obstructive disease
	Central retinal vein occlusion
	Retinal branch vein occlusion
	Pregnancy and retinal disease
10	Pregnancy-induced hypertension
	Hypertension
	The rheumatic disease
	Parafoveal telangiectasis
	Coats disease
15	Disseminated intravascular systemic coagulopathy and related vasculopathies
	Hemoglobinopathies
	Retinopathy of prematurity
	Acquired retinal macroaneurysms
	Eales disease
20	Radiation retinopathy
	The ocular ischemic syndrome
	Inflammatory Disease
	Ocular toxoplasmosis
	Ocular toxocariasis
25	Ocular cysticercosis
	Cytomegalovirus infections of the retina
	Retinal and ophthalmologic manifestations of AIDS
	Acute retinal necrosis syndrome

-49-

	Other Diseases
	Endogenous fungal infections of the retina and choroid
	Pars planitis
	Syphilis and tuberculosis
	Diffuse unilateral subacute neuroretinitis
5	Scleritis
	Birdshot retinochoroidopathy
	Punctate inner choroidopathy
	Sarcoidosis
	Acute multifocal placoid pigment epitheliopathy
10	Geographic helicoid peripapillary choroidopathy (GHPC): serpiginous choroiditis
	Sympathetic ophthalmia
	Vogt-Koyanagi-Harada syndrome (uveomeningitic syndrome)
15	Ciliochoroidal (uveal) effusion

Reproduced from: Stereoscopic Atlas of Ocular Diseases Diagnosis and Treatment, 2nd Edition, J. Donald O. Gass, Vol. 1 & 2, C.V. Mosley Co. (1987); and Retina Vol. II, Editor, Stephen J. Ryan, Medical Retina, C.V. Mosley Co. (1989).

20 2. **Therapeutic products**

Therapeutic products include but are not limited to, wild-type genes that are defective in ocular disorders, such as rhodopsin, or fragments thereof sufficient to correct the genetic defect, trophic factors, including growth factors, inhibitors and agonists of trophic factors, anti-apoptosis factors and other

25 products described herein or known to those of skill in the art to be useful for treatment of disorders of the eye or that can be treated by a product expressed by a photoreceptor.

OCULAR GENE THERAPY STRATEGIES		
GENERAL DISEASE	EXAMPLES	STRATEGY

-50-

OCULAR GENE THERAPY STRATEGIES		
Hereditary retinal and macular degeneration	<ul style="list-style-type: none"> • Retinitis pigmentosa • Stargardt's disease • Other macular dystrophies 	Growth factors (e.g., GDNF) anti-apoptotic factors (e.g., bcl2 gene) Stargardt Disease Gene (ABCR) [†]
Neovascular	<ul style="list-style-type: none"> • Diabetes • Choroidal neovascularization 	Anti-angiogenesis factors
Anti-tumor	Retinoblastoma	Antiproliferant
5 Glaucoma	Nerve fiber layer atrophy	Neuroprotective agent

[†] See Allikmets *et al.* (1997) *Science* 277:1805-1807.

For example, for treatment of retinitis pigmentosa the adenovirus vector can deliver a wild-type rhodopsin gene or a growth factor or trophic factor, such as ciliary neurotrophic factor CNTF; for treatment of Stargardt's disease, the
 10 vector can deliver a wild type ABCR (also called STGD1) or a growth factor or anti-angiogenic agent; for diabetic retinopathies, retinal vascularization the vector can deliver growth factors, such as a TGF (TGF β), to prevent degeneration.

15 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as
 20 host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and other
 25 epithelial-derived cell lines. As a result of the adenovirus transformation, the

-51-

293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

These cell lines allow the production and propagation of adenovirus-based gene delivery vectors that have deletions in preselected gene regions and that are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a viral vector, plasmid vectors that contain preselected functional units have been designed. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit that is alternately spliced to produce several different mRNA products. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcription unit. A DNA fragment extending from 175 nucleotides upstream of the E4 transcription start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Viol.*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAATTCAGGAGACACAACCTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create new sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute,

-52-

50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp. The pE4/Hygro plasmid has been deposited with the ATCC under accession number 97739. The complete nucleotide sequence of pE4/Hygro is set forth in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also

-53-

contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites
5 of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

10 The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter
15 provided by the pcDNA vector, a BglII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral
20 mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-
25 7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is included in SEQ ID NO: 8 bordered by BamHI/BglII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial
30 TPL is also listed separately as SEQ ID No. 22 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BglII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1);

-54-

28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BglII site.

The pCLF plasmid has been deposited with the ATCC as described in

- 5 Example 4. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA.

10 **C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins**

- The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*,
15 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond,
20 CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

- From expanded colonies, genomic DNA was isolated using the
25 "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6.

- 30 One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the product, indicating the presence of inserted DNA corresponding to most, if

-55-

not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 4. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected.

- 5 Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell
- 10 line, the labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event.

- Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211
- 15 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional
- 20 electroporation with the fiber-encoding pCLF plasmid as described above.

- Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 μ g/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate
- sublines of 211 were then screened for fiber protein expression by indirect
- 25 immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSV β gal (1 pfu/cell) and stained 24 hours post-infection.

- Lines positive for nuclear staining in this assay were then subjected to
- 30 Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the predicted molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including

-56-

211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 4.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a semipreparative electrophoresis system demonstrated that the fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein. The predicted molecular weight of a trimerized fiber is 186 kd. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the

-57-

pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli gpt* gene that allows stable transfectants to be isolated using hypoxanthine/amino-pterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C, alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for

-58-

use in generating recombinant adenovirus viral vectors thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

5 1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer
5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the
10 nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector
15 is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides dexamethasone-inducible E1 function as described for
20 DEX/E1 and expression of Ad5 fiber protein as described above.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998
25 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more
30 delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions performed as

-59-

previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

5 Plasmid pCLF prepared as described in Example 1B is partially digested with BglII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber
10 gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4
15 gene are located at respective nucleotide positions 21 and 3149 followed by fused BglII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BglII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BglII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide
20 positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

EXAMPLE 2

25 Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

Adenoviral delivery vectors are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector is replication competent but only via a
30 non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, these adenovirus delivery vectors have a higher capacity for insertion of foreign DNA.

-60-

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

- To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid pΔ
- 5 E1Bβgal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β-galactosidase gene was isolated from pSVβgal (Promega) by digesting with VspI, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with Bam HI. The resulting fragment was cloned into the EcoRV and BamHI
- 10 sites in the polylinker of pΔ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form pΔ E1B βgal that therefore contained the left end of the adenovirus genome with the Ela region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSVβ gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the
- 15 Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)
- 20 The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994) (see, also International PCT application No. WO 95/00655) using methods well known to one of skill in the art. This vector is also commercially available from Microbix and contains an Ad5 genome
- 25 with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme PacI. An 11.9 kb BamHI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the BamHI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. The p11.3
- 30 plasmid was then digested with PacI and Sall to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

-61-

This fragment was replaced with a 3,4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences:

5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17; and

5 5' CACAACGAGCTC AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18.

These primers incorporated sites for *PacI* and *BamHI*. Cloning this fragment into the *PacI* and blunt ended *Sall* sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resulting p11.3 plasmid containing the ITR and E4 regions, designated plasmid pDV43a, was then digested with *BamHI*. This *BamHI* fragment was then used to replace a *BamHI* fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb *BamHI* fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3. The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a *Sall* restriction site. pDV42 was then digested with *PacI*, which cuts at a unique site (bold type) in one of the PCR primers, and with *Sall*, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding *PacI*/*XhoI* fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique *XhoI* site), creating pDV43.

30 A plasmid designated pDV44 was constructed by replacing the 11.9 kb *BamHI* fragment of pBHG10 by the analogous *BamHI* fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the

-62-

deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was
5 constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10. pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Plasmids pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection
10 and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with p Δ E1B β gal, which contains the left end of the Ad5 genome with an SV40-driven β -galactosidase reporter gene inserted in place of the E1 region.
15 In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences
20 corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and p Δ E1B β gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a
25 full-length viral chromosome where pDV44 and p Δ E1B β gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of
30 the recombinant virus are produced by standard methods.

Because of the fiber deletion, a pDV44-derived virus is replication-defective, cells in which it is grown must complement this defect.

-63-

The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 4) was used for rescue and propagation of the virus described here. pDV44 and pΔE1βgal were cotransfected into 211B cells, and the monolayers
5 were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell
10 death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.βgal.ΔF) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7
15 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.βgal.ΔF, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis
20 via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at - 70°C. Purified Ad5.βgal.ΔF virus particles containing human adenovirus Ad5.βgal.ΔFgenome (described
25 further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 4.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of
30 virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2

-64-

ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of
5 pBHG10 and p Δ E1B β gal. In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1B β gal and pBHG10 produced virus.

In another embodiment, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector
10 having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to
15 prepare a viral vector lacking fiber. For genetic therapy, the fiber gene can be replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Methods for producing a fiberless vector with a complete TPL are described in Example 3.

Vectors for the delivery of any desired gene and preferably a therapeutic
20 gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1B β gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later
25 Examples.

1. Characterization of the Ad5. β gal. Δ F Genome

To confirm that the vector genomes had the proper structures and that the fiber gene was absent from the Ad5. β gal. Δ F chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by
30 adding 10 μ l of 10 mg/ml proteinase K, 40 μ l of 0.5 M EDTA and 50 μ l of 10% SDS to 800 μ l of adenovirus-containing culture supernatant. The suspension

-65-

was then incubated at 55°C for 60 minutes. The solution was then extracted once with 400 μ l of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 μ l of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from Ad5. β gal.wt and Ad5. β gal. Δ F produced the expected restriction patterns following digestion with either EcoRI or with NdeI. Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5. β gal.wt but not in Ad5. β gal. Δ F DNA. As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. E4 signal was readily detectable in both genomes at equal intensities. The complete nucleotide sequence of Ad5. β gal. Δ F is presented in SEQ ID NO: 23 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5. β gal. Δ F

To verify that Ad5. β gal. Δ F was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5. β gal. Δ F or with Ad5. β gal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5. β gal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

3. Growth of the Fiber-Deleted Ad5. β gal. Δ F Vector in Complementing Cells

Ad5. β gal. Δ F was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5. β gal. Δ F or Ad5. β gal.wt contained similar numbers of viral particles. The particles appeared to band normally on CsCl gradients. Infectivity of the Ad5. β gal. Δ F particles was lower than the Ad5. β gal.wt control, as indicated by an increased particle/PFU ratio. Ad5. β gal. Δ F was also found to plaque more slowly than the control

-66-

virus. When plated on 211B cells, Ad5. β gal.wt plaques appeared within 5-7 days, while plaques of Ad5. β gal. Δ F continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5. β gal. Δ F plaques was essentially normal.

5 **4. Production of Fiberless Ad5. β gal. Δ F Particles**

As Ad5. β gal. Δ F represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the
10 determination of whether such particles would be stable and/or infectious. Either Ad5. β gal.wt or Ad5. β gal. Δ F was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5. β gal. Δ F particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating
15 that there was not a gross defect in morphogenesis of fiberless capsids.

Particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. The Ad5. β gal. Δ F particles produced in 293 cells did not contain fiber protein.
20 211B-grown Ad5. β gal. Δ F also contained less fiber than the Ad5. β gal.wt control virus. The infectivities of the different viral preparations on epithelial cells correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5. β gal. Δ F was only
25 50-100 fold less than that of Ad5. β gal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. Composition and Structure of the Fiberless Ad5. β gal. Δ F Particles

The proteins contained in particles of 293-grown Ad5. β gal. Δ F were
30 compared to those in Ad5. β gal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant. The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a

-67-

first-generation vector, with the exception of reduced intensity of the composite band resulting from proteins IIIa and IV (fiber). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the

5 low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, having an extended stalk with a knob at the end, was faintly visible in favorable

10 orientations of wild-type Ad5 particles, but not in images of the fiberless particles. Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type

15 particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components

20 into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base

25 around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal.ΔF Particles

30 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates

-68-

binding to the cells (via $\beta 2$ integrins) and internalization (through interaction with αv integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. β gal.wt or with Ad5. β gal. Δ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy. The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells. Large differences were seen in plaquing efficiency on epithelial (211B) cells. Infection of THP-1 cells by either Ad5. β gal. Δ F or Ad5. β gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. β gal. Δ F from internalizing into the cells and delivering its genome to the nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the

-69-

standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

Chimeric fiber proteins can be produced according to known methods (see, *e.g.*, Stevenson *et al.* (1995) *J. Virol.*, 69:2850-2857). Determinants for fiber receptor binding activity are located in the head domain of the fiber and an isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods herein are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in above and in U.S. application Serial No. 09/482,682) as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with E4 and/or E1-encoding constructs.

Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotide sequences are available with the respective GenBank Accession Numbers

-70-

M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for
5 cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resulting products are then used to construct chimeric fiber constructs by PCR gene overlap extension (Horton *et al.* (1990) *BioTechniques*, 8:525-535). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region
10 encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region
15 encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1.
20 The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as
25 previously described. Other fiber chimeric constructs are obtained with the various adenovirus serotypes using a similar approach.

In an alternative embodiment, the use of modified proteins including with modified epitopes (see, *e.g.*, Michael *et al.* (1995) *Gene Therapy*, 2:660-668 and International PCT application Publication No. WO 95/26412, which describe
30 the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity). In particular, the authors described the

-71-

production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following synthesis.

Similar constructs are contemplated for use in the complementing adenoviral packaging cell systems for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic. Heterologous ligands contemplated for use herein to redirect fiber specificity range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end using routine procedures known to those of skill in the art. The skilled artisan will be with the preparation of linkers to accomplish sufficient protein presentation and to alter the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this disclosure, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20)

-72-

followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector
5 sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The
10 resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously
15 described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the
20 one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

EXAMPLE 3

25 Tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector are provided. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5
30 genomic DNA using the synthetic oligonucleotide primers
5'CTCAACAATTGTGGATCCGTACTCC3'(SEQ ID No. 24) and
5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID No. 25). The resulting

-73-

product was cloned to the BamHI and BglII sites of pΔE1Sp1a (Microbix Biosystems) using sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then
5 amplified using primers 5'GGCGCGTTC**GGATCC**ACTCTCTTCC3' (SEQ ID No. 26) and 5'CTACATGCTAGGC**AGATCT**CGTTCGGAG3' (SEQ ID No. 27), and cloned into the BamHI site of pDV52 (again using sites in the primers) to create pDV55.

This plasmid contains a 1.2 kb BamHI/BglII fragment containing the first
10 TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID No 28 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2);
15 1141-1146 nt fused BamHI and BglII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BglII site.

EXAMPLE 4

Deposit of Materials

The following cell lines and plasmids were deposited on September 25,
20 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty): Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737),
25 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were
30 deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

-74-

EXAMPLE 5**Preparation and Use of Adenoviral Packaging Cell Lines
Containing Plasmids Containing Alternative TPLs**

Plasmids containing tripartite leaders (TPLs) have been constructed. The
5 resulting plasmids that contain different selectable markers, such as neomycin
and zeocin, were then used to prepare fiber-complementing stable cell lines for
use as for preparing adenoviral vectors.

A. pDV60

Plasmid pDV60 was constructed by inserting this TPL cassette of SEQ ID
10 No. 28 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a
neomycin selectable plasmid (see, *e.g.*, U.S. application Serial No. 09/482,682
(also filed as International PCT application No. PCT/US00/00265 on January 14,
2000); see also Von Seggern *et al.* (1998) *J. Gen Virol.*, 79: 1461-1468). The nucleotide sequence of pDV60 is
15 listed in SEQ ID NO: 29. Plasmid pDV60 has been deposited in the ATCC under
accession number PTA-1144.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV
promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone
20 terminator was transferred from pCLF (ATCC accession number 97737; and
described in copending U.S. application Serial No. 09/482,682 (also filed as
International PCT application No. PCT/US00/00265 on January 14, 2000);), to a
zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially
available from Invitrogen and for which the sequence is known).

25 C. pDV67

In an analogous process, pDV67 containing complete TPL was
constructed by transferring an Asp 718/XbaI fragment from pDV60 into
pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is set forth in

-75-

SEQ ID No. 30. Plasmid pDV67 is available from the ATCC under accession number PTA-1145.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric
5 Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.* (1995) *J. Virol.*, 69: 2850-2857) using the primers 5'ATGGGAT
CAAGATGAAGCGCGCAAGACCG3' (SEQ ID No. 31) and
5'CACTATAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID No. 32), and cloned to
the BamHI and NotI sites of pcDNA3.1/Zeo(+) via new BamHI and NotI sites
10 engineered into the primers to create pDV68. Finally, the complete TPL
fragment described above was then added to the unique BamHI site of pDV68
to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID No. 33
and has been deposited in the ATCC under accession number PTA-1146.

E. Preparation of Stable Adenovirus Packaging Cell Lines

15 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC #
CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also
referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 34) and
pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in
SEQ ID No. 35), which provide complementation of the adenoviral E1 and E2a
20 functions, respectively. This line and its derivatives were grown in Richter's
modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were
electroporated as previously described (Von Seggern *et al.* (1998) *J. Gen Virol.*,
79: 1461-1468) with pDV61, pDV67, or with pDV69, and stable lines were
selected with zeocin (600 µg/ml).

25 The cell line generated with pDV61 is designated 601. The cell line
generated with pDV67 is designated 633 while that generated with pDV69 is
designated 644. Candidate clones were evaluated by immunofluorescent
staining with a polyclonal antibody raised against the Ad2 fiber. Lines
expressing the highest level of fiber protein were further characterized.

30 For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM
of dexamethasone was added to cell cultures 16-24 hours prior to challenge
with virus for optimal growth kinetics. For preparing viral plaques, 5 X 10⁵

-76-

cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5 μ M included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1⁻/E2a⁻ Vectors

5 The Adenovirus 5 genome was digested with Scal enzyme, separated on an agarose gel, and the 6,095 bp fragment containing the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A.,
10 under accession number VR-5. The Scal 6,095 bp fragment was digested further with Clal at bp 917 and BglII at bp 3,328. The resulting 2,411 bp Clal to BglII fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with Clal and BglII, to form pSE280-E.

15 Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an XhoI and SalI restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACCTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGA

20 CC-3' (SEQ ID No 36)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTTGGCATAG-3' (SEQ ID No. 37)

 This amplified DNA fragment (sometimes hereinafter referred to as
Fragment A) then was digested with XhoI and Clal, which cleaves at the native
25 Clal site (bp 917), and ligated to the XhoI and Clal sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

 PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an EcoRI restriction site. The primers which
30 were employed were as follows:

5' end, Ad5 bp 3323-3360:

-77-

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID No. 38);
and

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC

5 -3' (SEQ ID No. 39).

This amplified DNA fragment (sometimes hereinafter referred to as
Fragment B) was digested with BglII, thereby cutting at the Adenovirus 5 BglII
site (bp 3,382) and EcoRI, and ligated to the BglII and EcoRI sites of pSE280-AE
to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552
10 through 4,090. The resulting plasmid is designated pSE280-E1.

A construct containing the intact E1a/b region under the control of the
synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was
excised from pSE280-E1, which was modified previously to contain a BamHI site
3' to the E1 gene, by digesting with XhoI and BamHI. The XhoI to BamHI
15 fragment containing the E1a/b fragment was cloned into the unique XhoI and
BamHI sites of pGRE5-2/EBV (U.S. Biochemicals, Cleveland, Ohio) to form
pGRE5-E1).

Bacterial transformants containing the final construct were identified.
Plasmid DNA was prepared and purified by banding in CsTFA prior to use for
20 transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and SpeI, which cut
at bp 21,562 and 27,080, respectively. Fragments were separated on an
agarose gel and the 5,518 bp BamHI to SpeI fragment was isolated. The 5,518
25 bp BamHI to SpeI fragment was digested further with SmaI, which cuts at bp
23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an
agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and
digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI.

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site
30 at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites.
The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

-78-

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID No. 40);
3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID No. 41)

This amplified DNA fragment was digested with SmaI and EcoRI, and
5 ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the
complete E2a region from Ad5 bp 24,730 through 21,562. The resulting
construct is pSE280-E2a.

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the
E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and
10 recloned into the unique BamHI and NheI sites of pSE280. Subsequently, the
E2a region was excised from this construction with NheI and Sall in order to
clone into the NheI and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA)
multiple cloning site in a 5' to 3' orientation, respectively. The resulting
construct is pMAMneo E2a.

15 Bacterial transformants containing the final pMAMneo-E2a were
identified. Plasmid DNA was prepared and purified by banding in CsTFA.
Circular plasmid DNA was linearized at the XmnI site within the ampicillin
resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform
extraction and ethanol precipitation prior to use for transfection of cells.

20 Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium
phosphate precipitation, or other means of DNA delivery, of two plasmid
constructions each with a different viral gene, into a single tissue culture cell.
The cells were transfected with a first construct and selected for expression of
25 the associated drug resistance gene to establish stable integrants. Individual cell
clones were established and assayed for function of the introduced viral gene.
Appropriate candidate clones then were transfected with a second construct
including a second viral gene and a second selectable marker. Transfected cells
then were selected to establish stable integrants of the second construct, and
30 cell clones were established. Cell clones were assayed for functional expression
of both viral genes.

-79-

A549 (ATCC Accession No. CCL-185) were used for transfection.

Appropriate selection conditions were established for G418 and hygromycin B by standard kill curve determination.

Transfection of A549 cells with plasmids including E1 and E2a regions.

- 5 pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was
- 10 screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1, which contains the GRE5 promoted
- 15 E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus
- 20 establishing the expression of E1a/b and E2a in the positive cell clones.

A transfected A549 (A549 (ATCC Accession No. CCL-185);) cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

G. Preparation of Adenoviral Vectors Containing Ad5.βgal.ΔF Genome in S8 Improved Fiber-Complementing Cell Lines

- 25 To prepare adenoviral vectors containing Ad5.βgal.ΔF (Ad5.βgal.ΔF has been deposited the ATCC under accession number VR2636) in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5.βgal.ΔF in
- 30 211B cells was followed with the exception of pretreatment with 0.3 μM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless

-80-

Ad5. β gal. Δ F genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5. β gal. Δ F genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

Thus, these viral preparations, prepared as described herein are useful for
5 targeting delivery of the Ad5. β gal. Δ F, Ad5.GFP. Δ F, or other similarly constructed fiberless genome with either wild-type or modified fibers. Preferably for purposes herein the fibers are from an Ad serotype D virus, more preferably from Ad37.

EXAMPLE 6

10 **Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines**

A. Pseudotyping of Ad5. β gal. Δ F

To verify that adenoviral vectors were produced had altered tropisms,
viral particles were purified from either 633 or 644 cells and were then Western
15 blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects the Ad5 and chimeric 5T3H fiber proteins).

B. Infectivity of Cells with 633 or 644 Generated Virus Particles The
cell lines, 633 or 644, prepared as described above, were infected with the
indicated number of particles/cell of Ad5. β gal. Δ F and virus particles produced.
20 Virus was then used to infect selected cell lines, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light
25 microscopy where all experiments were done in triplicate.

The results indicated that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber proteins. Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing
30 the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

-81-

EXAMPLE 7**Transient Transcomplementation**

The ability of adenovirus type 5 (Ad5) to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it was thought that it would be difficult to use adenoviruses to deliver genes to specific cell types. A system for testing modified fiber genes to identify tropisms of interest is described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). An *in vitro* system has been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate modified fibers expressed on a viral particle. This system can be used to produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55 were prepared as described herein and in U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. β gal. Δ F and 211B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.

The fiber deletion mutation of Ad5. β gal. Δ F is complemented in *trans* by passing virions through 211B, a cell line that stably expresses functional Ad5

-82-

fiber. The present system was designed to complement Ad5. β gal. Δ F by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. β gal. Δ F genome that does not require propagation of the virus.

The feasibility of transcomplementation of Ad5. β gal. Δ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists for at least six days. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. β gal. Δ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility for quickly evaluating a bank of modified fibers for other binding properties, including new tropisms and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber for complementation with Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion, which should render it very suitable for gene therapy. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. A single Ad vector preparation can be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

-83-

EXAMPLE 8**Preparation of Adenoviral Gene Delivery Vectors Containing the Ad37 fiber protein**

This example describes construction of packaging cell lines expressing
5 the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad
vector (such as Ad5. β gal. Δ F) containing this fiber protein. The fiber protein is
attached to the viral capsid by binding to the penton base protein through its N-
terminus, and the Ad37 fiber was modified in order to make its N-terminal
sequence more closely match that of the Ad5 protein to ensure that it would
10 efficiently bind the Ad5 penton base in these vectors.

A. Materials and methods

Cell lines and wild-type adenovirus. Human A549 lung carcinoma
epithelial cells and human Chang C conjunctival cells (American Type Culture
Collection) were maintained in complete Dulbecco's Modified Eagle Medium
15 (DMEM) with 10% fetal bovine serum. Wild-type Ad19p and Ad37 (ATCC) were
propagated in A549 cells and purified by banding on CsCl₂ density gradients as
previously described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Viral protein
concentration was determined by the Bio-Rad Protein Assay, and was used to
calculate the number of viral particles based on the known molecular weight of
20 Ad2 virions (1 μ g = 4 x 10⁹ particles).

B. Construction of the Ad37 fiber expressing cell lines and the recombinant Ad37 knob protein.**1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)**

25 The plasmid designated pDV80 (see, SEQ ID No. 42) prepared for
expression of the Ad37 fiber protein in mammalian cells, uses the same
regulatory elements as the elements in pDV60, pDV67, and pDV69 to express
the Ad37 fiber in packaging lines. It was constructed in two steps.

First, the Ad37 fiber open reading frame was amplified from Ad37
30 genomic DNA using synthetic oligonucleotide primers, L37: 5' TGT CCT GGA
TCC AAG ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3' (SEQ ID
NO. 43) and 37FR: 5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3' SEQ
ID NO. 44). L37 contains nucleotides (underlined) that differ from the Ad37

-84-

genomic sequence in order to add a unique *Bam*H1 site (bold) before the start codon (italicized) and to create point mutations that make the N-terminal sequence of the fiber more closely match the N-terminal sequence of the Ad5 fiber protein as follows:

5 Ad37 MSKRLRVEDDFNPVYPY (SEQ ID No. 45)
 ↓ ↓ ↓ ↓ ↓
 KRARPS (SEQ ID No. 46)
 Ad5 MKRARPSDDTFNPVYPY (SEQ ID No. 47) .

37FR also incorporates a unique *Not*1 site (bold). The PCR product was inserted
 10 into the *Bam*H1 and *Not*1 sites of pCDNA3.1zeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber protein, including inserted changes, was confirmed by sequencing.

Two point mutations in the fiber gene in the 705 line, S356 to P356 and I362 to T362, were discovered by the sequencing. The mutations are not in the
 15 receptor binding domain in Ad37 fiber gene in the 705 cell line. They are buried in the knob trimer interface. To confirm that these mutations do not affect receptor binding, the Ad37 fiber protein with the correct sequence was recloned, and 293T cells transfected with the virus and subsequently infected with Ad5.GFPΔF to produce Ad37 pseudotyped virus. The results were the same as
 20 the results of the experiments with Ad37 pseudotyped virus produced from line 705 (see, Wu *et al.* (2001) *Virology* 279:78-89).

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (see EXAMPLE 3) and inserted into the *Bam* H1 site of pDV78 to create pDV80 (SEQ ID No 42). Plasmid pDV80 has
 25 been deposited in the ATCC under accession number PTA-1147.

2. Construction of the recombinant Ad37 knob protein

Recombinant Ad37 knob protein containing an N-terminal T7•Tag was produced in *E. coli* using the PET expression system (Novagen). Ad37 fiber DNA (GenBank accession number U69132) was PCR amplified from wild-type Ad37
 30 genomic DNA using the following primers (SEQ ID Nos. 48 and 49):
 5' GGATCCATGGGATACTTGGTAGCA 3' (*Bam*HI site underlined and
 5' GCAACTCGAGTCATTCTTGGGCAATATAGG 3'(XhoI site underlined).

-85-

The PCR reactions were performed at 94 °C (denaturation), 55 °C (annealing), 72 °C (extension, 30 cycles) using *Taq* DNA polymerase (Qiagen). The amplified DNA fragments, which contained residues 172 to 365 of the Ad37 fiber protein with the addition of an N-terminal start codon (italicized), were purified and subcloned into the pCR-TOPO vector using the TA-Cloning Kit (Invitrogen). No replication errors were found by DNA sequencing. Plasmids from cultured transformed colonies were purified and digested with *Bam*HI and *Xho*I. The fragment was inserted into the *Bam*HI and *Xho*I sites of the bacterial expression vector, pET21a (Novagen), and transformed into (DE3)pLYS S expression cells (Invitrogen). Colonies were selected for knob expression by induction with 1 mM IPTG for four hours at 37 °C and knob expression was determined by SDS-PAGE. The colony displaying highest knob expression was used for large-scale knob expression and induced with 0.5 mM IPTG at 30 °C for four hours.

The recombinant T7•Tagged Ad37 knob protein was purified from sonicated bacteria using the T7•Tag Affinity Purification Kit as recommended by the manufacturer (Novagen). Recovered protein was analyzed for purity by SDS-PAGE followed by Coomassie staining or Western blotting with an HRP-conjugated α -T7•Tag monoclonal antibody as described by the manufacturer (Novagen) or an α -Ad37 fiber rabbit antibody.

3. Preparation of Cell Lines that Express the Ad37 fiber protein

Plasmid pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (see Examples herein; see also, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178; and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468). Stable clones were selected with 600 μ g/ml zeocin (Invitrogen).

Clones were expanded and were screened for fiber expression by indirect immunofluorescence (Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468) using a rabbit polyclonal antibody directed against the Ad37 fiber (α -Ad37 fiber rabbit antibody) raised by immunizing rabbits with recombinant Ad37 fiber protein. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected.

-86-

EXAMPLE 9**Production of Pseudotyped Ad Vector Particles**

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately
5 1000 particles/cell) with Ad5. β gal. Δ F or with Ad5.GFP. Δ F.

Materials and methods**Ad5. β gal. Δ F**

The construction of Ad5. β gal. Δ F is described in Example 2 (it has been deposited on January 15, 1999, with the ATCC as listed above under accession
10 number VR2636; see also, Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; copending U.S. application Serial No. 09/482,682 filed January 14, 2000, and also International PCT application No. PCT/US00/00265, filed January 14, 2000).

Ad5.GFP. Δ F

15 Ad5.GFP. Δ F was constructed by recombination in bacteria using a modification of the AdEasy System (see, U.S. Patent No. 5,922,576; see, also He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the system is publicly available from the authors and other sources).

First, a fiber-deleted genomic plasmid was constructed by removing the
20 fiber gene from pAdEasy-1 (see, U.S. Patent No. 5,922,576; and He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the AdEasy system and vectors are publicly available from He *et al.* at Johns Hopkins University). Plasmid pAdEasy-1 contains the entire Ad5 genome, except for nucleotides 1-3,533, which encompass the E1 genes, and nucleotides 28,,130-30,820, which
25 encompass the E3 gene.

Plasmid pDV43 (see Example 2; see, also Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608) was digested with *Pac*1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated to produce plasmid pDV76. The resulting plasmid pDV76 is identical to
30 pDV43 except for loss of the *Pac*1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.23 kb fragment from PDV76 was amplified using the oligonucleotide primers (SEQ ID Nos. 50 and 51:

-87-

5' CGC GCT GAC TCT TAA GGA **CTA GTT** TC 3', including the unique *Spe*1 site in the Ad5 genome (bold); and 5' GCG CTT **AAT TAA** CAT CAT CAA TAA TAT ACC TTA TTT T 3', including a new *Pac*1 site (bold) adjacent to the right Ad5 ITR. Hence the resulting PCR amplified fragment contains nucleotides
5 27,082 to 35,935 of the Ad5 genome with deletions of nucleotides 28,133 to 32,743 (the E3 and fiber genes), and was used to replace the corresponding *Spe*1/*Pac*1 fragment of pAdEasy 1 (see, U.S. Patent No. 5,922,576) to create pDV77.

Second, *E. coli* strain BJ5183 was electroporated with a mixture of
10 pDV77 and *Pme*1-linearized pAdTrack as described (U.S. Patent No. 5,922,576; He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete Ad5 genome with E1-, E3-, and fiber-deletions with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full length
15 Ad chromosome was isolated by *Pac*1 digestion, and transfected into the E1- and fiber-complementing 633 cells (Von Seggern *et al.* (2000) *J. Virol.* 74:354-362). The 633 cells were produced by electroporating pDV67 (SEQ ID No. 30, deposited under ATCC accession number PTA-1145) into the E1-2a S8 cells, described above. The recovered virus Ad5.GFP.ΔF was then plaque purified by
20 plating on 633 cells and virus stocks were prepared by freeze-thawing cell pellets.

Ad5-pseudotype particle production

Particles with Ad5 fiber

Ad5-pseudotyped particles were generated by virus growth in 633 cells,
25 which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients (Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C)). For analysis of viral proteins, ten μg of the purified particles were electrophoresed on 8-16% gradient gels and the protein
30 transferred to nylon membranes. The resulting blot was probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells.

-88-

Particles with Ad37 fiber

Cells from the Ad37 fiber producing cell line 705 were infected at approximately 1000 particles/cell with Ad5. β gal. Δ F or with Ad5.GFP. Δ F. Viral particles were isolated and purified over CsCl gradients. The bands were
5 harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C.

Viral protein analyses

For analysis of viral proteins, 10 μ g of purified Ad5. β gal. Δ F particles with no fiber (grown in 293 cells), the Ad5 fiber (grown in 633 cells), or the Ad37
10 fiber (grown in 705 cells) were electrophoresed by 8-16% polyacrylamide gradient SDS-PAGE and the proteins were transferred to nylon membranes. The blot was then probed with α -Ad37 fiber rabbit antibody. Ad5 fiber and penton base were detected by reprobing the blot with polyclonal antibodies raised against recombinant proteins expressed in baculovirus-infected cells (Wickman *et al.* (1993) *Cell* 2:309-319).
15

Adenovirus infection and cell binding assays

Adherent Chang C and A549 cells were infected with GFP expressing Ad5 vectors containing the Ad5 fiber (Ad5.GFP. Δ F/5F) or the Ad37 fiber (Ad5.GFP. Δ F/37F) at 10,000 particles per cell for 3 hours at 37°C, 5% CO₂ in
20 DMEM, 10% FCS. Cells were washed twice with saline and then cultured overnight at 37°C, 5% CO₂. The next day, the cells were detached with buffer containing 0.05% (w/v) trypsin and 0.5 mM EDTA (Boehringer Mannheim) for 5 minutes at 37°C. Suspended cells were washed once with PBS and then resuspended in phosphate-buffered saline (PBS), pH 7.4. GFP fluorescence was
25 measured with a FACScan flow cytometer. A threshold established by the fluorescence of uninfected cells was used to distinguish cells expressing GFP. To assess the role of CAR in Ad infection, 10,000 attached cells were pre-incubated with 180 μ g/ml RmcB, a function-blocking anti-CAR monoclonal antibody (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), in complete DMEM for 1
30 hour at 4°C. A small volume containing Ad5.GFP. Δ F/5F or Ad5.GFP. Δ F/37F was then added at 10,000 particles per cell. The cells were infected for 3 hours, cultured overnight, harvested, and analyzed for GFP expression. Percent

-89-

cells expressing GFP was determined by the percent of cells detected above a threshold set by the fluorescence of uninfected Chang C cells.

To measure adenovirus binding to cells, wild type Ad37 was labeled with ^{125}I using Iodogen (Pierce) according to manufacturer instructions and separated
5 from free ^{125}I by gel filtration as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Binding of radiolabeled wild type Ad37 on Chang C cells was then quantitated as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Non-specific binding was determined by incubating cells and labeled Ad37 particles in the presence of 100-fold concentration of unlabeled Ad37. Specific
10 binding was calculated by subtracting the non-specific binding from the total cpm bound. To examine if divalent cations are required for binding, 10 mM ethylenediaminetetraacetic acid (EDTA) or various concentrations of CaCl_2 , or MgCl_2 were added to cells before incubation with labeled virus. To examine if the receptor for Ad37 is a protein, cells were pretreated with 10 $\mu\text{g}/\text{ml}$ trypsin
15 (GIBCO), subtilisin (Sigma), proteinase K (Boehringer-Mannheim), and bromelain (Sigman) at 37 °C for 1 hour, then washed twice with complete DMEM before adding labeled virus. Cells were >95% viable after protease treatment.

Ad37 binding to conjunctival cells is calcium-dependent. Specific ^{125}I -labeled Ad37 binding to Chang C cells was measured in the presence of 10 mM
20 EDTA and in the presence of varying concentrations of calcium chloride or magnesium chloride. Specific binding was determined by subtracting the nonspecific counts in the presence of 100-fold excess unlabeled virus from the total counts.

Pretreatment of conjunctival cells with proteases inhibits Ad37 binding.
25 Change C cells were pretreated with various proteases for 1 hour before binding ^{125}I -labeled Ad37 to the cells. Nonspecific binding was measured by adding 100-fold unlabeled Ad37 to cells with ^{125}I -labeled Ad37 and subtracting from total counts for specific binding. Percent inhibition represents the difference in specific binding of untreated cells and pretreated cells as a percentage of the
30 specific binding of untreated cells.

-90-

Virus overlay protein blot assay (VOPBA)

For VOPBA of human conjunctival membrane proteins probed with Ad37 in the presence of EDTA or calcium chloride, Chang C membrane fractions were separated by 8% SDS-PAGE and transferred to a PDVF membrane. The

5 membrane was subsequently probed with or without whole Ad37 particles, a polyclonal antibody against Ad37 fiber, and finally a horseradish peroxidase conjugated anti-rabbit antibody, in the presence of EDTA or calcium chloride. Transferred Chang C membrane proteins were probed with recombinant Ad37 knob protein, instead of Ad37 knob, in the presence of calcium chloride.

10 Confluent monolayers of Chang C and A549 cells were detached by scraping, pelleted by centrifugation, and then resuspended in 250 mM sucrose, 20 mM HEPES, pH 7.0, 1 mM EDTA, and 2 μ g/ml aprotinin and leupeptin. Cells were transferred into a dounce homogenizer and disrupted with 30 strokes. Organelles and nuclei were pelleted at 500g for 15 min. Plasma membrane
15 fragments were then pelleted from the supernatant of cell lysates at 200,000g for 1 hour and then resuspended in 10 mM Tris•Cl, pH 8.1, 10 μ g/ml aprotinin and leupeptin.

Cell membranes of Chang C or A549 cells were incubated (1:1) with a 2% SDS, non-reducing buffer and separated on an 8% polyacrylamide gel
20 without boiling. Membrane proteins were then electroblotted onto a PVDF membrane (Immobilon-P) and blocked in 5% (w/v) milk in PBS, pH 7.4, 0.02% Tween-20 (PBS-T). After blocking, the membrane was incubated with 1 μ g/ml wild-type Ad19p or Ad37 in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 , for 1 hour at room temperature. The membrane was then washed once with phosphate-
25 buffered saline, pH 7.4 (PBS), 1 mM CaCl_2 , and incubated with 1:500 dilution of α -Ad37 fiber rabbit antibody in 0.5% (w/v) milk in PBS-T, 1mM CaCl_2 , for 30 minutes at room temperature. The membrane was washed again with PBS, 1 mM CaCl_2 , and incubated with 1:5000 dilution of horseradish peroxidase (HRP) conjugated α -rabbit antibody (Sigma) in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 ,
30 for 30 minutes at room temperature. The membrane was washed four times in PBS, 1 mM CaCl_2 , once with PBS-T, 1 mM CaCl_2 , and once in 1 mM CaCl_2 . The blot was developed with enhanced chemiluminescence reagents (Pierce) for 5

-91-

minutes and placed onto a piece of Biomax film (Kodak) for 5 seconds to 1 minute. For divalent metal cation experiments, membranes were incubated in the presence of 2 mM EDTA instead of 1 mM CaCl_2 in all solutions. To assay fiber knob binding to cell membrane proteins, membrane filters were incubated with 1 $\mu\text{g}/\text{ml}$ purified T7-tagged Ad37 knob protein in Tris-buffered saline, 0.1% Tween-20, 1 mM CaCl_2 , for 1 hour at room temperature. α -Ad37 fiber rabbit antibody and HRP-conjugated anti-rabbit antibody were applied and the membrane was developed with substrate solution as described above.

Results: Comparison of adenovirus infection of human conjunctival and lung epithelial cells with virus particles retargeted with Ad5 or Ad37 fiber proteins

Packaging cell lines producing the Ad37 fiber protein were generated. Since the N-terminal amino acid sequences of the Ad5 and Ad37 fiber proteins differ significantly, and to ensure that the Ad37 fiber would be efficiently incorporated into Ad5 vector particles, several residues in the wild-type Ad37 fiber were mutated to more closely match the Ad5 sequence. Stable cell lines producing this fiber under control of the CMV promoter and the adenovirus type 5 tripartite leader were then generated and screened for fiber expression by indirect immunofluorescence. One clone (line 705), which expressed the Ad37 fiber at a high level, was selected for further study.

Cells from one cell line 633, which expresses the wild-type Ad5 fiber protein, and line 705 were infected with a fiber-deleted Ad5 vector carrying a β galactosidase reporter gene. The resulting vector particles contained the Ad5 fiber protein (Ad5. β gal. Δ F/5F) and the Ad37 fiber protein (Ad5. β gal. Δ F/37F), respectively. Incorporation of the correct fiber protein into viral particles was verified by Western blotting. Adenoviral vectors containing the GFP reporter gene, Ad5.GFP. Δ F/5F and Ad5.GFP. Δ F/37F, were created in the same fashion.

Infection of a variety of cell types using the retargeted adenovirus particles was examined. As assayed by GFP fluorescence, Ad5.GFP. Δ F/5F exhibited good gene delivery to lung epithelial (A549) and conjunctival cells (Chang C). In contrast, Ad5.GFP. Δ F/37F efficiently delivered GFP to Chang C cells, but exhibited very poor gene delivery to A549 cells. Although CAR is expressed on the surface of A549 cells, as indicated by AD5.GFP. Δ F/5F

-92-

infection, Ad5.GFP. Δ F/37F was unable to infect these cells efficiently. This experiment shows that the Ad37 fiber protein can confer preferential infection of human conjunctival cells, but not CAR-expressing human lung epithelial cells.

Hence CAR is not the primary receptor for Ad37. Recent studies reported
5 that expression of CAR on the surface of chinese hamster ovary (CHO) cells did not improve Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 does not use CAR as a primary receptor. In order to verify this on human conjunctival cells, A549 and Chang C cells were pretreated with RmcB (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), a function-blocking monoclonal
10 antibody against CAR. The RmcB antibody inhibited infection of A549 cells by Ad5.GFP. Δ F/5F, but it had little effect on infection of Chang C cells by Ad5.GFP. Δ F/37F. This indicates that CAR is not the primary receptor for Ad37 on Chang C conjunctival cells.

Ad37 binding to conjunctival cells requires divalent metal cations. It has
15 been proposed (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) that a combination of fiber binding to CAR and penton base binding to α_v -integrins allows some adenovirus serotypes to attach to cells. Although α_v -integrin binding to the RGD motif of the adenovirus penton base is of relatively low affinity (Wickman *et al.* (1993) *Cell* 2:309-319), it may nonetheless contribute to viral attachment to the
20 cell surface. Ad37 shows a particularly strong affinity for binding to integrin $\alpha_v\beta_5$ (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675), suggesting that integrin $\alpha_v\beta_5$ might be a primary receptor for Ad37. Binding of the RGD motif by α_v -integrins requires the presence of divalent cations, such as calcium or magnesium (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531). In contrast, no divalent cations were
25 required for binding in the CAR-Ad12 knob complex (Bewley *et al.* (1999) *Science* 286:1579-1583).

To investigate the potential role of α_v -integrins and divalent metal cations in Ad37 receptor binding, 125 I-labeled Ad37 binding to Chang C cells was examined in the absence or presence of EDTA. EDTA inhibited Ad37 binding to
30 conjunctival cells but did not alter Ad5 binding. These findings suggest a requirement for divalent metals for Ad37 binding.

-93-

The presence of either calcium or magnesium ions helps $\alpha_v\beta_5$ organize in focal contacts (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531), suggesting that calcium and magnesium aid in integrin $\alpha_v\beta_5$ function. To further test the potential role of integrin $\alpha_v\beta_5$ in Ad37 cell attachment, ^{125}I -labeled Ad37 binding
5 to Chang C cells was measured in the presence of varying concentrations of calcium or magnesium chloride. Magnesium ions had little effect on Ad37 binding to Chang C cells. In contrast, calcium ions dramatically enhanced Ad37 binding to Chang C cells. The optimal concentration of calcium chloride for Ad37 binding was 1 mM, while higher concentrations of calcium actually
10 decreased virus binding to cells. The fact that calcium, but not magnesium, promoted Ad37 attachment is not consistent with integrin $\alpha_v\beta_5$ as the primary receptor for viral attachment to the cells since either metal will support ligand binding to integrin $\alpha_v\beta_5$. Moreover, A549 cells express abundant α_v -integrins (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675) but were unable to support
15 efficient binding of Ad37.

Wild-type Ad37 particles bind to three conjunctival membrane proteins. Recent studies reported that protease treatment of CHO cells abolished Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 bound to a protein receptor on CHO cells. Scatchard analysis of Ad37 binding to Chang C
20 cells showed that each cell expresses approximately 24,000 fiber binding sites (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). To determine if the Ad37 binding site on human conjunctival cells is also a protein, Chang C cells were treated with different proteases prior to measuring binding of ^{125}I -labeled Ad37. Digestion of surface proteins by all four proteases inhibited Ad37 binding to
25 Chang C cells by greater than 50%. This finding showed that Ad37 also binds to a protein receptor on Chang C cells.

Virus overlay protein blot assays (VOPBAs) were used to identify candidate viral protein receptors. This Western blot technique uses intact viral particles in place of antibodies to probe viral-receptors interactions. VOPBA was
30 used herein to identify Chang C membrane proteins that bind to Ad37. In the absence of Ad37 particles, no protein bands were observed, while addition of virus in the absence of calcium revealed binding to a single 45 kDa protein. In

-94-

the presence of 1 mM calcium chloride, Ad37 reacted with three proteins with approximate molecular weights of 45, 50 and 60 kDa. The same three proteins were detected using a recombinant Ad37 fiber knob alone, indicating that Ad37-receptor interactions are fiber mediated and do not involve interactions of other capsid proteins such as the penton base. The size of the calcium-independent protein (45 kDa) is very similar to the known molecular weight of CAR. A direct comparison of the Ad37 VOPBA and a CAR Western blot showed that the 45 kDa receptor co-migrates with CAR on SDS-PAGE. Moreover, two other members of subgroup D adenoviruses, Ad9 and Ad15, have been shown to bind to CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915).

Since CAR does not appear to mediate Ad37 binding on intact Chang C cells, the possibility that the 50 or 60 kDa protein serves this function was tested by examining an adenovirus serotype that does not bind to Chang C cells. Ad19p, a closely related subgroup D adenovirus, binds poorly to Chang C cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) and Ad19p recognition of the Ad37 receptor is therefore unlikely. Ad19p particles bound to the 45 and 60 kDa receptors in the VOPBA, but did not bind to the 50 kDa receptor. Moreover, the 50 kDa receptor is expressed on Chang C cells, but not A549 cells, which only support low levels of Ad37 binding and infection. Taken together, these data indicate that the 50 kDa protein is a primary candidate receptor for Ad37 on human conjunctival cells.

Discussion

The identification of the CAR protein as a major adenovirus receptor does not explain why certain subgroup D members, such as Ad37, preferentially infect ocular cells. A 50 kDa human conjunctival cell membrane protein is identified herein as a primary candidate for the receptor for Ad37. This 50 kDa protein is not present on A549 lung epithelial cells. Ad37 binding to this receptor is calcium-dependent, which is consistent with Ad37 binding and infection experiments. Ad37 also bound to a 60 kDa protein that is present on human conjunctival and lung epithelial cells. It does not, however, appear to be serotype specific. The molecular weights of MHC class I heavy chain, which has been proposed as a receptor for Ad5, and $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins, receptors for

-95-

the penton base, are distinct from the 50 or to kDa receptor characterized in this study.

The studies of Ad37-receptor interaction using VOPBAs are consistent with previous studies showing that subgroup D adenoviruses can bind to the extracellular domain of CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). Biochemical and structural studies on knob-CAR interactions indicate that the CAR binding site is located on the AB-loop of the fiber knob. Alignment of the fiber sequences of Ad37 and other adenoviruses reveals that the AB-loop of Ad37 is similar to those of Ad12 and Ad5. Moreover, a phylogenetic tree of adenovirus knobs (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) shows that fiber proteins of subgroup D are similar to those of subgroup C and E, which use CAR as their primary receptor. Ad37 does not, however, appear to effectively use CAR as a primary receptor, as demonstrated by virus binding and infection studies on Chang C conjunctival cells and A549 lung epithelial cells.

It has been reported that Ad37 uses sialic acid as a receptor on chinese hamster ovary (CHO) cells and human lung carcinoma (A549) cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). Human conjunctival cells were not studied. Human corneal epithelial (HCE) cells were the only ocular cell line studied and Ad37 binds relatively poorly to these cells, compared to binding on A549 cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). In addition, $8,4 \times 10^7$ wheat germ agglutinin molecules per cell were required to significantly inhibit Ad37 binding to sialic acid on sialic acid positive CHO cells (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), three orders of magnitude higher than the number of Ad37 receptors on Chang C conjunctival cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Clearly, sialic acid is not the only factor responsible for Ad37 binding to the cell surface and its influence on Ad37 tropism is unclear.

The results herein show that Ad37 selects a 50 kDa cellular receptor for binding to conjunctival cells, but it is possible that sialic acid also plays a role in this interaction. The characterization and identification of the Ad37 receptor have therapeutic implications and also explain the different tropism of Ad37. The 50 kDa receptor for Ad37 may also be the receptor for other subgroup D adenoviruses that cause severe cases of EKC, Ad19a and Ad8. Ad19p is a

-96-

nonpathogenic variant of Ad19 (Arnberg *et al.* (1998) *Virology* 227:239-244) while Ad19A, along with Ad8 and Ad37, are major causes of EKC. Ad19a and Ad37 have identical fiber proteins (Arnberg *et al.* (1998) *Virology* 227:239-244) and have similar tropism in vivo. Ad8, Ad19a, and Ad37 agglutinate dog and guinea pig erythrocytes more effectively than four other serotypes that are associated with less severe forms of conjunctivitis (Arnberg *et al.* (1998) *Virology* 227:239-244), implying that the receptors of Ad18, Ad19A, and Ad37 have similar characteristics. Hence, this 50 kDa receptor is an attractive drug target against EKC caused by adenoviruses to provide therapeutic intervention of ocular diseases associated with these viruses.

EXAMPLE 10

Targeting of the Ad5 vector to photoreceptor cells

The fiber-deleted adenovirus vector Ad5.GFP.ΔF was propagated in 705 cells, which express a modified Ad37 fiber protein. Viral particles (Ad5.GFP.Δf/37F) were harvested, CsCl-purified and dialized into 0.9% NaCl, 10 mM Tris, pH 8.1, and 10% glycerol. Two to three μ l of the resulting solution, containing approximately 1×10^9 particles/ μ l was injected into the vitreous chamber of a mouse eye. Seven days post-injection, eyes were harvested, fixed with paraformaldehyde and cryo-sectioned. Sections were stained with an anti-rhodopsin antibody to identify photoreceptor cells and with DAPI to show all cell nuclei. The resulting sections showed red anti-rhodopsin staining in the photoreceptors, blue DAPI-stained nuclei, and green GFP staining in any transduced cells. The results revealed substantially exclusive transduction of photoreceptors. Co-localization of rhodopsin staining and GFP expression indicated selective transduction of photoreceptor cells.

As a control, contralateral eyes were injected with a stock of the fiber-deleted vector AD5.βgal.ΔF grown in the same Ad37 fiber-expressing cells. Since this virus (Ad5.βgal.ΔF/37F) produces βgal rather than GFP, the green staining is absent from the photoreceptors.

Additional experiments using the AD37 fiber for targeting to the photoreceptor cells have been performed. Subretinal and intravitreal injection have been used in mouse models and the results demonstrate targeting to the

-97-

photoreceptors. As with intravitreally injected eyes, the major cell type infected via subretinal administration was the photoreceptor.

As noted, Ad5.GFP. Δ F /37F infected Chang C cells efficiently, but A549 cells poorly. Ad37 fiber protein confers preferential infection on human
5 conjunctival cells, but not CAR-expressing human lung epithelial cells. Binding to conjunctival cells requires divalent cations.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-98-

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule, comprising:
adenovirus inverted terminal repeat sequences; an adenovirus packaging
signal operatively linked thereto; and a photoreceptor-specific promoter.
- 5 2. The isolated nucleic acid molecule of claim 1, further comprising a
nucleic acid encoding a therapeutic product operatively linked to the promoter.
3. The isolated nucleic acid molecule of claim 1, wherein the
promoter is a rhodopsin promoter.
4. The nucleic acid molecule of claim 1, wherein the adenovirus
10 genome does not encode a functional fiber protein such that packaging the
nucleic acid requires complementation in a packaging cell.
5. A recombinant adenovirus vector, comprising the nucleic acid
molecule of any of claims 1-4 packaged therein.
6. A recombinant adenovirus vector of claim 5, wherein inverted
15 terminal repeat sequences (ITR) and a packaging signal are derived from
adenovirus type 2 or adenovirus type 5.
7. A recombinant adenovirus vector of claim 5, wherein the virus
comprises a fiber protein.
8. A recombinant adenovirus vector of claim 7, wherein the fiber
20 protein selectively binds to photoreceptors in the eye of a mammal.
9. A recombinant adenovirus vector of claim 7, wherein the fiber is a
chimera composed of N-terminal sequences from adenovirus type 2 or type 5,
and a sufficient portion of an adenovirus serotype D fiber for selective binding to
photoreceptors in the eye of a mammal.
- 25 10. A method for targeted delivery of a gene product to the eye of a
mammal, comprising:
administering a recombinant adenovirus virus that comprises heterologous
DNA encoding the gene product or resulting in expression of the gene product,
wherein the recombinant virus comprises a fiber protein that specifically or
30 selectively binds to receptors that are expressed on cells in the eye.

-99-

11. The method of claim 10, wherein the cells are photoreceptors.

12. The method of claim 10, wherein administration is effected by intraocular delivery.

13. The method of claim 10, wherein administration is effected by a method selected from subretinal injection, intravenous administration, periorbital administration, and intravitreal administration.

14. The method of claim 10, wherein the recombinant virus comprises a fiber protein from an adenovirus type D serotype.

15. The method of any of claims 10-14, wherein the fiber protein is an adenovirus type 37.

16. The method of any of claims 10-14, wherein the fiber is a chimeric protein containing a sufficient portion of the N-terminus of an adenovirus type 2 or type 5 fiber protein for interaction with an adenovirus type 2 or type 5 penton, and a sufficient portion of an adenovirus serotype D knob portion of the fiber for selective binding to photoreceptors in the eye of a mammal.

17. The method of any of claims 10-16, wherein the recombinant virus is an adenovirus type D serotype.

18. The method of any of claims 10-17, wherein the encapsulated nucleic acid comprises a photoreceptor-specific promoter operatively linked to a nucleic acid comprising the therapeutic product.

19. The method of claim 18, wherein the therapeutic product is selected from the group consisting of a trophic factor, an anti-apoptotic factor, a gene encoding a rhodopsin protein, a wild-type Stargardt disease gene (STDG1), an anti-cancer agent and a protein that regulates expression of a photoreceptor-specific gene product.

20. The method of any of claims 10-19, wherein delivery is effected for treatment of an ocular disease.

21. The method of claim 20, wherein the disorder is a retinal degenerative disease.

22. The method of claim 20, wherein the disease is retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma.

-100-

23. The method of any of claims 10-22, wherein the mammal is a human.

24. The method of any of claims 10-22, wherein the viral nucleic acid comprises:

- 5 an adenovirus inverted terminal repeat (ITR) sequences; and
 an adenovirus packaging signal operatively linked thereto.

25. The method of claim 24, wherein the ITRs and packaging signal are derived from an adenovirus serotype B or C.

26. The method of claim 24, wherein the ITRs and packaging signal
10 are derived from an adenovirus type 2 or 5.

27. The method of claim 24, wherein the viral nucleic acid further comprises a photoreceptor-specific promoter.

28. A method of targeted gene therapy, comprising:
 administering a recombinant viral vector that comprises an adenovirus
15 type 37 fiber protein or portion thereof, whereby the vector selectively transduces photoreceptors and delivers a gene product encoded by the recombinant viral vector; wherein the portion is sufficient for selective binding to photoreceptors.

29. The method of claim 28, wherein the vector is administered into
20 the eye.

30. The method of claim 28, wherein the vector is administered to the vitreous cavity of the eye.

31. The method of claim 28, wherein administration is effected by subretinal injection, intravenous administration, periorbital administration or
25 intravitreal administration.

32. The method of any of claims 10-31, wherein at least about 10^7 plaque forming units of virus are administered.

33. The method of any of claims 10-31, wherein about 1 plaque forming unit to about 10^{14} plaque forming units of virus are administered.

SEQUENCE LISTING

<110> VON SEGGERN, DANIEL
NEMEROW, GLEN R.
FRIEDLANDER, MARTIN

<120> VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY

<130> 756.1PCT/NOV0205P

<140>
<141> 2001-05-01

<150> 09/562,934
<151> 2000-05-01

<160> 51

<170> PatentIn Ver. 2.1

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 1
cggtacacag aattcaggag acacaactcc 30

<210> 2
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 2
gcctggatcc gggaagttac gtaacgtggg aaaac 35

<210> 3
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: linker

<400> 3
cgcggtatccg cg 12

<210> 4
<211> 8710
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 4

```

cacctaaatt gtaagcggtta atatTTTTgtt aaaatttcgcg ttaaattttt gttaaattcag 60
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 120
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaactgga 180
ctccaacgct aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc 240
accctaataca agtTTTTtgg ggtcgaggtg ccgtaaagca ctaaactcga accctaaagg 300
gagccccga tttagagctt gacggggaaa gccggcgaaac gtggcgagaa aggaagggaa 360
gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgt gcggtcacgc tgcgcgtaac 420
caccacaccc gccgcgctta atgcgcgcgt acagggcgcg tcccattcgc cattcaggtc 480
gcgcaactgt tgggaagggc gatcggtgcg ggctctctcg ctattacgcc agctggcgaa 540
aggggggatgt gctgcaaggc gattaagtgt ggtaacgcc gggttttccc agtcacgacg 600
ttgtaaaacg acggccagtg aattgtaata cgactcacta tagggcgaat tgggtaccgg 660
gccccccctc gaggtcgacg gtatcgataa gcttgatatt gaattcagga gacacaactc 720
caagtgcata ctctatgtca ttttcatggg actgggtctg ccacaactac attaatgaa 780
tatttgccac atcctcttac actttttcat acattgccca agaataaaga atcgtttgtg 840
ttatgtttca acgtgtttat ttttcaattg cagaaaaatt caagtcattt ttcattcagt 900
agtatagccc caccaccaca tagcttatac agatcacctg accttaatac aactcacaga 960
accctagtat tcaacctgcc acctccctcc caacacacag agtacacagt cttttctccc 1020
cggctggcct taaaaagcat catatcatgg gtaacagaca tattcttagg tgttatattc 1080
cacacgggtt cctgtcgagc caaacgctca tcagtgatat taataaactc cccgggcagc 1140
tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgctgtcc aacttgcggt 1200
tgcttaacgg gcggcgaaagg agaagtccac gcctacatgg gggtagagtc ataactgtgc 1260
atcaggatag ggcgggtgtg ctgcagcagc gcgcgaataa actgctgccc cgcccgctcc 1320
gtcctgcagg aatacaacat ggcagtggtc tcctcagcga tgattcgcac cgcccgagc 1380
ataaggcgct ttgtcctccg ggcacagcag cgcacctga tctcacttaa atcagcagag 1440
taactgcagc acagcaccac aatattgttc aaaatcccac agtgcaaggc gctgtatcca 1500
aagctcatgg cggggaccac agaaccacag tggccatcat accacaagcg caggtagatt 1560
aagtggcgac cctcataaa cacgctggac ataaacatta cctcttttgg catgttgtaa 1620
ttcaccacct cccgtacca tataaacctc tgattaaaca tggcgccatc caccaccatc 1680
ctaaaccagc tggccaaaaa ctgcccgcgc gctatacact gcagggaacc gggactggaa 1740
caatgacagt ggagagccca ggactcgtaa ccatggatca tcatgctcgt catgatatac 1800
atgttggcac aacacaggca cacgtgcata cacttcctca ggattacaag ctccctccgc 1860
gttagaacca tatcccaggg aacaacccat tcctgaatca gcgtaaatcc cacactgcag 1920
ggaagacctc gcacgtaact cacgttgtgc attgtcaaaag tgttacattc gggcagcagc 1980
ggatgatcct ccagtatggg agcgcgggtt tctgtctcaa aaggaggtag acgatcccta 2040
ctgtacggag tgcgcgaga caaccgagat cgtgttggtc gtagtgtcat gccaaatgga 2100
acgccggagc tagtcatatt tctgaagca aaaccaggtg cgggcgtgac aaacagatct 2160
gcgtctccgg tctcgccgct tagatcgctc ttgttagtag ttgtagtata tccactctct 2220
caaagcatcc aggcgcctcc tggttcggg tcttatgtaa actccttcac gcgcgctg 2280
cctgataaca tccaccaccg cagaataagc cacaccagc caacctacac attcgttctg 2340
cgagtacac acgggaggag cgggaagagc tgggaagaacc atgtttttt ttttattcca 2400
aaagattatc caaaacctca aaatgaagat ctattaagtg aacgcgctcc cctccggtgg 2460
cgtgggtcaa ctctacagcc aaagaacaga taatggcatt tgtaagatgt tgcacaatgg 2520
cttccaaaag gcaaacggcc ctacgtcca agtggacgta aaggctaaac ccttcagggt 2580
gaatctctc tataaacatt ccagcacctt caacctatgc caaataattc tcatctcgcc 2640
acctctctca tatatctcta agcaaatccc gaatatgaag tccggccatt gtaaaaaatc 2700
gctccagagc gccctccacc ttcagcctca agcagcgaat catgattgca aaaattcagg 2760
ttctcacag acctgtataa gattcaaaag cggaacatta acaaaaatac cgcgatcccc 2820
taggtccctt cgcaggggcca gctgaacata atcgtgcagg tctgcacgga ccagcgcggc 2880
cacttccccg ccaggaacct tgacaaaaga acccacactg attatgacac gcatactcgg 2940
agctatgcta accagcgtag ccccgatgta agctttgttg catgggcggc gatataaaat 3000
gcaaggtgct gctcaaaaaa tcaggcaagg cctcgcgcaa aaaagaaagc acatcgtagt 3060
catgctcatg cagataaagg caggtaaagt ccggaaccac cacagaaaaa gacaccattt 3120
ttctctcaaa catgtctgcg ggtttctgca taaacacaaa ataaaaatac aaaaaaacat 3180
ttaaaccatta gaagcctgtc ttacaacagg aaaaacaacc cttataagca taagacggac 3240
tacggccatg ccggcgtgac cgtaaaaaaa ctggtcaccg tgattaaaaa gcaccaccga 3300
cagctcctcg gtcgatgccg gagtcataat gtaaacacat gtaaacacat caggttgatt 3360
catcggtcag tgctaaaaag cgaccgaaat agccgggggg aatacatacc cgcaggcgta 3420
gagacaacat tacagcccc ataggaggta taacaaaatt aataggagag aaaaacacat 3480
aaacacctga aaaacctcc tgcctaggca aaatagcacc ctcccgtcc agaacaacat 3540

```

acagcgcttc	acagcggcag	cctaacagtc	agccttacca	gtaaaaaaga	aaacctatta	3600
aaaaaacacc	actcgacacg	gcaccagctc	aatcagtcac	agtgtaaaaa	agggccaagt	3660
gcagagcgag	tatatatagg	actaaaaaat	gacgtaacgg	ttaaaagcca	caaaaaaacac	3720
ccagaaaacc	gcacgcgaac	ctacgcccag	aaacgaaagc	caaaaaaccc	acaacttcct	3780
caaatcgta	cttcgcgtttt	cccacgttac	gtaacttccc	ggatccgcgg	cattcacagt	3840
tctccgcaag	aattgattgg	ctccaattct	tggagtggtg	aatccgttag	cgaggtgccg	3900
ccggcttcca	ttcaggtcga	ggtggcccg	ctccatgcac	cgcgacgcaa	cgcggggagg	3960
cagacaagg	atagggcg	gcctacaatc	catgccaa	cgttccatgt	gctcgccgag	4020
gcggcataaa	tcgcccgtgac	gatcagcgg	ccagtgatcg	aagttaggct	ggtaagagcc	4080
gcgagcgatc	cttgaagctg	tccctgatgg	tcgtcatcta	cctgcctgga	cagcatggcc	4140
tgcaacgcgg	gcattcccga	gccgcggaa	gcgagaagaa	tcataatggg	gaaggccatc	4200
cagcctcgcg	tcgcgaacgc	cagcaagacg	tagcccagcg	cgtcgcccg	catgccctgc	4260
ttcatccccg	tggcccggtt	ctcgcggtt	ctggcggtgt	ccccggaaga	aatatatatt	4320
catgtcttta	gttctatgat	gacacaaacc	ccgcccagcg	tcttgtcatt	ggcgaattcg	4380
aacacgcaga	tgcagtcggg	gcggcgcggt	cccaggtcca	cttcgcatat	taagggtgac	4440
cgtgtggcct	cgaacaccga	gcgaccctgc	agcgaccgcg	ttaacagcgt	caacagcgtg	4500
ccgcagatcc	cgggcaatga	gatattgaaa	agcctgaact	caccgcgacg	tctgtcgaga	4560
agtttctgat	cgaaaagttc	gacagcgtct	ccgacctgat	gcagctctcg	gagggcgaa	4620
aatctcgtgc	tttcagcttc	gatgtaggag	ggcgtggata	tgtcctgcgg	gtaaatagct	4680
gcgccgatgg	tttctacaaa	gatcgttatg	tttatcgga	ctttgcatcg	gccgcgctcc	4740
cgattccgga	agtgcctgac	attggggaat	tcagcgagag	cctgacctat	tgcattctcc	4800
gccgtgcaca	gggtgtcacg	ttgcaagacc	tgccgtgaa	cgaactgccc	gctgttctgc	4860
agccggtcgc	ggaggccatg	gatgcgatcg	ctgcggccga	tcttagccag	acgagcgggt	4920
tcggcccatt	cggaccgcaa	ggaatcggtc	aatacactac	atggcgatg	ttcatatgcg	4980
cgattgctga	tccccatgtg	tatcactggc	aaactgtgat	ggacgacacc	gtcagtgcgt	5040
ccgtcgcgca	ggctctcgat	gagctgatgc	tttgggcccga	ggactgcccc	gaagtccggc	5100
acctcgtgca	cgcggatttc	ggctccaaca	atgtccctgac	ggacaatggc	cgcataaacg	5160
cggtcattga	ctggagcgag	gcgatgttcg	gggattccca	atacgaggtc	gccaacatct	5220
tcttctggag	gccgtgggtt	gcttggtatg	agcagcagac	gcgctacttc	gagcggaggc	5280
atccggagct	tgcaggatcg	ccgcggctcc	gggcgtatat	gctccgcatt	ggtccttgacc	5340
aaacttatca	gacgttgggt	gacggcaatt	tcgatgatgc	agcttggggc	cagggtcgat	5400
gcgacgcaat	cgctccgatcc	ggagccggga	ctgtcgggcg	tacacaaatc	gcccgcagaa	5460
gcgcggccgt	ctggaccgat	ggctgtgtag	aagtactcgc	cgatagtggg	aaccgacgcc	5520
ccagcactcg	tccgagggca	aaggaatagg	ggagatgggg	gaggctaact	gaaacacgga	5580
aggagacaat	accggaagga	acccgcgcta	tgacggcaat	aaaaagacag	aataaaacgc	5640
acgggtgttg	gtcgttttgt	tcataaacgc	ggggttcgg	cccagggtcg	gcactctgtc	5700
gataccccac	cgagacccca	ttggggccaa	tacgcccgcg	tttcttccct	ttccccaccc	5760
caccccccaa	gttcgggtga	aggcccagg	ctcgacgcca	acgtcggggc	ggcaggccct	5820
gccatagcca	ctggccccgt	gggttaggga	cgggggtccc	catgggggaat	ggtttatggt	5880
tcgtgggggt	tattattttg	ggcgttgctg	ggggtctggt	ccacgactgg	actgagcaga	5940
cagacccatg	gtttttggat	ggcctgggca	tggaccgcat	gtactggcgc	gacagcaaca	6000
ccgggcgtct	gtggctgcca	aacacccccg	acccccaaaa	accaccgcgc	ggatttctgg	6060
cgcccagtcg	cgtcgaccgg	tcattggctgc	gccccgacac	ccgccaacac	ccgctgacgc	6120
gccctgacgg	gcttgtctgc	tcccggcatc	cgcttacaga	caagctgtga	ccgtctccgg	6180
gagctgcatg	tgtcagaggt	tttcaccgtc	atcacgaaa	cgcgcgaggc	agccggatca	6240
taatcagcca	taccacattt	gtagagggtt	tacttgcttt	aaaaaacctc	cccacctccc	6300
cctgaacctg	aaacataaaa	tgaatgcaat	tgttggtgtt	aacttgttta	ttgcagctta	6360
taatggttac	aaataaagca	atagcatcac	aaatttcaca	aataaagcat	ttttttcact	6420
gcattctagt	tgtggtttgt	ccaaactcat	caatgtatct	tatcatgtct	ggatccacta	6480
gttctagagc	ggccgccacc	gcgggtggagc	tccagctttt	gttcccttta	gtgaggggta	6540
atctcgagct	tggcgtaatc	atggctcatag	ctgtttcctg	tgtgaaattg	ttatccgctc	6600
acaattccac	acaacatacg	agccggaagc	ataaagtgtg	aagcctgggg	tgccataatga	6660
gtgagctaac	tcacattaat	tgcggttgccg	tcactgcccg	ctttccagtc	gggaaacctg	6720
tcgtgccagc	tgcattaatg	aatcgccaa	cgcgcgggga	gaggcggttt	gcgtattggg	6780
cgctcttccg	cttcctcgct	cactgactcg	tcgctcggt	tcgttcggct	gcggcgagcg	6840
gtatcagctc	actcaaaggc	ggtaatacgg	ttatccacag	aatcagggga	taacgcagga	6900
aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaacc	gtaaaaaggc	cgcggttgctg	6960
gcgtttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	ctcaagtcag	7020
aggtggcgaa	accgcacagg	actataaaga	taccaggcgt	ttccccctgg	aagctccctc	7080
gtgcgctctc	ctgttccgac	cctgcccgtt	accggatacc	tgtccgcctt	tctcccttcg	7140
ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggtatc	tcagttcggt	gtaggtcggt	7200
cgctccaagc	tgggctgtgt	gcacgaacc	cccgttcagc	ccgaccgctg	cgccttatcc	7260

```

ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc 7320
actggtaaca ggattagcag agcgaggatg gtaggcgggtg ctacagagtt cttgaagtgg 7380
tggcctaact acggctacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca 7440
gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500
ggtaggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggatt 7620
ttgggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680
tttaaatcaa tctaaagtat atatgagtâa acttggtctg acagttacca atgcttaatc 7740
agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800
gtcgtgtaga taactacgat acgggagggc ttaccatctg gcccagtgac tgcaatgata 7860
ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920
gccgagcgca gaagtgggtc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980
cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacggttg tgccattgct 8040
acaggcatcg tgggtgtcacg ctcgctggtt ggtatggctt cattcagctc cggttcccaa 8100
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcgggttag ctccctcggg 8160
cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggg tatggcagca 8220
ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtagtagc 8280
tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca 8340
atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacct 8460
actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca 8520
aaaacaggaa ggcaaaatgc cgcaaaaaaag ggaataaggg cgacacggaa atgttgaata 8580
ctcatactct tcctttttca atattattga agcatttatc agggttattg tctcatgagc 8640
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc 8700
cgaaaagtgc                                     8710

```

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 5
atgggatcca agatgaagcg cgcaagaccg 30

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
cataacgcgg ccgcttcttt attcttgggc 30

<210> 7
<211> 7148
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 7
gacggatcgg gagatctccc gatccccat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttaggggtag	gcgtttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cggttgacatt	240
gattattgac	tagttatttaa	tagtaatcaa	ttacgggggc	attagttcat	agcccatata	300
tggagtcccg	cgttacataa	cttacggtaa	atggcccgc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacggcc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcgggttg	660
actcacgggg	attttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaattgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttgggtacc	900
gagctcggat	ccaagatgaa	gcgcgcaaga	ccgtctgaag	ataccttcaa	ccccgtgtat	960
ccatatgaca	cggaaaccgg	tcttccaact	gtgccttttc	ttactcctcc	ctttgtatcc	1020
cccaatgggt	ttcaagagag	tccccctggg	gtactctctt	tgcgcctatc	cgaacctcta	1080
gttacctcca	atggcatgct	tgcgctcaaa	atgggcaacg	gcctctctct	ggacgaggcc	1140
ggcaacctta	cctcccaaaa	gttaaccact	gtgagcccac	ctctcaaaaa	aaccaagtca	1200
aacataaacc	tggaaatatc	tgcacccctc	acagttacct	cagaagccct	aactgtggct	1260
gccgccgcac	ctctaattggt	cgcgggcaac	acactcacca	tgcaatcaca	ggccccgcta	1320
accgtgcacg	actccaaact	tagcattgcc	acccaaggac	ccctcacagt	gtcagaagga	1380
aagctagccc	tgcaaacatc	aggccccctc	accaccaccg	atagcagtac	ccttactatc	1440
actgcctcac	ccctctaac	tactgccact	ggtagcttgg	gcattgactt	gaaagagccc	1500
atztatacac	aaaatggaaa	actaggacta	aagtacgggg	ctcctttgca	tghtaacagac	1560
gacctaaaca	ctttgaccgt	agcaactggt	ccagggtgtga	ctattaataa	tacttccttg	1620
caaactaaag	ttactggagc	cttggggttt	gattcacaag	gcaatatgca	acttaatgta	1680
gcaggaggag	taaggattga	ttctcaaaac	agacgcctta	tacttgatgt	tagttatccg	1740
tttgatgctc	aaaaccaact	aaatctaaga	ctaggacagg	gccctctttt	tataaactca	1800
gcccacaact	tggatattaa	ctacaacaaa	ggcctttact	tgtttacagc	ttcaaacaat	1860
tccaaaaagc	ttgagggttaa	cctaagcact	gccaaggggt	tgatgtttga	cgctacagcc	1920
atagccatta	atgcaggaga	tgggcttgaa	tttggttcac	ctaattgcacc	aaacacaaa	1980
ccctcaaaa	caaaaattgg	ccatggccta	gaatttgatt	caaacaaggc	tatggttcct	2040
aaactaggaa	ctggccttag	ttttgacagc	acaggtgcca	ttacagtagg	aaacaaaaat	2100
aatgataagc	taactttgtg	gaccacacca	gctccatctc	ctaactgtag	actaaatgca	2160
gagaaagatg	ctaaactcac	tttgggtctta	acaaaatgtg	gcagtcaaat	acttgctaca	2220
gtttcagttt	tggctgttaa	aggcagtttg	gctccaatat	ctggaacagt	tcaaagtgtc	2280
catcttatta	taagatttga	cgaaaattga	gtgctaacta	acaatttcctt	cctgggacca	2340
gaatattgga	acttttagaaa	tggagatctt	actgaaggca	cagcctatac	aaacgctgtt	2400
ggatttatgc	ctaacttatc	agcttatcca	aaatctcacg	gtaaaactgc	caaaagtaac	2460
attgtcagtc	aagtttactt	aaacgggagc	aaaactaaac	ctgtaacact	aaccattaca	2520
ctaaacggta	cacaggaac	aggagacaca	actccaagtg	catactctat	gtcattttca	2580
tgggactggg	ctagccacaa	ctacattaat	gaaatatttg	ccacatcctc	ttacactttt	2640
tcatacattg	cccaagaata	aagaagcggc	cgctcgagca	tgcacttaga	gggccctatt	2700
ctatagtgtc	acctaaatgc	tagagctcgc	tgatcagcct	cgactgtgcc	ttctagtgtc	2760
cagccatctg	ttgtttgccc	ctcccccggtg	ccttccttga	ccctggaagg	tgccactccc	2820
actgtccttt	cctaataaaa	tgaggaaaatt	gcctgcatt	gtctgagtag	gtgtcattct	2880
attctggggg	gtgggggtggg	gcaggacagc	aagggggagg	attgggaaga	caatagcagg	2940
catgctgggg	atgcggtggg	ctctatggct	tctgaggcgg	aaagaaccag	ctggggctct	3000
aggggggtatc	cccacgcgcc	ctgtagcggc	gcattaaagc	cggcgggtgt	ggtgggttacg	3060
cgcagcgtga	ccgctacact	tgcacgcgcc	ctagcgcgcc	ctcctttcgc	tttcttccct	3120
tcccttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	taaatcgggg	catcccttta	3180
gggttccgat	ttagtgcctt	acggcacctc	gaccccaaaa	aacttgatta	gggtgatggt	3240
tcacgtagtg	ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	3300
ttctttaata	gtggactctt	gttccaaact	ggaacaacac	tcaaccctat	ctcgggtctat	3360
tcttttgatt	tataagggat	tttggggatt	tccgcctatt	ggttaaaaaa	tgagctgatt	3420
taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	tcagttaggg	tgtggaaagt	3480
ccccaggctc	cccaggcgag	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	3540
aggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcactcfaat	3600
tagtcagcaa	ccatagtccc	gcccctaact	ccgcccattc	cgccttaac	tccgcccagt	3660
tccgcccatt	ctccgcccc	tggctgacta	atttttttaa	tttatgcaga	ggccagggcc	3720
gcctctgcct	ctgagctatt	ccagaagtag	tgaggaggct	tttttggagg	cctagggctt	3780
tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	ctgatcaaga	gacaggatga	3840
ggatcgtttc	gcatgattga	acaagatgga	ttgcacgcag	gttctccggc	cgcttgggtg	3900

gagaggctat	tccggtatga	ctggggcacaa	cagacaatcg	gctgctctga	tggcgccgtg	3960
ttccggctgt	cagcgcaggg	gcgcccgggt	ctttttgtca	agaccgacct	gtccggtgcc	4020
ctgaatgaac	tgcaggacga	ggcagcgcgg	ctatcgtggc	tggccacgac	ggcggttcct	4080
tgcgcagctg	tgctcgacgt	tgctactgaa	gcgggaaggg	actggctgct	attgggcgaa	4140
gtgccggggc	aggatctcct	gtcatctcac	cttgctcctg	ccgagaaagt	atccatcatg	4200
gctgatgcaa	tgcggcggct	gcatacgctt	gacccggcta	cctgcccatt	cgaccacca	4260
gcgaaacatc	gcacgagcg	agcacgtact	cgatggaag	ccggtcttgt	cgatcaggat	4320
gatctggacg	aagagcatca	ggggctcgcg	ccagccgaac	tgttcgccag	gctcaaggcg	4380
cgcatgcccg	acggcgagga	tctcgtcgtg	acccatggcg	atgcctgctt	gccgaatatc	4440
atggtggaaa	atggccgctt	ttctggattc	atcgactgtg	gccggctggg	tgtggcggac	4500
cgctatcagg	acatagcggt	ggctaccggt	gatattgctg	aagagcttgg	cggcgaatgg	4560
gctgaccggt	tctcgtgct	ttacgggtatc	gccgctcccg	attcgcagcg	catcgcttc	4620
tatcgcttc	ttgacgagtt	cttctgagcg	ggactctggg	gttcgaaatg	accgaccaag	4680
cgacgcccc	cctgccatca	cgagatttcg	attccaccgc	cgccttctat	gaaagggttg	4740
gcttcggaat	cgttttccgg	gacgcgggct	ggatgatcct	ccagcgcggg	gatctcatgc	4800
tggagtctct	cgcccacccc	aacttgttta	ttgcagctta	taatggttac	aaataaagca	4860
atagcatcac	aaatttcaca	aataaagcat	ttttttcact	gcattctagt	tgtggtttgt	4920
ccaaactcat	caatgtatct	tatcatgtct	gtataccgtc	gacctctagc	tagagcttgg	4980
cgtaatcatg	gtcatagctg	tttctgtgt	gaaattgtta	tccgctcaca	attccacaca	5040
acatacgagc	cggaaacata	aagtgtaaag	cctgggggtgc	ctaataagtg	agctaactca	5100
cattaattgc	gttgcgctca	ctgcccgtt	tccagtcggg	aaacctgtcg	tggcagctgc	5160
attaatgaat	cggccaacgc	gcggggagag	gcggtttgct	tattgggcgc	tcttccgctt	5220
cctcgctcac	tgactcgctg	cgctcgggtc	ttcggctgct	gcgagcggta	tcagctcact	5280
caaaggcggt	aatacggtta	tccacagaat	caggggataa	cgcaggaaaag	aacatgtgag	5340
caaaaggcca	gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	ttttccata	5400
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	5460
cgacaggact	ataaagatac	caggcgtttc	cccctggaag	ctccctcgtg	cgctctcctg	5520
ttccgaccct	gccgcttacc	ggatacctgt	ccgcctttct	cccttcggga	agcggtggcg	5580
tttctcaatg	ctcacgctgt	aggtatctca	gttcgggtga	ggtcgttcgc	tccaagctgg	5640
gctgtgtgca	cgaacccccc	gttcagcccg	accgctgcgc	cttatccggt	aactatcgtc	5700
ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	5760
ttagcagagc	gaggtatgta	ggcggtgcta	cagagttctt	gaagtgggtg	cctaactacg	5820
gctacactag	aaggacagta	tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	5880
aaagagttgg	tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggg	gggttttttg	5940
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	6000
ctacggggtc	tgacgctcag	tggaaacgaaa	actcacgtta	agggattttg	gtcatgagat	6060
tatcaaaaag	gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aaatcaatct	6120
aaagtatatata	tgagtaaaact	tggcttgaca	gttaccaatg	cttaatcagt	gaggcaccta	6180
tctcagcgat	gtgtctattt	cgttcaccca	tagttgcctg	actcccgcgc	gtgtagataa	6240
ctacgatagc	ggagggctta	ccatctggcc	ccagtgtctg	aatgataccg	cgagaccac	6300
gctcaccggc	tccagatttt	tcagcaataa	accagccagc	cggaaagggc	gagcgcagaa	6360
gtgggtcctgc	aactttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	6420
taagtagttc	gccagttaat	agtttgcgca	acgttggtgc	cattgctaca	ggcatcgtag	6480
tgtcacgctc	gtcgtttggg	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	6540
ttacatgatc	ccccatggtg	tgcaaaaaaag	cggttagctc	cttcggctct	ccgatcgttg	6600
tcagaagtaa	gttgcccgca	gtgttatcac	tcattggtat	ggcagcactg	cataattctc	6660
ttactgtcat	gccatccgta	agatgctttt	ctgtgactgg	tgagtaactca	accaagtcat	6720
tctgagaata	gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	6780
ccgcgccaca	tagcagaact	ttaaaagtgc	tcatcattgg	aaaacgttct	tcggggcgaa	6840
aactctcaag	gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcacca	6900
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	6960
aaaatgccgc	aaaaaaggga	ataagggcga	cacggaaatg	ttgaatactc	atactcttcc	7020
tttttcaata	ttattgaagc	atztatcagg	gttattgtct	catgagcgga	tacatatattg	7080
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	7140
ctgacgtc						7148

<210> 8

<211> 7469

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

```

gacggatcgg gagatctccc gatccccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcy atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcccatg gacgtcaata atgacgtatg ttcccatagt aacgcccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgcccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gcttgggtacc 900
gagctcggat ctgaattcga gctcgctgtt gggctcgcgg ttgaggacaa actcttcgcy 960
gtctttccag tactcttgga tcggaaaacc gtccgctcc gaacggtact ccgccaccga 1020
gggacctgag cgagtccgca tcgaccggat cggaaaacct ctcgagaaag gcgtctaacc 1080
agtcacagtc gcaaggtagg ctgagcaccc tggcggggcg cagcgggtgg cggtcgggggt 1140
tggttctggc ggaggtgctg ctgatgatgt aattaaagta ggcggtcttg agacggcgga 1200
tggtcgaggt gaggtgtggc aggccttgaga tccaagatga agcgcgcaag accgtctgaa 1260
gataccttca accccgtgta tccatatgac acggaaacct gtccctccaac tgtgcctttt 1320
cttactcctc cctttgtatc ccccaatggg agttacctcc aatggcatgc ttgcgctcaa aatgggcaac 1440
ttgcgcctat ccgaacctct agttacctcc acctcccaa atgtaaccac tgtgagccca 1500
ggcctctctc tggacgaggg cggcaacctt ctggaaatat ctgcacccct cacagttacc 1560
cctctcaaaa aaaccaagtc aaacataaac cctctaattg tcgcggggcaa cacactcacc 1620
tcagaagccc taactgtggc aaccgtgcac gactccaaac ttagcattgc cacccaagga 1680
atgcaatcac aggcctcgct aaagctagcc ctgcaaacat caggcccccct caccaccacc 1740
ccctcacag tgtcagaagg cactgcctca cccctctaa ctactgccac tggtagcttg 1800
gatagcagta cccttactat catttataca caaatggaa aactaggact aaagtacggg 1860
ggcattgact tgaaagagcc cgacctaaac actttgaccg tagcaactgg tccaggtgtg 1920
gctcctttgc atacttcctt gcaaaactaaa gttactggag ccttgggttt tgattcacia 1980
actattaata aacttaatgt agcaggagga ctaaggattg attctcaaaa cagacgcctt 2040
ggcaatatgc ttagttatcc gtttgatgct caaaaccaac taaatctaag actaggacag 2100
atacttgatg ttataaaact agcccacaac cttggatatta actacaacaa aggcctttac 2160
ggcctctttt ttataaaact ttccaaaaag cttagggtta acctaagcac tgccaagggg 2220
ttgtttacag cttcaaacag ttccaaaaag aatgcaggag atgggcttga atttggttca 2280
ttgatgtttg acgtacacag tcccctcaaa acaaaaattg gccatggcct agaatttgat 2340
cctaattgcac caaacacaaa taaactagga actggcctta gttttgacag cacaggtgcc 2400
tcaaacaagg ctatggttcc taatgataag ctaactttgt ggaccacacc agctccatct 2460
attacagtag gaaacaaaaa gactaaatgc agagaaagat ctttgggtctt aacaaaatgt 2520
cctaactgta gactaaatgc tacttgctac agtttcagtt ttggctgtta aaggcagttt ggctccaata 2580
ggcagtcaaa tacttgctac tcatcttatt ataagatttg acgaaaatgg agtgctacta 2640
tctggaacag ttcaaagtgc tcatcttatt aactttagaa atggagatct tactgaaggc 2700
aacaattcct tcctggaccc agaattattg aactttatag cagcttatcc aaaatctcac 2760
acagcctata caaacgctgt tggatttatg cctaaccctat caagtttact taaacggaga caaaactaaa 2820
ggtaaaactg ccaaaagtta cactgtcagt acacaggaaa caggagacac aactccaagt 2880
cctgtaacac taaccattac actaaacggg acacaggaaa actacattaa tgaaatattt 2940
gcatactcta tgtcattttc atgggactgg tctggccaca cccaagaat aaagaagcgg ccgctcgagc 3000
gccacatcct cttacacttt ttcatacatt gcccataatg cacttaaatg ctgagctcg ctgactagcc 3060
atgcatctag agggccctat tctatagtgt gttgtttgcc cctccccctg gccttccttg 3120
tcgactgtgc cttctagtgt ccagccactc cactgtcctt tcctaataaa atgaggaaat tgcacgcat 3180
accctggaag gtgccactcc tattctgggg ggtgggggtg ggaggagacag caagggggag 3240
tgtctgagta ggtgtcattc tattctgggg gatgcgggtg gctctatggc ttctgaggcg 3300
gattgggaag acaatagcag gcatgctggg ccccacgcgc cctgtagcgg cgcattaagc 3360
gaaagaacca gctggggctc tagggggtat accgctacac ttgccagcgc cctagcggcc 3420
gcggcgggtg tgggtggttac gcgcagcgtg gccacgttgc cgggctttcc ccgtcaagct 3480
gctcctttcg ctttcttccc ttcttttctc gccacgttgc cgggctttcc ccgtcaagct 3480

```


ctaaatcggg	gcatcccttt	agggttccga	tttagtgctt	tacggcacct	cgaccccaaa	3540
aaacttgatt	aggggtgatg	ttcacgtagt	gggccatcgc	cctgatagac	ggtttttcgc	3600
cctttgacgt	tggagtcac	gttctttaat	agtggactct	tgttccaaac	tggaaacaaca	3660
ctcaacccta	tctcgggtota	ttcttttgat	ttataagggg	ttttggggat	ttcggcctat	3720
tggttaaaaa	atgagctgat	ttaacaaaaa	tttaacgcga	attaattctg	tggaaatgtg	3780
gtcagttagg	gtgtggaaag	tccccaggct	ccccaggcag	gcagaagtat	gcaaaagcatg	3840
catctcaatt	agtcagcaac	caggtgtgga	aagtccccag	gctccccagc	aggcagaagt	3900
atgcaaagca	tgcattctcaa	ttagtcagca	accatagttcc	cgccccctaac	tccgcccac	3960
ccgccccctaa	ctccgcccag	ttccgcccac	tctccgcccc	atggctgact	aatTTTTTTT	4020
atTTatgcag	aggccgaggc	cgctctgccc	tctgagctat	tccagaagta	gtgaggaggc	4080
ttttttggag	gcctaggctt	ttgcaaaaag	ctcccgaggag	cttgatatatc	catttttcgga	4140
tctgatcaag	agcaggatg	aggatcggtt	cgcattgattg	aacaagatgg	attgcacgca	4200
ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	actgggcaca	acagacaatc	4260
ggctgctctg	atgccgcctg	gttccggctg	tcagcgcagg	ggcgcccggt	tctttttgtc	4320
aagaccgacc	tgtccgggtg	cctgaatgaa	ctgcaggacg	aggcagcgcg	gctatcgtgg	4380
ctggccacga	cgggcggttc	ttgcgcagct	gtgctcgacg	ttgtcactga	agcgggaaagg	4440
gactggctgc	tattgggcga	agtgcggggg	caggatctcc	tgtcatctcc	ccttgctcct	4500
gccgagaaag	tatccatcat	ggctgatgca	atgcggcgcc	tgcatacgct	tgatccggct	4560
acctgcccac	tcgaccacca	agcgaaacat	cgcattcgagc	gagcacgtac	tcggatggaa	4620
gccggctcttg	tcgatcagga	tgatctggac	gaagagcatc	aggggctcgc	gccagccgaa	4680
ctgttcgccca	ggctcaaggc	gcgcattgccc	gacggcgagg	atctcgtcgt	gacccatggc	4740
gatgcctgct	tgccgaatat	catgggtggaa	aatggccgct	tttctggatt	catcgactgt	4800
ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	tggctaccog	tgataattgct	4860
gaagagcttg	gcggcgaaatg	ggctgaccgc	ttcctcgtgc	tttacgggat	cgccgctccc	4920
gattcgcagc	gcattcgctt	ctatcgctt	cttgacgagt	tcttctgagc	gggactctgg	4980
ggttcgaaat	gaccgaccaa	gcgacgcccc	acctgccatc	acgagatttc	gattccaccg	5040
ccgcttctta	tgaaagggtt	ggcttcggaa	tcgttttccg	ggacgcccgc	tggaatgatt	5100
tccagcgcg	ggatctcatg	ctggagttct	tcgcccaccc	caacttgttt	attgcagctt	5160
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	5220
tgcatcttag	ttgtgggttg	tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	5280
cgacctctag	ctagagcttg	gcgtaatcat	ggctatagct	gtttcctgtg	tgaaattggt	5340
atccgctcac	aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcttgggggtg	5400
cctaattgagt	gagctaactc	acattaattg	cgttgcgctc	actgcccgtc	ttccagtcgg	5460
gaaacctgtc	gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	5520
gtattggggc	ctcttcgcgt	tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	5580
ggcgagcgg	atcagctcac	tcaaaaggcg	taatacgggt	atccacagaa	tcagggggata	5640
acgcagggaaa	gaacatgtga	gcaaaaaggc	agcaaaaaggc	caggaaccgt	aaaaaggccg	5700
cgttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatacaaaa	aatcgacgct	5760
caagtcaag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	5820
gctccctcgt	gcgctctcct	gttccgaccc	tgcgctctac	cggataacctg	tccgcctttc	5880
tcccttcggg	aagcgtggcg	ctttctcaat	gctcacgctg	taggtatctc	agttcggttg	5940
aggtcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	6000
ccttatccgg	taactatcgt	cttgagtcca	accggttaag	acacgactta	tcgccactgg	6060
cagcagccac	tggttaacagg	attagcagag	cgaggtatgt	aggcggtgct	acagagttct	6120
tgaagtgggt	gcctaactac	ggctacacta	gaaggacagt	atttggtatc	tcgcctctgc	6180
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	6240
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	6300
aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	aactcacggt	6360
aagggaattt	ggtcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	6420
aatgaagttt	taaatcaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	6480
gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	atagttgcct	6540
gactccccgt	cgtgtagata	actacgatac	gggagggtct	accatctggc	cccagtgctg	6600
caatgatacc	gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	6660
ccggaagggc	cgagcgcaga	agtggctcgt	caactttatc	cgctccatc	cagcttatta	6720
attgttgccg	ggaagtagat	gtaagtagtt	cgactgttaa	tagtttgccg	aacgtgttg	6780
ccattgtctac	aggcatcgtg	gtgtcacgct	cgtcgttttg	tatggcttca	ttcagctccg	6840
gttcccaacg	atcaaggcga	gttacatgat	ccccatggt	gtgcaaaaaa	gcgggttagct	6900
ccttcgggtcc	tccgatcgtt	gtcagaagta	agttggccgc	agtgttatca	ctcatgggtta	6960
tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	7020
gtgagtactc	aaccagaatc	ttctgagaat	agtgtatcgc	gcgaccgagt	tgctcttgcc	7080
cggcgtcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	7140
gaaaacgttc	ttcggggcga	aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	7200

```

tgtaacccac tcgtgcaccc aactgatott cagcatcttt tactttcacc agcgtttctg 7260
ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 7320
ggtgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 7380
tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 7440
catttccccg aaaagtgcc cctgacgtc 7469

```

<210> 9
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 9
tgcttaagcg gccgcgaagg agaagtcc 28

```

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 10
ccgagctagc gactgaaaat gag 23

```

<210> 11
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

```

<400> 11
cctctcgaga gacagcaaga cac 23

```

<210> 12
 <211> 11152
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

```

<400> 12
aagcttgggc agaaatgggt gaactcccg gagtgtccta cacctagggg agaagcagcc 60
aaggggttgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcatttctctg ctgcaaactt ggcatagtct tgctttgcct ggggctattg 180
ggggaagttg cggttcgtgc tcgcagggtc ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttacia gccgcacgca ttttgtcctt cagaaataga aataagaatg 360
cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt attagttact 420
atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaagggg aaaaagagtg tttttgtcaa aataggagac 600
aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggataggt gggttacagt caatggctat 720

```

aaagtgttat	atagatccct	cccttttctgt	gaaagactcg	ccagagctag	acctccttgg	780
tgtatgttgt	ctcaagaaga	aaaagacgac	atgaaacaac	aggtacatga	ttatatattat	840
ctaggaacag	gaatgcactt	ttgggggaaag	attttccata	ccaaggaggg	gacagtggct	900
ggactaatag	aacattatct	tgcaaaaaact	catggcatga	gttattatga	atagccttta	960
ttggcccaac	cttgcggttc	ccagggctta	agtaagtttt	tggttacaaa	ctgttcttaa	1020
aacgaggatg	tgagacaagt	ggtttctctga	cttggtttgg	tatcaaaggt	tctgatctga	1080
gctctgagtg	ttctattttc	ctatgttctt	ttggaattta	tccaaatctt	atgtaaagtc	1140
ttatgtaaac	caagatataa	aagagtgtctg	attttttgag	taaacttgca	acagtcttaa	1200
cattcacctc	ttgtgtgttt	gtgtctgttc	gccatcccgt	ctccgctcgt	cacttatcct	1260
tcactttcca	gagggctccc	ccgcagaccc	cggcgaccct	caggtcggcc	gactgcggca	1320
gctggcgccc	gaacagggac	cctcggataa	gtgacccttg	tctctatttc	tactatttgg	1380
tgtttgtctt	gtatgtctc	tttcttgtct	ggcatcatc	acaagagcgg	aacggactca	1440
ccatagggac	caagctagcg	actgaaaatg	agacatatta	tctgccacgg	aggtgttatt	1500
accgaagaaa	tggccgccag	tcttttggac	cagctgatcg	aagaggtact	ggctgataat	1560
cttccacctc	ctagccatct	tgaaccacct	acccttcacg	aactgtatga	tttagacgtg	1620
acggcccccg	aagatcccaa	cgaggaggcg	gtttcgcaga	tttttcccga	ctctgtaatg	1680
ttggcggtgc	aggaagggat	tgacttactc	acttttccgc	cggcgcccgg	ttctccggag	1740
ccgcctcacc	tttcccgga	gcccagacag	ccggagcaga	gagccttggg	tccggtttct	1800
atgccaaacc	ttgtaccgga	ggtgatcgat	cttacctgcc	acgaggctgg	ctttccaccc	1860
agtgacgacg	aggatgaaga	gggtgaggag	tttgtgttag	attatgtgga	gcaccccggg	1920
cacggttgca	ggtcttgtca	ttatcaccgg	aggaatacgg	gggaccaga	tattatgtgt	1980
tcgctttgct	atatgaggac	ctgtggcatg	tttgtctaca	gtaagtga	attatgggca	2040
gtgggtgata	gagtggtggg	tttgggtgtg	taattttttt	tttaattttt	acagttttgt	2100
ggtttaaaga	attttgtatt	gtgatttttt	taaaaggtcc	tgtgtctgaa	cctgagcctg	2160
agcccgagcc	agaaccggag	cctgcaagac	ctaccgcgcg	tcctaaaatg	gcgcctgcta	2220
tcctgagacg	cccagacatca	cctgtgtcta	gagaatgcaa	tagtagtacg	gatagctgtg	2280
actccggtcc	ttctaacaca	cctcctgaga	tacaccgggt	ggtcccgtcg	tgccccatta	2340
aaccagttgc	cgtgagagtt	ggtgggcgtc	gccaggctgt	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tgggcaacct	ttggacttga	gctgtaaaacg	ccccaggcca	taagggtgtaa	2460
acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgctga	atgagttgat	gtaagtttaa	2520
taaagggtga	gataatgttt	aacttgcatt	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atccttggtta	catctgacct	catggaggct	tgggaggtgt	2640
tgggaagattt	ttctgtctgtg	cgtaacttgc	tggaaacagag	ctctaacagt	acctcttggg	2700
tttggagggtt	tctgtggggc	tcaccccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atttgaagag	cttttgaaat	cctgtggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcacaaagac	tttggatttt	tcacacccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gtttttataaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cgggggggtac	ctgctggatt	ttctggccat	gcacatctgtg	agagcggttg	3000
tgagacacaa	gaatcgctcg	ctactgttgt	cttccgtccg	cccggcgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gaggaagcca	ggcggcgggc	gcaggagcag	agccccatga	3120
accgcagagc	cggcctggac	gaatgttgta	caggttggtg	caggttggtg	aactgtatcc	3180
agaactgaga	cgcatttttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgcg	ctaattgagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgccagccagg	3420
ggatgatttt	gaggaggcta	ttaggggtata	tgcaaagggtg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaaacttg	taaatatcag	gaattgtttgc	tacattttctg	ggaacggggc	3540
cgagggtggag	atagatacgg	aggataggggt	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccggggggtg	cttggcatgg	acgggggtgtg	tattatgaat	gtaagggtta	ctggcccca	3660
tttttagcgtg	acggtttttcc	tggccaatac	caaccttatc	ctacacgggtg	taagcttcta	3720
tgggtttaaac	aatacctgtg	tggaaagcctg	gaccgatgta	aggggttcggg	gctgtgcctt	3780
ttactgctgc	tggaaagggg	tgggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	aggtgtacct	tgggttatcct	gtctgagggt	aactccaggg	tgcgccacaa	3900
tgtggcctcc	gactgtgggt	gcttcatgct	agtgaagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactgcg	aggacaggcg	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgcaaggcct	ggccagtgtt	4080
tgagcataac	atactgacct	gctgttcctt	gcatttgggt	aacaggaggg	gggtgttcc	4140
accttaccaa	tgaattttga	gtcacactaa	gatattgctt	gagcccgaga	gcattgtcaa	4200
ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaaaggtg	tgaggtacga	4260
tgagaccgcg	gaccgttgca	gaccctgcga	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttggtgctgg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtgggcgtgg	4440

cttaaggggtg	ggaaagaata	tataaggtgg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggceggggg	gcgtcagaat	gtgatgggct	ccagcattga	4620
tgggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttgagg	actgcagcct	ccgccgcgcg	ttcagccgct	gcagccaccg	cccgccgggat	4740
tgtgactgac	tttgctttcc	tgagcccgct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctctttttgg	acaattggat	tctttgaccc	gggaacttaa	4860
tgtcgtttct	cagcagctgt	tggtactgcg	ccagcagggt	tctgccctga	aggcttcttc	4920
ccctcccaat	gcgggtttaaa	acataaataa	aaaaccagac	tctgttttga	tttggatcaa	4980
gcaagtgtct	tgctgtctct	cgagggatct	ttgtgaagga	accttacttc	tgtgggtgtga	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaacta	ctgattctaa	ttgtttgtgt	atttttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gtttagtaat	agaactcttg	cttgctttgc	tatttacacc	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatatct	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaattgtgta	cctttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgccttga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttgttgt	taacttgttt	attgcagctt	ataatgggta	caaataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcattctag	ttgtggtttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtcccca	ggctccccag	caggcagaag	tatgcaaaagc	6000
atgcatactca	attagtcagc	aacctatagc	ccgcgccctaa	ctccgcccat	cccgccccca	6060
actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taattttttt	tattttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttggga	6180
ggcctagggt	tttgcaaaaa	gcttgagcac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	ccgcgctcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actgggtttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctggggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccc	taagccgtgg	cggctctggt	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgtcatg	tcgataccgt	ttgtatttcc	agctacgata	acgacaacca	6600
gcgcgagctt	aaagtgtctg	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggtg	gataccgggtg	gtactgcggg	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tcgtccgctg	gttgatgact	atgttgttga	6780
tatcccgcaa	gataactgga	ttgaacagcc	gtgggatatg	ggcgtcgat	tcgtcccgcc	6840
aatctccggt	cgctaactct	ttcaacgcct	ggcgttgctg	ggcgttgctt	tttttaacct	6900
caggcggtgt	acaatagttt	ccagtaagta	ttctggaggc	tgcattccatg	acacaggcaa	6960
acctgagcga	aaccctgttc	aaaccccgct	ttaaacatcc	tgaaacctcg	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgcagtccgc	ccttgatggg	aaaaccatcc	7080
ctcactggta	tcgcatgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	ggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtgggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaata	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtgggtggaat	7440
gcctttaatg	aggaaaacct	gttttgctca	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactcctcca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcagtctg	tgtttagtaa	tagaactcct	7620
gcttgctttt	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctatgaacct	tataagtagg	ataaacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaatttgtgt	7800
accttttagct	tttttaatttg	taaaggggtt	aataagggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	cccctgaacc	tgaaacataa	aatgaatgca	attgttggtg	ttacttgtgt	7980
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
atTTTTTTTca	ctgcattcta	gttgtgggtt	gtccaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtcct	cataaacctc	aacctcctct	acttgagagg	8160

acattccaat	cataggctgc	ccatccaccc	tctgtgtcct	cctgttaatt	aggtcactta	8220
acaaaaagga	aattgggtag	gggtttttca	cagaccgctt	tctaagggtta	attttaaaat	8280
atctgggaag	tcccttcac	tgctgtgttc	cagaagtgtt	ggtaaacagc	ccacaaatgt	8340
caacagcaga	aacatacaag	ctgtcagctt	tgcacaaggg	cccaacaccc	tgctcatcaa	8400
gaagcactgt	ggttgctgtg	ttagtaatgt	gcaaaacagg	aggcacattt	ccccacctg	8460
tgtaggttcc	aaaatatcta	gtgttttcat	ttttacttgg	atcaggaacc	cagcactcca	8520
ctggataagc	attatcctta	tccaaaacag	ccttgtggtc	agtgttcac	tgctgactgt	8580
caactgtagc	atTTTTtggg	gttacagttt	gagcaggata	tttggtcctg	tagtttgcta	8640
acacaccctg	cagctccaaa	ggttccccac	caacagcaaa	aaaatgaaaa	tttgaccctt	8700
gaatggggtt	tccagcacca	ttttcatgag	ttttttgtgt	ccctgaatgc	aagttttaaca	8760
tagcagttac	cccaataacc	tcagttttta	cagtaacagc	ttcccatc	aaaatatatt	8820
cacaggttaa	gtcctcattt	aaattaggca	aaggaattct	tgaagacgaa	agggcctcgt	8880
gatacgcta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	cgtcaggtgg	8940
cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	tacattcaaa	9000
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	9060
gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcct	9120
tctgtttttt	gctcaccag	aaacgctggg	gaaagtaaaa	gatgctgaag	atcagttggg	9180
tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	9240
ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcgggtatt	9300
atcccgtgtt	gacgccgggc	aagagcaact	cggtcgcgcg	atacactatt	ctcagaatga	9360
cttggttgag	tactcaccag	tcacagaaaa	gcactctacg	gatggcatga	cagtaagaga	9420
attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	ttctgacaa	9480
gatcgaggga	ccgaaggagc	taaccgcttt	tttgacaaac	atgggggatc	atgtaactcg	9540
ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	9600
gatgcctgca	gcaatggcaa	caacgttgcg	caaactatta	actggcgaac	tacttactct	9660
agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagtgtcag	gaccattctt	9720
gcgctcggcc	cttcgggctg	gctggtttat	tgctgataaa	tctggagccg	gtgagcgtgg	9780
gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	tcgtagtatt	9840
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	9900
tgctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	9960
tgatttaaaa	cttcattttt	aatttaaaag	gatctagggt	aagatccttt	ttgataatct	10020
catgaccaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	10080
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	10140
aaaaccaccg	ctaccagcgg	tggtttgttt	gccggatcaa	gagctaccaa	ctctttttcc	10200
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	10260
gttagggcac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatact	10320
gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	10380
atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	10440
cttggaagcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	10500
cacgcttccc	gaaggagaa	aggcggacag	gtatccggtg	agcggcaggg	tcggaacagc	10560
agagcgcagc	agggagcttc	cagggggaaa	cgctcggtat	ctttatagtc	ctgtcgggtt	10620
tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	10680
gaaaaacgcc	agcaacgcgg	ccttttttacg	gttcctggcc	ttttgctggc	cttttgctca	10740
catgttcttt	cctgcgttat	cccctgatcc	tgtggataac	cgtattaccg	cctttgagtg	10800
agctgatacc	gctcgcgcga	gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	10860
ggaagagcgc	ctgatgcggg	atcttctcct	tacgcactctg	tgcggtatct	cacaccgcac	10920
atggtgcact	ctcagtacaa	tctgctctga	tgccgcatag	ttaagccagt	atacactccg	10980
ctatcgctac	gtgactgggt	catggctgcg	ccccgacacc	cgccaacacc	cgctgacgcg	11040
ccctgacggg	cttgtctgct	cccggcatcc	gcttacagac	aagctgtgac	cgtctccggg	11100
agctgcatgt	gtcagaggtt	ttcaccgtca	tcaccgaaac	gcgcgaggca	gc	11152

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 13

gacggatcgg gagatctcc

19

<210> 14
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 14
 ccgcctcaga agccatagag cc

22

<210> 15
 <211> 14455
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 15
 aagcttgggc agaaatgggt gaactccga gagtgtccta cacctagggg agaagcagcc 60
 aaggggttgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
 aaagacatat tcattctctg ctgcaaaactt ggcataagctc tgctttgcct ggggctattg 180
 ggggaagtgt cggttcgtgc tcgcaggggt ctcacccttg actcttttaa tagctcttct 240
 gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
 cagccaactt cctcttataa gccgcacga ttttgtcctt cagaaataga aataagaatg 360
 cttgctaataa attatatttt taccaataag accaatccaa taggtagatt attagttact 420
 atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagtttagaa 480
 atgggaatag aaaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
 ttgaccacag gcctagaagt aaaaaaggga aaaaagagtgt tttttgtcaa aataggagac 600
 aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
 ttaccatata caggaagata tgacttaaat tgggataggt ggggtacagt caatggctat 720
 aaagtgttat atagatccct cccttttcgt gaaaagactcg ccagagctag acctccttgg 780
 tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatattat 840
 ctagggaacag gaatgcactt ttggggaaag attttccata ccaaggaggg gacagtggct 900
 ggactaatag aacattattc tgcaaaaact catggcatga gttattatga atagccttta 960
 ttggcccaac cttgcggttc ccagggttta agtaagtgtt tggttacaaa ctgttcttaa 1020
 aacgaggatg tgagacaagt ggtttcctga cttgggttgg tatcaaagggt tctgatctga 1080
 gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140
 ttatgtaaac caagatataa aagagtgtctg attttttgag taaacttgca acagtcctaa 1200
 cattcacctc ttgtgtgttt gtgtctgttc gccatccgt ctccgctcgt cacttatcct 1260
 tcactttcca gagggctccc ccgcagaccc cggcgaccct caggtcggcc gactgcggca 1320
 gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380
 tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440
 ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
 accgaagaaa tggccgccag tcttttggac cagctgatcg aagaggtact ggctgataat 1560
 cttccacctc ctagccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620
 acggccccc cagatcccaa cgaggaggcg gtttcgcaga tttttcccga ctctgtaatg 1680
 ttggcggtgc aggaagggat tgacttactc acttttccgc cggcgcccgg ttctccggag 1740
 ccgcctcacc tttcccggca gcccgagcag ccggagcaga gagccttggg tccggtttct 1800
 atgccaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860
 agtgacgacg aggatgaaga gggtagaggg tttgtgttag attatgtgga gcaccccggg 1920
 caggtgtgca ggtcctgtca ttatcacgg cctgtgtcta ggaatacgg gggaccaga tattatgtgt 1980
 tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
 gtgggtgata gagtgggtggg tttggtgtgg taattttttt ttttaattttt acagttttgt 2100
 ggttttaaga attttgtatt gtgatttttt taaaagggtcc tgtgtctgaa cctgagcctg 2160
 agcccagagc agaaccggag cctgcaagac ctacccgccc tcctaaaatg ggcctgtcta 2220
 tccctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280
 actccggtcc ttctaacaca cctcctgaga tacaccgggt ggtcccgtctg tgccccatta 2340
 aaccagttgc cgtgagagtt ggtgggcgtc gccaggctgt ggaatgtatc gaggacttgc 2400
 ttaacgagcc tgggcaacct ttggacttga gctgtaaacg ccccaggcca taagggtgtaa 2460

acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgctga	atgagttgat	gtaagtttaa	2520
taaaggggtga	gataatgttt	aacttgcattg	gcgtgttaaa	tggggcgggg	cttaaagggg	2580
atataatgcg	ccgtgggcta	atcttgggta	catctgacct	catggaggct	tgggagtggt	2640
tgggaagattt	ttctgtctgtg	cgtaaccttgc	tggaaacagag	ctctaacagt	acctcttggt	2700
tttggagggtt	tctgtggggc	tcatcccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atttgaagag	cttttgaaat	cctgtgggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcatacaagac	tttggatttt	tccacaccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gtttttataaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cgggggggtac	ctgctggatt	ttctggccat	gcactctgtg	agagcggttg	3000
tgagacacaa	gaatcgccctg	ctactgttgt	cttccgtccg	cccggcgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gaggaagcca	ggcggcgggc	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcgggaat	gaatgttgta	caggtggctg	aactgtatcc	3180
agaactgaga	cgcatttttga	caattacaga	ggatgggag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtga	ttacttttca	acagatcaag	gataattgag	ctaattgagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tcgagccagg	3420
ggatgatttt	gaggaggcta	ttaggggtata	tgcaaagggtg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaacttg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgaggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccgggggtg	cttggcatgg	acgggggtgt	tattatgaat	gtaaggttta	ctggccccaa	3660
tttttagcgg	acggtttttc	tgccaatac	caaccttatc	ctacacgggtg	taagcttcta	3720
tgggttttaac	aataacctgtg	tggaaagcctg	gacctagtga	agggttcggg	gctgtgcctt	3780
ttactgctgc	tggaaagggg	tgggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	agggtgtacct	tgggtatcct	gtctgagggt	aactccaggg	tgcgccacaa	3900
tgtggcctcc	gactgtgggt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactcgc	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgcaaggcct	ggccagtggt	4080
tgagcataac	atactgacct	gctgttcctt	gcatttgggt	aacaggaggg	gggtgttcct	4140
accttaccaa	tgcaatttga	gtcacactaa	gatattgctt	gagcccagag	gcatgtccaa	4200
ggtgaacctg	aacgggggtgt	ttgacatgac	catgaagatc	tggaaagggtg	tgaggtacga	4260
tgagacccgc	accaggtgca	gacctgcga	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttgggtgctg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgagggt	actgaaatgt	gtgggcgtgg	4440
cttaaggggtg	ggaaagaata	tataagggtg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	ggttgatgga	agcatttgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggtc	ccagcatgga	4620
tgggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttgagg	actgcagcct	ccgcgcgcgc	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgcttttc	tgagcccgcct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttgcc	acaattggat	tcttttgacc	gggaacctaa	4860
tgtcgtttct	cagcagctgt	tggatctgcg	ccagcaggtt	tctgccctga	aggcttcctc	4920
ccctcccaat	gcggttttaa	acataaataa	aaaaccagac	tctgttttga	tttggatcaa	4980
gcaagtgtct	tgctgtctct	cgaggggatct	ttgtgaagga	accttacttc	tgtgggtgtga	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataaatg	tgttaaacta	ctgattctaa	ttgttttgtg	atttttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tgggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gtttagtaat	agaactcttg	ccttgctttgc	tatttacacc	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatatct	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaatttgtgt	ccttttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgccttgc	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaaccaaaa	5700
atgaatgcaa	ttgttggtgt	taacttggtt	ttctcagctt	ataatgggta	caaataaagc	5760
aatagcatca	caaattttcac	aaataaagca	ttttttttcac	tgcattctag	ttgtgggtttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtcccca	ggctccccc	caggcagaag	tatgtcaaac	6000
atgcatctca	attagtgcg	aaccatagtc	ccgcccctaa	ctccgcccct	cccgcgccct	6060
actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taattttttt	tattttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	ctttttttgga	6180

ggcctaggct	tttgcaaaaa	gcttggacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgtcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actgggttttt	agtgcgccag	atctctataa	tctcgcgcaa	cctatttttcc	cctcgaaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccc	taagccgtgg	cggctctggta	ccgggtgctg	tactggcgcg	6540
tgaactgggt	attcgtcatg	tcgataccgt	ttgtatttcc	agctacgatac	acgacaacca	6600
gcgcgagctt	aaagtgtctga	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggtg	gataccgggtg	gtactgcgggt	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	togtccgctg	gttgatgact	atgttggtga	6780
tatcccgcga	gatacctgga	ttgaacagcc	gtgggatatg	ggcgtcgtat	tcgtcccgcc	6840
aatctccgggt	cgctaactctt	ttcaacgcct	ggcactgccc	ggcgttggttc	tttttaactt	6900
caggcggggtt	acaatagttt	ccagtaagta	ttctggaggc	tgcattccatg	acacaggcaa	6960
acctgagcga	aaccctgttc	aaaccccgt	ttaaacatcc	tgaacactcg	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgcagtccgc	ccttgatgggt	aaaaccatcc	7080
ctcactggta	tcgcattgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gaccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	gggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtgggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatggggagca	gtggtggaat	7440
gcctttaatg	aggaaaacct	gttttgctca	gaagaactgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactcctcca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcattgctg	tgtttagtaa	tagaactcct	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataaacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaatttgtgt	7800
accttttagct	tttttaatttg	taaaggggtt	aataaggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	cccctgaacc	tgaaacataa	aatgaatgca	attgttggtg	tttaacttgtt	7980
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
attttttttca	ctgcattcta	gttgtgggtt	gtccaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtcct	cataaaccct	aacctcctct	acttgagagg	8160
acattccaat	cataggctgc	ccatccaccc	tctgtgtcct	cctgttaatt	aggctactta	8220
acaaaaagga	aattgggtag	gggtttttca	cagaccgctt	tctaagggtta	attttaaact	8280
atctgggaag	tcccttccac	tgctgtgttc	cagaagtgtt	ggtaaacagc	ccacaaatgt	8340
caacagcaga	aacatacaag	ctgtcagctt	tgcaaacagg	cccaacaccc	tgctcatcaa	8400
gaagcactgt	ggttgtctgtg	ttagtaatgt	gcaaaacagg	aggcacattt	tccccacctg	8460
tgtagggttc	aaaatatcta	gtgttttcat	ttttacttgg	atcaggaacc	cagcactcca	8520
ctggataaagc	attatcctta	tccaaaacag	ccttgtggtc	agtgttcac	tgctactgtg	8580
caactgtagc	attttttggg	gttacagttt	gagcaggata	tttggtcctg	tagtttgcta	8640
acacaccctg	cagctccaaa	ggttccccac	caacagcaaa	aaaatgaaaa	tttgaccctt	8700
gaatgggttt	tccagcacca	ttttcatgag	ttttttgtgt	ccctgaatgc	aagttaaaca	8760
tagcagttac	cccaataacc	tcagttttta	cagtaacagc	ttcccacatc	aaaaatattc	8820
cacagggttaa	gtcctcattt	aaattaggca	aaggaattct	tgaagacgaa	agggcctcgt	8880
gatacgctta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	cgtcagggtg	8940
cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	tacattcaaa	9000
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	9060
gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcct	9120
tctgtttttt	gctcaccacg	aaacgctgggt	gaaagtataa	gatgctgaag	atcagttggg	9180
tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	9240
ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcgggtatt	9300
atcccggtgt	gacgccgggc	aagagcaact	cggctcgcgc	atacactatt	ctcagaatga	9360
cttggttgag	tactccacg	tcacagaaaa	gcactcttacg	gatggcatga	cagtaagaga	9420
attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaaacttac	ttctgacaac	9480
gatcgaggga	ccgaaggagc	taaccgcttt	tttgcacaac	atgggggatc	atgtaactcg	9540
ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	9600
gatgcctgca	gcaatggcaa	caacgttgcg	caaaactatta	actggcgaac	tacttactct	9660
agcttcccg	caacaattaa	tagactggat	ggaggcgat	aaagttgcag	gaccactctt	9720
gcgctcggcc	cttccggctg	gctgggttat	tgctgataaa	tctggagccg	gtgagcgtgg	9780
gtctcgcggg	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	tcgtagttat	9840
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	9900

tgccctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	9960
tgatttataaa	cttcattttt	aattttaaag	gatctagggtg	aagatccttt	ttgataatct	10020
catgacaaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	10080
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	10140
aaaaccaccg	ctaccagcgg	tggtttgttt	gocggatcaa	gagctaccaa	ctctttttcc	10200
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	10260
gttagggcac	cacttcaaga	actctgtage	accgcctaca	tacctcgctc	tgctaactct	10320
gttaccagt	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	10380
atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	10440
cttgaggcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	10500
cacgcttccc	gaaggagaaa	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	10560
agagcgcacg	agggagcttc	cagggggaaa	cgctgtgtat	ctttatagtc	ctgtcgggtt	10620
tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	10680
gaaaaacgcc	agcaacgcgg	ccttttttacg	gttcctggcc	ttttgctggc	cttttgctca	10740
catgttcttt	cctgcgttat	cccctgatcc	tgtggataac	cgtattaccg	cctttgagtg	10800
agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	10860
gggaagagcgc	ctgatgcggg	atcttctcct	tacgcattctg	tcgggtatatt	cacaccgcat	10920
accgcctcag	aagccataga	gcccaccgca	tccccagcat	gcctgctatt	gtcttcccaa	10980
tcctccccct	tgctgtcctg	ccccacccca	ccccccagaa	tagaatgaca	cctactcaga	11040
caatgcatg	caatttcctc	atcttattag	gaaaggacag	tgaggagtggc	accttccagg	11100
gtcaagggaag	gcacggggga	gggggcaaca	acagatgggt	ggcaactaga	aggcacagtc	11160
gaggctgac	agcgtgctct	agcatttagg	tgactgacaa	gaatagggcc	ctctagatgc	11220
atgctcgagc	ggcgcgttct	ttattcttgg	gcaatgtatg	aaaaagtgtg	agaggatgtg	11280
gcaaataattt	cattaatgta	gttgtggcca	gaccagtcct	atgaaaatga	catagagtat	11340
gcacttgagg	ttgtgtctcc	tgtttctcgt	gtaccgttta	gtgtaatggg	tagtggttaca	11400
ggtttagttt	tgctcccggt	taagtaaaact	tgactgacaa	tgttactttt	ggcagtttta	11460
ccgtgagatt	ttggataagc	tgatagggtta	ggcataaaatc	caacagcggt	tgtatagggt	11520
gtgccttcag	taagatctcc	atcttctaaag	ttccaatatt	ctgggtccag	gaaggaattg	11580
tttagtagca	ctccattttc	gtcaaactct	ataataagat	gagcactttg	aactgttcca	11640
gatattggag	ccaaactgcc	tttaacagcc	aaaactgaaa	ctgtagcaag	tatttgactg	11700
ccacattttt	ttaagaccaa	agttagttta	cgatctttct	ctgcatttag	tctacagtta	11760
ggagatggag	ctgggtgtgg	ccacaaagtt	agcttatcat	tatttttgtt	tcctactgta	11820
atggcacctg	tgctgtcaaa	actaaggcca	gttctagttt	taggaaccat	agccttggtt	11880
gaatcaaatt	ctaggccatg	gccaaatttt	gttttgaggg	gatttgtgtt	tggtgcatta	11940
ggtagaacaa	attcaagccc	atctcctgca	ttaattggcta	tggtctgtagc	gtcaaacatc	12000
aaccctctgg	cagtgccttag	gttaacctca	agcttttttg	aattgtttga	agctgttaac	12060
aagtaaaggc	ctttgtttgta	gttaatatcc	aagttgtggg	ctgagtttat	aaaaagaggg	12120
ccctgtccta	gtccttagatt	tagttgggtt	tgagcatcaa	acggataaact	aacatcaagt	12180
ataaggcgct	tgtttttgaga	atcaatcctt	agtcctcctg	ctacattaag	ttgcatattg	12240
ccttgtgaat	caaaacccaa	ggctccagta	actttagttt	gcaagggaagt	attatttaata	12300
gtcacacactg	gaccagttgc	tacggtcaaa	gtgttttaggt	cgtctgttac	atgcaaagga	12360
gccccgtact	ttagtccctag	ttttccattt	tgtgtataaa	tggtctcttt	caagtcaatg	12420
cccaagctac	cagtggcag	agtttagagg	ggtagggcag	tgatagtaag	ggtactgcta	12480
tcgggtgggtg	tgagggggcc	tgatgtttgc	agggctagct	ttccttctga	cactgtgagg	12540
ggctccttggg	tggaatgct	aagtttggag	tcgtgcacgg	ttagcggggc	ctgtgattgc	12600
atgggtgagtg	tggtgcccgc	gaccattaga	gggtgcggcg	cagccacagt	tagggcttct	12660
gaggtaactg	tgaggggtgc	agatatttcc	aggtttatgt	ttgacttggg	ttttttgaga	12720
gggtgggctca	cagtgggttac	atcttgggag	gtaagggttc	cggtcctcgtc	cagagagagg	12780
ccgttgccca	ttttgagcgc	aagcatgcc	ttggaggtaa	ctagagggtc	ggataggcgc	12840
aaagagagta	ccccaggggg	actctcttga	aacctattgg	gggatacaaa	gggaggagta	12900
agaaaaggca	cagttggagg	accggtttcc	gtgtcatatg	gatacacggg	gttgaaggta	12960
tcttcagacg	gtcctgcgcg	cttcatcttg	gatctcaagc	ctgccacacc	tcacctcgac	13020
catccgcccgt	ctcaagaccg	cctactttta	ttacatcatc	agcagcacct	ccgccagaaa	13080
caaccccgac	cgccaccgcg	tgccgcctcc	cacgggtgctc	agcctacctt	gcgcatgtga	13140
ctgggttagac	gccttctctg	agaggttttc	cgatccgggtc	gatgcggact	cgctcaggtc	13200
cctcggtggc	ggagtaccgt	tcggaggccg	acgggtttcc	gatccaagag	tactggaaag	13260
accgcgaaga	gtttgtcctc	aaccgcgagc	ccaacagcga	gctcgaattc	agatccgagc	13320
tcggtaccaa	gcttgggtct	ccctatagtg	agtcgtatta	atttcgataa	gccagtaagc	13380
agtggtgtct	ctagtttagc	agagagctct	gcttatatag	acctcccacc	gtacacgcct	13440
accgcccatt	tgctgcaatg	gggcggaggt	gttacgacat	tttggaaagt	cccgttgatt	13500
ttggtgccaa	aacaaactcc	cattgacgtc	aatgggggtg	agacttgga	atccccgtga	13560
gtcaaacccg	tatccacgcc	cattgatgta	ctgccaaaaac	cgcatcacca	tggtaatagc	13620

gatgactaat	acgtagatgt	actgccaaagt	aggaaagtcc	cataagggtca	tgtactgggc	13680
ataatgccag	gcggggccatt	taccgtcatt	gacgtcaata	ggggggcgtag	ttggcatatg	13740
atacacttga	tgtactgcca	agtgggcagt	ttaccgtaaa	tagtccaccc	attgacgtca	13800
atggaaagtc	cctattggcg	ttactatggg	aacatacgtc	attattgacg	tcaatgggcg	13860
gggggtcggtg	ggcgggtcagc	caggcggggcc	atthaccgta	agttatgtaa	cgcggaactc	13920
catatatggg	ctatgaacta	atgaccccg	aattgattac	tattaataac	tagtcaataa	13980
tcaatgtcaa	cgcgtatata	tggcccgtac	atcgcggaagc	agcgcaaaac	gcctaaccct	14040
aagcagattc	ttcatgcaat	tgtcgggtcaa	gccttgccctt	gttgtagctt	aaattttgct	14100
cgcgcaactac	tcagcgacct	ccaacacaca	agcagggagc	agatactggc	ttactatgc	14160
ggcatcagag	cagattgtac	tgagagtcga	ccatagggga	tcgggagatc	ccccgatccg	14220
tctatgggtgc	actctcagta	caatctgctc	tgatgccgca	tagttaagcc	agtatacact	14280
ccgctatcgc	tacgtgactg	ggtcattggc	gcgcccgcac	acccgccaac	acccgctgac	14340
gcgcccgtgac	gggcttgtct	gctcccggca	tccgcttaca	gacaagctgt	gaccgtctcc	14400
gggagctgca	tgtgtcagag	gttttcaccg	tcataccga	aacgcgcgag	gcagc	14455

<210> 16

<211> 10610

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 16

gacggatcgg	gagatccgcg	cggtacacag	aattcaggag	acacaactcc	aagtgcatac	60
tctatgtcat	tttcatggga	ctgggtctggc	cacaactaca	ttaatgaaat	atthgccaca	120
tcctcttaca	ctttttcata	cattgcccac	gaataaagaa	tcgtttgtgt	tatgtttcaa	180
cgtgtttatt	tttcaattgc	agaaaatttc	aagtcattht	tcattcagta	gtatagcccc	240
accaccacat	agctttatac	gatcaccgta	ccttaaatcaa	actcacagaa	ccctagtatt	300
caacctggcca	cctccctccc	aacacacaga	gtacacagtc	ctttctcccc	ggctggcctt	360
aaaaagcatc	atatcatggg	taacagacat	attcttaggt	gttatattcc	acacgggtttc	420
ctgtcgagcc	aaacgctcat	cagtgatatt	aataaactcc	ccgggcagct	cacttaagtt	480
catgtcgctg	tccagctgct	gagccacagg	ctgctgtcca	acttgccggt	gcttaacggg	540
cggcgaagga	gaagtccacg	cctacatggg	ggtagagtca	taatcgtgca	tcaggatagg	600
gcgggtgggtc	tgacgcagcg	cgcgaaataaa	ctgctggcgc	cgccgctccg	tcctgcagga	660
atacaacatg	gcagtggtct	cctcagcgat	gattcgcacc	gcccgcagca	taaggcgcct	720
tgtcctccgg	gcacagcagc	gcaccctgat	ctcacttaaa	tcagcacagt	aactgcagca	780
cagcaccaca	atattgttca	aaatcccaca	gtgcaaggcg	ctgtatccaa	agctcatggc	840
ggggaccaca	gaacccacgt	ggccatcata	ccacaagcgc	aggtagatta	agtgccgac	900
cctcataaac	acgctggaca	taaacattac	ctcttttggc	atgttgtaat	tcaccacctc	960
ccggtaccat	ataaacctct	gattaaacat	ggcgccatcc	accaccatcc	taaaccagct	1020
ggccaaaacc	tgcccgcggg	ctatacactg	cagggaaccg	ggactgggac	aatgacagtg	1080
gagagcccag	gactcgtaac	catggatcat	catgctcgtc	atgatataca	tgthggcaca	1140
acacaggcac	acgtgcatac	acttctcag	gattacaagc	tcctcccgcg	ttagaacat	1200
atcccaggga	acaacccatt	cctgaatcag	cgtaaatccc	acactgcagg	gaagacctcg	1260
cacgtaactc	acgttgtgca	ttgtcaaagt	gttacattcg	ggcagcagcg	gatgatcctc	1320
cagtatggta	gcgcgggttt	ctgtctcaaa	aggaggtaga	cgatccctac	tgtacggagt	1380
gcgccgagac	aaccgagatc	gtgttggtcg	tagtgtcatg	ccaaatggaa	cgccggacgt	1440
agtcataatt	cctgaagcaa	aaccagggtc	ggcgctgaca	aacagatctg	cgtctccggt	1500
ctcgccgctt	agatcgctct	gtgtagtagt	tgtagtatat	ccactctctc	aaagcatcca	1560
ggcgccccct	ggcttcgggt	tctatgtaaa	ctccttcatt	cgccgctgcc	ctgataacat	1620
ccaccaccgc	agaataagcc	acacccagcc	aacctacaca	ttcgthctgc	gagtcacaca	1680
cgggaggagc	gggaagagct	ggaagaacca	tgtttttttt	tttattccaa	aagattatcc	1740
aaaacctcaa	aatgaagatc	tattaaagta	acgcgctccc	ctccggtggc	gtgggtcaaac	1800
tctacagcca	aagaacagat	aatggcattt	gtaagatgtt	gcacaatggc	ttccaaaagg	1860
caaacggccc	tcacgtccaa	gtggacgtaa	aggctaaacc	cttcagggtg	aatctcctct	1920
ataaacattc	cagcaccttc	aaccatgccc	aaataattct	catctcgcca	ccttctcaat	1980
atatctctaa	gcaaatcccg	aatattaagt	ctggcatttg	taaaaatctg	ctccagagcg	2040
ccctccacct	tcagcctcaa	gcagcgaatc	atgattgcaa	aaattcaggt	tcctcacaga	2100
cctgtataag	attcaaaagc	ggaacattaa	caaaaatacc	gcgatcccgt	aggtcccttc	2160
gcagggccag	ctgaacataa	tcgtgcaggt	ctgcacggac	cagcgcggcc	acttcccgcg	2220

caggaacctt	gacaaaagaa	cccacactga	ttatgacacg	catactcgga	gctatgctaa	2280
ccagcgtagc	cccgatgtaa	gctttgttgc	atgggcgggc	atataaaatg	caaggtgctg	2340
ctcaaaaaat	caggcaaagc	ctcgcgcaaa	aaagaaagca	catcgtagtc	atgctcatgc	2400
agataaaggc	aggtaagctc	cggaaaccacc	acagaaaaag	acaccatttt	tctctcaaac	2460
atgtctgcgg	gtttctgcat	aaacacaaaa	taaaataaca	aaaaaacatt	taaacatttag	2520
aagcctgtct	tacaacagga	aaaacaaccc	ttataagcat	aagacggact	acggccatgc	2580
cggcgtgacc	gtaaaaaaac	tggtcaccgt	gattaaaaag	caccacgcac	agctcctcgg	2640
tcagtgtccg	agtcataatg	taagactcgg	taaacacatc	agggtgattc	atcggtcagt	2700
gctaaaaagc	gaccgaaata	gcccggggga	atacatacc	gcaggcgtag	agacaacatt	2760
acagccccc	taggaggtat	aacaaaatta	ataggagaga	aaaacacata	aacacctgaa	2820
aaacccctct	gcctaggcaa	aatagcacc	tcccgtccca	gaacaacata	cagcgcttca	2880
cagcggcagc	ctaacagtc	gccttaccag	taaaaagaa	aacctattaa	aaaaacacca	2940
ctcgacacgg	caccagctca	atcagtcaca	gtgtaaaaa	gggccaagt	cagagcgagt	3000
atatatagga	ctaaaaaatg	acgtaacgg	taaagtccac	aaaaaacacc	cagaaaaccg	3060
cacgcgaacc	tacgcccaga	aacgaaagcc	aaaaaaccca	caacttctct	aaatcgtcac	3120
ttccggtttc	ccacgtttac	taacttcccc	gatcctctcc	cgatccctca	tggtcgactc	3180
tcagtacaat	ctgctctgat	gcccgcata	taagccagta	tctgctccct	gcttggtgtg	3240
tggaggtcgc	tgagtagtgc	gcgagcaaaa	tttaagctac	aacaaggcaa	ggcttgaccg	3300
acaattgcat	gaagaatctg	cttaggggtta	ggcggttttg	gctgcttcgc	gatgtacggg	3360
ccagatatac	gcgttgacat	tgattattga	ctagttatta	atagtaatca	attacgggg	3420
cattagttca	tagcccatat	atggagttcc	gcgttacata	acttacggta	aatggcccgc	3480
ctggctgacc	gcccacgcac	ccccgcccat	tgagctcaat	aatgacgtat	gttcccatag	3540
taacgccaat	agggactttc	cattgacgtc	aatgggtgga	ctattttacg	taaactgccc	3600
acttggcagt	acatcaagt	tatcatatgc	caagtacgcc	ccctattgac	gtcaatgacg	3660
gtaaatggcc	cgcttgcat	tatgcccgat	acatgacctt	atgggacttt	cctacttgcc	3720
agtacatcta	cgtattagtc	atcgctatta	ccatgggtat	gcgggttttg	cagtacatca	3780
atgggcgtgg	atagcgggtt	gactcacggg	gatttccaag	tctccacccc	attgacgtca	3840
atgggagttt	gtttttggcac	caaaatcaac	gggactttcc	aaaatgtcgt	aacaactccg	3900
ccccattgac	gcaaatgggc	ggtaggcgtg	tacggtggga	gggtctatata	agcagagctc	3960
tctggctaac	tagagaaccc	actgcttact	ggcttatcga	aattaatacg	actcactata	4020
gggagaccga	agcttggtac	cgagctcgga	tctgaattcg	agctcgctgt	tgggctcgcg	4080
gttgaggaca	aactcttcgc	gggtctttcca	gtactcttgg	atcggaacc	cgtcggcctc	4140
cgaacggtac	tccgccaccg	agggacctga	gcgagtcgc	atcgaccgga	tcggaaaacc	4200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgcaaggtag	gctgagcacc	gtggcgggcg	4260
gcagcgggtg	gcggtcgggg	ttgtttctgg	cggaggtgct	gctgatgatg	taattaaagt	4320
aggcggctct	gagacggcgg	atggtcgagg	tgaggttggg	caggcttgag	atccaagatg	4380
aagcgcgcaa	gaccgtctga	agataccttc	aaccccggtg	atccatatga	cacggaaacc	4440
ggctctccaa	ctgtgccttt	tcttactcct	ccctttgtat	cccccaatgg	gtttcaagag	4500
agtccccctg	gggtactctc	tttgcgccct	tccgaacctc	tagttacctc	caatggcatt	4560
cttgcgctca	aaatgggcaa	cggcctctct	ctggacgagg	cgggcaacct	tacctcccaa	4620
aatgtaacca	ctgtgagccc	acctctcaaa	aaaaccaagt	caaacataaa	cctggaaata	4680
tctgcacccc	tcacagttac	ctcagaagcc	ctaactgtgg	ctgccgcgcg	acctctaatt	4740
gtcgcgggca	acacactcac	catgcaatca	caggccccgc	taaccgtgca	cgactccaaa	4800
cttagcattg	ccacccaagg	accctcaca	gtgtcagaag	gaaagctagc	cctgcaaaca	4860
tcaggccccc	tcaccaccac	cgatagcagt	acccttacta	tcactgcctc	acccctctca	4920
actactgcca	ctggtagctt	gggcattgac	ttgaaagagc	ccatttatac	acaaaatgga	4980
aaactaggac	taaagtacgg	ggctcctttg	catgtaacag	acgacctaaa	cactttgacc	5040
gtagcaactg	gtccaggtgt	gactattaat	aatacttcct	tgcaaaactaa	agttactgga	5100
gccttggggt	ttgattcaca	aggcaatatg	caacttaatt	tagcaggagg	actaaggatt	5160
gattctcaaa	acagacgcct	tatacttgat	gttagttatc	cgtttgatgc	tcaaaaaccaa	5220
ctaaatctaa	gactaggaca	gggccctctt	tttataaaact	cagcccacaa	cttggtatatt	5280
aactacaaca	aaggcccttta	cttggtttaca	gcttcaaaca	attccaaaaa	gcttgagggt	5340
aacctaaagc	ctgccaaggg	gttgatgttt	cagcgtacag	ccatagccat	taatgcagga	5400
gatgggcttg	aatttggttc	acctaattgca	ccaaacacaa	atccctcaa	aacaaaattt	5460
ggccatggcc	tagaatttga	ttcaaacaag	gctatgggtc	ctaaactagg	aactggcctt	5520
agttttgaca	gcacaggtgc	cattacagta	ggaaacaaaa	ataatgataa	gctaactttg	5580
tggaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaga	tgctaaactc	5640
actttggctc	taacaaaatg	tggcagtcac	atacttgcta	cagtttcagt	tttggctgtt	5700
aaaggaagtt	tggctccaat	atctggaaca	gttcaaagtg	ctcatcttat	tataagattt	5760
gacgaaaatg	gagtgctact	aaacaattcc	ttcctggacc	cagaatattg	gaactttaga	5820
aatggagatc	ttactgaagg	cacagcctat	acaaacgctg	ttggatttat	gcctaacctc	5880
tcagcttatc	caaaatctca	cggtaaaaact	gcaaaaagta	acattgtcag	tcaagtttac	5940

ttaaaccggag	acaaaactaa	acctgtaaca	ctaaccatta	cactaaacgg	tacacaggaa	6000
acaggagaca	caactccaag	tgcatactct	atgtcatttt	catgggactg	gtctggccac	6060
aactacatta	atgaaatatt	tgccacatcc	tcttacactt	tttcatacat	tgcccaagaa	6120
taaagaagcg	gccgctcgag	catgcatcta	gagggcccta	ttctatagtg	tcacctaata	6180
gctagagctc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	tgttgtttgc	6240
ccctcccccg	tgccttccct	gaccctggaa	ggtgccactc	ccactgtcct	ttcctaataa	6300
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	6360
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	6420
ggctctatgg	cttctgaggg	ggaaagaacc	agctggggct	ctagggggta	tccccacgcg	6480
ccctgtagcg	gcgcattaag	cgcggcgggt	gtggtgggta	cgcgcagcgt	gaccgctaca	6540
cttgccagcg	ccctagcgcc	cgctcctttc	gcttctctcc	cttccctttc	cgccacgttc	6600
gccggctttc	cccgtaagc	tctaaatcgg	ggcatccctt	taggggtccg	atttagtgct	6660
ttacggcacc	tgcaccccaa	aaaacttgat	taggggtgatg	gttcacgtag	tgggccatcg	6720
ccctgataga	cggtttttcg	ccctttgacg	ttggagtcca	cgttctttta	tagtggactc	6780
ttgttccaaa	ctggaacaac	actcaacctt	atctcgggtct	attcttttga	tttataaggg	6840
attttgggga	tttcggccta	ttgggttaaaa	aatgagctga	tttaacaaaa	atttaacgcg	6900
aattaattct	gtggaatgtg	tgctcagttag	gggtgtggaaa	gtccccaggc	tccccaggca	6960
ggcagaagta	tgcaaacgat	gcactcaaat	tagtcagcaa	ccagggtgtgg	aaagtcccca	7020
ggctccccag	caggcagaag	tatgcaaagc	atgcatctca	attagtcagc	aaccatagtc	7080
ccgccccctaa	ctccgccccat	cccgccccct	actccgcccc	gttccgcccc	ttctccgccc	7140
catggctgac	taattttttt	tatttatgca	gagggccagg	ccgctctctg	ctctgagcta	7200
ttccagaagt	agtgaggagg	ctttttttgga	gctctaggct	tttgcaaaaa	gctcccgga	7260
gcttgatat	ccatttttcg	atctgatcaa	gagacaggat	gaggatcggt	tcgcatgatt	7320
gaacaagatg	gattgcacgc	agggtctccg	gccgcttggtg	tggagaggct	attcgggtat	7380
gactgggcac	aacagacaat	cggtctctct	gatgccggcg	tggtccgggt	gtcagcgag	7440
gggcgcccgg	ttctttttgt	caagaccgac	ctgtccgggtg	ccctgaatga	actgcaggac	7500
gaggcagcgc	ggctatcggt	gctggccacg	acgggcgttc	cttgccgagc	tgtgctcgac	7560
gttgtcactg	aagcgggaag	ggactgggtg	ctattgggcg	aagtgccggg	gcaggatctc	7620
ctgtcatctc	accttgctcc	tgccgagaaa	gtatccatca	tggctgatgc	aatgccggcg	7680
ctgcatacgc	ttgatccggc	tacctgcccc	ttcgaccacc	aagcgaaaca	tcgcatcgag	7740
cgagcacgta	ctcggatgga	agccgggtct	gtcgatcagg	atgatctgga	cgaagagcat	7800
caggggctcg	cgccagccga	actgttcgcc	aggctcaagg	cgcgcatgcc	cgacggcgag	7860
gatctcgctg	tgacccatgg	cgatgcctgc	ttgccgaata	tcatggtgga	aaatggccgc	7920
ttttctggat	tcatcgactg	tgcccggtg	ggtgtggcgg	accgctatca	ggacatagcg	7980
ttggctaccc	tcgatattgc	tgaagagctt	ggcggcgaa	gggctgaccg	cttctcgtg	8040
ctttacggta	tcgcccgtcc	cgattcgag	cgcactgcct	tctatcgct	tcttgacgag	8100
ttcttctgag	cgggactctg	gggttcgaaa	tgaccgacca	agcgacgccc	aacctgccat	8160
cacgagattt	cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	atcggtttcc	8220
gggacgccgg	ctggatgac	ctccagcgcg	gggatctcat	gctggagttc	ttcgcccacc	8280
ccaacttggt	tattgcagct	tataatgggt	acaaataaag	caaatgcatc	acaaatttca	8340
caaataaagc	atttttttca	ctgcaattcta	gttgtgggtt	gtccaaactc	atcaatgtat	8400
cttatcatgt	ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatca	tggtcatagc	8460
tgtttcctgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	8520
taaagtgtaa	agcctggggg	gcctaattgag	tgagctaact	cacattaatt	gcgttgcgct	8580
cactgcccgc	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	8640
gcgcggggag	aggcggtttg	cgtattgggc	gctcttcgcg	ttctctcgct	actgactcgc	8700
tgcgctcgg	cgttcggtcg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacgg	8760
tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaagg	cagcaaaaagg	8820
ccaggaaccg	taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	8880
agcatcacia	aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgcagga	ctataaagat	8940
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	9000
ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	9060
gtaggtatct	cagttcgggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	9120
ccgttcagct	cgaccgctgc	gccttatccg	gtcaactatc	tcttgagtcc	aaccgggtaa	9180
gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgagggtatg	9240
taggcgggtg	tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	9300
tatttggtat	ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	9360
gatccggcaa	acaaaccacc	gctggtagcg	gtgggttttt	tggttgcaag	cagcagatta	9420
cgcgcaaaaa	aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	9480
agtggaaacga	aaactcacgt	taagggtatt	tggtcatgag	attatcaaaa	aggatcttca	9540
cctagatcct	tttaaatata	aatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	9600
cttgggtctga	cagttaccaa	tgcttaataca	gtgaggcacc	tatctcagcg	atctgtctat	9660

```

ttcgtttcatc catagtgtgcc tgactccccg tcgtgtagat aactacgata cgggaggggct 9720
taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaceg gctccagatt 9780
tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtoct gcaactttat 9840
ccgcctccat ccagctctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 9900
atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9960
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 10020
tgtgcaaaaa agcggttagc tccttcgggc ctccgatcgt tgtcagaagt aagttggccg 10080
cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 10140
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10200
ggcgaccgag ttgctcttgc ccggcggtcaa tacgggataa taccgcgcca catagcagaa 10260
ctttaaaggt gctcatcatt ggaaaacggt cttcggggcg aaaactctca aggatcttac 10320
cgctggttag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 10380
ttactttcac cagcgtttct gggtagagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 10440
gaataagggc gacacggaaa tggtgaatac tcatactctt cctttttcaa tattattgaa 10500
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 10560
aacaaatagg ggttccgcgc acatttcccc gaaaagtgc acctgacgtc 10610

```

<210> 17
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 17
 tgtacaccgg atccggcgca cacc 24

<210> 18
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 18
 cacaacgagc tcaattaatt aattgccaca tcctc 35

<210> 19
 <211> 4
 <212> PRT
 <213> adenovirus

<400> 19
 Thr Leu Trp Thr
 1

<210> 20
 <211> 12
 <212> PRT
 <213> adenovirus

<400> 20
 Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser
 1 5 10

<210> 22
 <211> 327
 <212> DNA

<213> adenovirus

<400> 22

agatctgaat	tcgagctcgc	tgttgggctc	gcggttgagg	acaaactctt	cgcggtcttt	60
ccagtactct	tggatcgga	acccgtcggc	ctccgaacgg	tactccgcca	ccgagggacc	120
tgagcgagtc	cgcacgcacc	ggatcggaaa	acctctcgag	aaaggcgtct	aaccagtcac	180
agtcgcaagg	taggctgagc	accgtggcgg	gcggcagcgg	gtggcggctc	gggttgtttc	240
tggcggaggt	gctgctgatg	atgtaattaa	agtaggcggg	cttgagacgg	cggatggtcg	300
aggtgaggtg	tggcaggctt	gagatct				327

<210> 23

<211> 32480

<212> DNA

<213> adenovirus

<400> 23

catcatcaat	aatatacctt	atthttggatt	gaagccaata	tgataatgag	ggggtggagt	60
ttgtgacgtg	gcgcggggcg	tgggaacggg	gcgggtgacg	tagtagtggtg	gcgggaagtgt	120
gatgttgcaa	gtgtggcgga	acacatgtaa	gcgacggatg	tggcaaaagt	gacgtttttg	180
gtgtgcccgc	gtgtacacag	gaagtgcaca	ttttcgcgcg	gttttagggc	gatgttgtag	240
taaatttggg	cgtaaccgag	taagatttgg	ccattttcgc	gggaaaactg	aataagagga	300
agtgaattct	gaataatttt	gtgttactca	tagcgcgtaa	tctctagcat	cgatgtcgcg	360
aagcttgaat	tcgattaatg	tgagtttagct	cactcattag	gcaccccagg	ctttacactt	420
tatgcttccg	gctcgtatgt	tgtgtggaat	tgtgagcggg	taacaatttc	acacaggaaa	480
cagctatgac	catgattacg	aattcggcgc	agcaccatgg	cctgaaataa	cctctgaaag	540
agggaacttg	ttaggtacct	tctgaggcgg	aaagaaccag	ctgtggaatg	tgtgtcagtt	600
aggggtgtgg	aagtccccag	gctccccagc	aggcagaagt	atgcaaagca	tgcatctcaa	660
ttagtcagca	accaggtgtg	gaaagtcccc	aggctcccca	gcaggcagaa	gtagcgaag	720
catgcatctc	aattagtcag	caaccatagt	cccgcacctc	actccgcccc	ccccgcccct	780
aactccgccc	agttccgccc	attctccgcc	ccatggctga	ctaatttttt	ttattttatgc	840
agaggccgag	gcgcctcggg	cctctgagct	attccagaag	tagtgaggag	gcttttttgg	900
aggcctaggc	ttttgcaaaa	agcttgggat	ctctataatc	tcgcgcaacc	tattttcccc	960
tcgaacactt	tttaagccgt	agataaacag	gctgggacac	ttcacatgag	cgaaaaatac	1020
atcgtcacct	gggacatgtt	gcagatccat	gcacgtaaac	tcgcaagccg	actgatgcct	1080
tctgaacaa	ggaaggcat	tattgcgcta	agccgtggcg	gtctgggtacc	ggtgggtgaa	1140
gaccagaaac	agcacctcga	actgagccgc	gatattgccc	agcgtttcaa	cgcgctgtat	1200
ggcgagatcg	atcccgtcgt	tttacaacgt	cgtgactggg	aaaaccctgg	cgttacccaa	1260
cttaatcgcc	ttgcagcaca	cccccttttc	gccagctggc	gtaatagcga	agaggcccg	1320
accgatcgcc	cttcccaaca	gttgccgcagc	ctgaatggcg	aatggcgctt	tgccctggtt	1380
ccggcaccag	aagcgggtgc	ggaaagctgg	ctggagtgcg	atcttctctga	ggccgatact	1440
gtcgctcgcc	cctcaaactg	gcagatgcac	ggttacgatg	cgcccatcta	caccaacgta	1500
acctatccca	ttacgggtcaa	tccgcggttt	gttcccacgg	agaatccgac	gggttggttac	1560
tcgctcacat	ttaatgttga	tgaaagctgg	ctacaggaag	gccagacgcg	aattattttt	1620
gatggcggtt	actcggcggt	tcactctgtg	tgcaacgggc	gctgggtcgg	ttacggccag	1680
gacagtcgtt	tgccgtctga	atthgacctg	agcgcatttt	tacgcgcggg	agaaaaccgc	1740
ctcgcggtga	tgggtgctgc	ttggagtgcg	ggcagttatc	tggagatca	ggatatgtgg	1800
cggatgagcg	gcattttccg	tgacgtctcg	ttgctgcata	aaccgactac	acaaatcagc	1860
gatttccatg	ttgccactcg	ctttaatgat	gatttcagcc	gcgctgtact	ggaggctgaa	1920
gttcagatgt	gcggcgagtt	gcgtgactac	ctacgggtaa	cagtttcttt	atggcagggt	1980
gaaacgcagg	tcgccagcgg	caccgcgcct	ttcggcgggtg	aaattatcga	tgagcgtggt	2040
ggttatgccg	atcgcgtcac	actacgtctg	aacgtcgaaa	acccgaaact	gtggagcgcc	2100
gaaatcccga	atctctatcg	tgccggtgggt	gaactgcaca	ccgccgacgg	cacgctgatt	2160
gaagcagaag	cctgcgatgt	cgggtttccgc	gaggtgcgga	ttgaaaatgg	tctgctgctg	2220
ctgaacggca	agccgttgct	gattcgaggc	gttaaccgtc	acgagcatca	tcctctgcac	2280
ggtcagggtc	tggatgagca	gacgatgggtg	caggatctcc	tgctgatgaa	gcgaacaac	2340
tttaacgcgg	tgcgctgttc	gcattatccg	aaccatccgc	tgtggtacac	gctgtgcgac	2400
cgctacggcc	tgtatgtggt	ggatgaagcc	aataattgaaa	cccacggcat	gggtgccaatg	2460
aatcgtctga	ccgatgatcc	gcgctggcta	ccggcgatga	gcgaacgcgt	aacgcgaatg	2520
gtgcagcgcg	atcgtaatca	cccgaagtgtg	atcatctggt	cgctggggaa	tgaatcagtc	2580
cacggcgcta	atcacgacgc	gctgatatgc	tggtatcaaat	ctgtcgatcc	ttcccgcccg	2640
gtgcagtatg	aaggcggcgg	agccgacacc	acggccaccg	atattatttg	cccgatgtac	2700
gcgcgcgtgg	atgaagacca	gcccttcccc	gctgtgcccga	aatgggtccat	caaaaaatgg	2760

ctttcgctac	ctggagagac	gcgcccgcgtg	atccttttgcg	aatacgccca	cgcgatgggt	2820
aacagtcttg	gcggttttcgc	taaataactgg	caggcgtttc	gtcagtatcc	ccgttttacag	2880
ggcggcttcg	tctgggactg	ggtggatcag	tgcgtgatta	aatatgatga	aaacggcaac	2940
ccgtgggtcg	cttacggcgg	tgattttggtc	gatacgccga	acgatcgcca	gttctgtatg	3000
aacgggtctgg	tcttttgccga	ccgcacgcgc	catccagcgc	tgacggaagc	aaaacaccag	3060
cagcagtttt	tccagttccg	tttatccggg	caaacatcg	aagtgaccag	cgaataacctg	3120
ttccgtcata	gcgataacga	gctcctgcac	tggatgggtg	cgctggatgg	taagccgctg	3180
gcaagcgggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccgggcaa	ctctggctca	cagtacgcgt	agtgcaccgc	3300
aacgcgaccg	catggtcaga	agccggggc	atcagcgct	ggcagcagtg	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccgcgcg	tcccacgcca	tcccgcatct	gaccaccagc	3420
gaaatggatt	tttgcacga	gctgggta	aagcgttggc	aatttaaccg	ccagtccaggc	3480
tttctttcac	agatgtggat	tggcgataaa	aaacaactgc	tgacgccgct	gcgcgatcag	3540
ttcaccgcgtg	caccgctgga	taacgacatt	ggcgtaaagt	aagcgaccgc	cattgacct	3600
aacgcctggg	tgaacgctg	gaaggcggcg	ggccattacc	aggccgaagc	agcgttgttg	3660
cagtgcacgg	cagatacact	tgctgatgcg	gtgctgatta	cgaccgctca	cgctggcgag	3720
catcagggga	aaaccttatt	tatcagccgg	aaaacctacc	ggattgatgg	tagtgggtcaa	3780
atggcgatta	ccgttgatgt	tgaagtggcg	agcgatacac	cgcatccggc	gcggattggc	3840
ctgaactgcc	agctggcgca	ggtagcagag	cggttaaact	ggctcggatt	agggccgcaa	3900
gaaaactatc	ccgaccgcct	tactgcgcgc	tgttttgacc	gctgggatct	gccatttgtca	3960
gacatgtata	ccccgtacgt	cttcccgcgc	gaaaacggtc	tgcgctgcgg	gacgcgcgaa	4020
ttgaattatg	gcccacacca	gtggcgcggc	gacttccagt	tcaacatcag	ccgctacagt	4080
caacagcaac	tgatggaaac	cagccatcgc	catctgctgc	acgcggaaga	aggcacatgg	4140
ctgaatatcg	acggtttcca	tatggggatt	ggtggcgacg	actcctggag	cccgctcagta	4200
tggcggaat	tccagctgag	cgccgggtgc	taccattacc	agttgggtctg	gtgtcaaaa	4260
taataataac	cgggcaggcc	atgtctgccc	gtatttcgcg	taaggaaatc	cattatgtac	4320
tatttaaaaa	acacaaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttatc	4380
atgggagcct	acttcccgtt	tttcccgcgt	tggctacatg	acatcaacca	tatcagcaaa	4440
agtgatacgg	gtattatttt	tgccgcctatt	tctctgttct	cgctattatt	ccaaccgctg	4500
tttggctcgc	tttctgacaa	actcggaact	tgtttattgc	agcttataat	ggttacaaat	4560
aaagcaatat	catcacaaat	ttcacaaata	aagcattttt	ttcactgcat	tctagtgtgtg	4620
gtttgtccaa	actcatcaat	gtatcttatc	atgtctggat	ccagatctgg	gcgtggctta	4680
aggggtgggaa	agaatatata	aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	4740
gcgcgcgcgc	ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	4800
acgcgcacgc	ccccatgggc	cggggtgcgt	cagaatgtga	tgggctccag	cattgatggg	4860
cgccccgtcc	tgcccgcaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaaacgcg	4920
ttggagactg	cagcctccgc	cgccgcctca	gccgctgcag	ccaccgccc	cgggattgtg	4980
actgactttg	ctttcctgag	cccgccttga	agcagtgacg	cttcccgttc	atccgcccgc	5040
gattgacaagt	tgacggctct	tttggcaca	ttggattctt	tgaccggga	acttaattgc	5100
gtttctcagc	agctgttggg	tctgcgcag	caggtttctg	ccctgaaggc	ttctccct	5160
cccaatgcgg	tttaaaacat	aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	5220
gtgtcttgct	gtctttat	aggggttttg	cgcgcgcggt	aggcccggga	ccagcggct	5280
cggtcggtga	gggtcctgtg	tattttttcc	aggacgtggt	aaaggtgact	ctggatgttc	5340
agatacatgg	gcataagccc	gtctctgggg	tggaggtagc	accactgcag	agcttcacgc	5400
tgccgggtgg	tggtgtagat	gatccagtcg	tagcaggagc	gctgggcgtg	gtgcctaaaa	5460
atgtctttca	gtagcaagct	gattgccagg	ggcaggccct	tggtgtaagt	gtttacaaag	5520
cggttaagct	gggatgggtg	catacgtggg	gatatgagat	gcactcttga	ctgtat	5580
aggttggcta	tggtcccagc	catatccctc	cggggattca	tggtgtgcag	aaccaccagc	5640
acagtgtatc	cgggtgcactt	gggaaatttg	tcatgtagct	tagaaggaaa	tgctgggaag	5700
aacttgagga	cgcccttggtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	5760
atgggcccac	gggcggcggc	ctgggcgaag	atatttctgg	gatcactaac	gtcatagttg	5820
tggtccagga	tgagatcgtc	ataggccatt	tttacaaagc	gcgggcggag	ggtgccagac	5880
tgcgggtataa	tggttccatc	cggcccaggg	gcgtagttac	cctcacagat	ttgcatttcc	5940
cacgctttga	gttcagatgg	ggggatcg	tctacctg	ggcgatgaa	gaaaacgggt	6000
tccggggtag	gggagatcag	ctgggaagaa	agcaggttcc	tgagcagctg	cgacttaccg	6060
cagccgggtg	gcccgtaaat	cacacctatt	accgggtgca	actggtagtt	aagagagctg	6120
cagctgccgt	catccctgag	cagggggggc	acttcgttaa	gcagtccct	gactcgcacg	6180
ttttccctgc	ccaaatccgc	cagaaggcgc	tcgcgcgcc	gcgatagcag	ttcttgcaag	6240
gaagcaaatg	ttttcaacgg	tttgagacgc	tccgcgtag	gcagtctttt	gagcgtttga	6300
ccaagcagtt	ccaggcggtc	ccacagctcg	gtcacctgct	ctacggcatc	tcgatccagc	6360
atatctcttc	gtttcgcggg	ttggggcggc	tttcgctgta	cggcagtagt	cggtgctcgt	6420
ccagacgggc	cagggtcatg	tctttccacg	ggcgcagggt	cctcgtcagc	gtagtctggg	6480

tcacggtgaa	gggggtgcgct	ccgggctgcg	cgctggccag	ggtgcgcttg	aggetggtcc	6540
tgctggtgct	gaagcgctgc	cggtcttcgc	cctgcgcgctc	ggccaggtag	catttgacca	6600
tggtgtcata	gtccagcccc	tccgcggcgt	ggcccttggc	gcgagcttg	cccttgagg	6660
aggcgccgca	cgaggggag	tgcagacttt	tgagggcgta	gagcttgggc	gcgagaaata	6720
ccgattccgg	ggagtaggca	tccgcgccgc	aggcccgca	gacggtctcg	cattccacga	6780
gccaggtgag	ctctggccgt	tcgggggtcaa	aaaccaggtt	tccccatgc	tttttgatgc	6840
gtttcttacc	tctggtttcc	atgagccggt	gtccacgctc	ggtgacgaaa	aggctgtccg	6900
tgtccccgta	tacagacttg	agaggcctgt	cctcgagcgg	tgttccgcgg	tcctcctcgt	6960
atagaaactc	ggaccactct	gagacaaagg	ctcgctcca	ggccagcacg	aaggaggcta	7020
agtgggaggg	gtagcggctg	ttgtccacta	gggggtccac	tcgctccagg	gtgtgaagac	7080
acatgtcgcc	ctcttcggca	tcaagggaagg	tgattggttt	gtaggtgtag	gccagctgac	7140
cgggtgttcc	tgaagggggg	ctataaaaagg	gggtgggggc	gcgttcgtcc	tcactctctt	7200
ccgcatcgct	gtctgcgagg	gccagctggt	ggggtgagta	ctccctctga	aaagcgggca	7260
tgacttctgc	gctaagattg	tcagtttcca	aaaacgagga	ggatttgata	ttcacctggc	7320
ccgcggtgat	gcctttgagg	gtggcccgcat	ccatctggtc	agaaaagaca	atctttttgt	7380
tgtcaagctt	ggtggcaaac	gacccgtaga	gggcgttggg	cagcaacttg	gcgatggagc	7440
gcagggtttg	gtttttgtcg	cgatcgccgc	gctccttggc	cgcatgttt	agctgcacgt	7500
attcgccgcg	aacgcaccgc	cattcgggaa	agacggtggt	gcgctcgtcg	ggcaccaggt	7560
gcacgcgcca	accgcggttg	tgcaggggtga	caaggtcaac	gctggtggct	acctctccgc	7620
gtaggcgctc	gttgggtccag	cagaggcggc	cgcccttgcg	cgagcagaat	ggcggtaggg	7680
ggtctagctg	cgctcgtcc	gggggggtctg	cgctccaggt	aaagaccccg	ggcagcagcg	7740
gcgcgtcgaa	gtagtctatc	ttgcatcctt	gcaagtctag	cgctcgtgc	catgcgcggg	7800
cggcaagcgc	gcgctcgtat	gggttgagtg	ggggacccca	tggcatgggg	tgggtgagcg	7860
cggaggcgta	catgccgcaa	atgtcgtaaa	cgtagagggg	ctctctgagt	attccaagat	7920
atgtagggta	gcactttcca	ccgcggatgc	tggcgcgcac	gtaatcgat	agttcgtgcg	7980
agggagcgag	gaggtcgga	ccgaggttgc	tacgggcggg	ctgctctgct	cggaaagacta	8040
tctgcctgaa	gatggcatgt	gagttggatg	atatggttgg	acgctggaag	acgttgaagc	8100
tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	gtaggagtgc	cgcagcttgt	8160
tgaccagctc	ggcgggtgacc	tgcacgtcta	gggcgcagta	gtccaggggt	tccttgatga	8220
tgtcatactt	atcctgtccc	ttttttttcc	acagctcgcg	gttagaggaca	aactcttcgc	8280
ggtctttcca	gtactcttgg	atcggaaacc	cgctggcctc	cgaacggtaa	gagccttagca	8340
tgtagaactg	gttgacggcc	tggtaggcgc	agcatccctt	ttctacgggt	agcgcgtatg	8400
cctgcgcggc	cttccggagc	gaggtgtggg	tgagcgcaaa	ggtgtccctg	accatgactt	8460
tgaggtactg	gtatttgaag	tcagtgtcgt	cgcattccgc	ctgctcccag	agcaaaaagt	8520
ccgtgcgctt	tttggaacgc	ggatttggca	tggcgaagg	gacatcgttg	aagagtatct	8580
ttcccgcgcg	aggcataaag	ttgcgtgtga	tggcgaagg	tcccggcacc	tcggaacggg	8640
tgtaattac	ctgggcggcg	agcacgatct	cgtcaaagcc	gttgatgttg	tggccacaaa	8700
tgtaaagttc	caagaagcgc	gggatgccct	tgatggaagg	caatttttta	agttcctcgt	8760
aggtgagctc	ttcaggggag	ctgagcccg	gctctgaaag	ggcccagtct	gcaagatgag	8820
ggttggaagc	gacgaattgag	ctccacaggt	cacgggcccat	tagcatttgc	aggtgggtgc	8880
gaaaggtcct	aaactggcga	cctatggcca	ttttttctgg	ggtgatgcag	tagaaggtaa	8940
gcgggtcttg	ttcccagcgg	tcccatccaa	gggtcgcggc	taggtctcgc	gcggcagtca	9000
ctagaggctc	atctccgcgg	aacttcatga	ccagcatgaa	gggcacgagc	tgcttcccaa	9060
aggcccccac	ccaagtatag	gtctctacat	cgtaggtgac	aaagagacgc	tcgggtgcgag	9120
gatgcgagcc	gatcggaag	aactggatct	cccgccacca	attggaggag	tggctattga	9180
tgtggtgaaa	gtagaagtcc	ctgcgacggg	ccgaacactc	gtgctggctt	ttgtaaaaac	9240
gtgcgcagta	ctggcagcgg	tgcacgggct	gtacatcctg	cacgaggttg	acctgacgac	9300
cgcgcacaa	gaagcagagt	gggaatttga	gcccctcgcc	tggcgggtt	ggctggtggt	9360
cttctacttc	ggctgcttgt	ccttgaccgt	ctggctgctc	gaggggagtt	acggtggatc	9420
ggaccaccac	gccgcgcgag	cccaaagtcc	agatgtccgc	gcgcggcggt	cggagcttga	9480
tgacaacatc	gcgcagatgg	gagctgtcca	tggctctggag	ctcccgcggc	gtcaggtcag	9540
gcgggagctc	ctgcaggttt	acctcgcata	gacgggtcag	ggcgcgggct	agatccaggt	9600
gataccta	ttccaggggc	tgggtgggtg	cggcgtcgat	ggcttgcaag	agcccgcatc	9660
cccgcgcgcg	gactacggta	ccgcgcggcg	ggcggtgggc	cgcgggggtg	tccttggatg	9720
atgcatctaa	aagcgggtgac	gcgggcgagc	ccccggaggt	agggggggct	ccggacccgc	9780
cgggagaggg	ggcaggggca	cgtcggcgcc	gcgcgcgggc	aggagctgg	gctgcgcgcg	9840
taggttgctg	gcgaacgcga	cgacgcggcg	ggtgatctcc	tgaatctggc	gcctctcgct	9900
gaagacgacg	ggcccgggtga	gcttgagcct	gaaagagagt	tcgacagaat	caatttcggt	9960
gtcgttgacg	gcggcctggc	gcaaaatctc	ctgcacgtct	cctgagttgt	cttgataggc	10020
gatctcgccc	atgaactgct	cgatctcttc	ctcctggaga	tctccgcgctc	cggctcgctc	10080
cacgggtggcg	gcgaggtcgt	tggaaatgcg	ggccatgagc	tgcgagaagg	cgttgaggcc	10140
tcctcgttc	cagacgcggc	tgtagaccac	gcccccttcg	gcatcgcggg	cgcgcagatg	10200

cacctgcgcg	agattgagct	ccacgtgccg	ggcgaagacg	gcgtagtttc	gcaggcgctg	10260
aaagaggtag	ttgagggtgg	tggcggtgtg	ttctgccacg	aagaagtaca	taaccacagc	10320
tcgcaacgtg	gattcggtga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	10380
gtccacggcg	aagttgaaaa	actgggagtt	gcgcgccgac	acggttaact	cctcctccag	10440
aagacggatg	agctcggcga	cagtgtcgcg	cacctcgcgc	tcaaaggcta	caggggcctc	10500
ttcttcttct	tcaatctcct	cttccataag	ggcctccctc	tcttcttctt	ctggcgggcg	10560
tgggggaggg	gggacacggc	ggcgacgacg	gcgcaccggg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	10680
gcgcagttgg	aagacgccgc	ccgtcatgtc	ccggttatgg	ggtggcgggg	ggctgccatg	10740
cggcagggat	acggcgctaa	cgatgcatct	caacaattgt	tgtgtaggta	ctccgccgcc	10800
gagggacctg	agcgagtccg	catcgaccgg	atcggaatac	ctctcgagaa	aggcgctctaa	10860
ccagtccacag	tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	10920
gttgtttctg	gcggaggtgc	tgtgatgat	gtaattaaag	taggcggtct	tgagacggcg	10980
gatggtcgac	agaagcacca	tgtccttggg	tccggcctgc	tgaatgcgca	ggcggtcggc	11040
catgccccag	gcttcgthtt	gacatcgggc	caggtctttg	tagtagtctt	gcatgagcct	11100
ttctaccggc	acttcttctt	ctccttcttc	ttgtcctgca	tctcttgcat	ctatcgctgc	11160
ggcgggcgcg	gagtttggcc	gtaggtggcg	ccctcttctt	cccatgcgtg	tgaccgccga	11220
gccccctatc	ggctgaagca	gggctaggtc	ggcgacaacg	cgctcggcta	atatggcctg	11280
ctgcacctgc	gtgagggtag	actggaagtc	atccatgtcc	acaaagcggt	ggtatgcgcc	11340
cgtgttgatg	gtgtaagtgc	agttggccat	aacggaccag	ttaacggctc	ggtgacccgg	11400
ctgcgagagc	tcggtgtacc	tgagacgcga	gtaagccctc	gagtcaaata	cgtagtcgtt	11460
gcaagtccgc	accaggtact	ggtatcccac	caaaaagtgc	ggcgggcggt	ggcggtagag	11520
gggcccagcg	agggtggccg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	11580
tccgtagatg	tacctggaca	tccaggtgat	ggcgggcgcg	gtggtggagg	cgcgcgga	11640
gtcgcgagc	cggttccaga	tgttgccgag	ggcgaataag	tgctccatgg	tcgggacgct	11700
ctggccgggtc	aggcgcgccg	aatcgttgac	gctctagacc	gtgcaaaagg	agagcctgta	11760
agcgggcact	cttccgtggt	ctggtggata	aattcgcaag	ggtatcatgg	cggacgaccg	11820
gggttcgagc	cccgtatccg	gcegtccgcc	gtgatccatg	cggttaccgc	ccgcgtgtcg	11880
aaaccaggtg	tgcgacgtca	gacaacgggg	gagtgctcct	tttggtctcc	ttccaggcgc	11940
ggcggtctgt	gcgctagctt	ttttggccac	tggccgcgcg	cagcgtaagc	ggttaggctg	12000
gaaagcgaaa	gcattaagtg	gctcgctccc	tgtagccgga	gggttatttt	ccaaggggtg	12060
agtcgcggga	cccccggttc	gagtcctcga	ccggcccgac	tgccggcgaac	gggggtttgc	12120
ctccccgtca	tgcaagaccc	cgcttgcaaa	ttcctccgga	aacagggacg	agcccccttt	12180
ttgcttttcc	cagatgcata	cggtgctgcg	gcagatgcgc	ccccctcctc	agcagcgcca	12240
agagcaagag	cagcgccaga	catgcaggcg	accctcccct	cctcctaccg	cgtcaggagg	12300
ggcgacatcc	gcggttgacg	cggcagcaga	tggtgattac	gaacccccgc	ggcgccgggg	12360
ccggcactac	ctggacttgg	aggagggcga	gggcctggcg	cggctaggag	cgccctctcc	12420
tgagcggtag	ccaaggggtg	agctgaagcg	tgatacgcgt	gaggcgtacg	tgccgcggca	12480
gaacctgttt	cgcgaccgcg	agggagagga	gcccagaggag	atgcgggatc	gaaagtttca	12540
cgcaggggtc	gagctgcggc	atggcctgaa	tcgcgcgcgg	ttgctgcgcg	aggaggactt	12600
tgagcccagc	gcgcgaaccg	ggattagtcc	cgcgcgcgca	cacgtggcgg	ccgcgcacct	12660
ggtaaccgca	tacgagcaga	cggtgaacca	ggagattaac	tttcaaaaaa	gctttaacaa	12720
ccacgtgcgt	acgcttgttg	cgcgcgagga	ggtggctata	ggactgatgc	atctgtggga	12780
ctttgtaagc	gcgctggagc	aaaaccccaa	tagcaagccg	ctcatggcgc	agctgttctt	12840
tatagtgcag	cacagcaggg	acaacgaggg	attcagggat	gcgctgctaa	acatagtaga	12900
gcccaggggc	cgctggctgc	tcgatttgat	aaacatcctg	cagagcatag	tggtgcagga	12960
gcgcagcttg	agcctggctg	acaaggtggc	cgccatcaac	tattccatgc	ttagcctggg	13020
caagttttac	gcccgcaga	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgct	gaaggtgctt	accttgagcg	acgacctggg	13140
cgttttatcg	aacgagcgca	tcacacaagg	cgtgagcgtg	agccggcggg	gcgagctcag	13200
cgaccgcgag	ctgatgcaca	gcctgcaaa	ggccctggct	ggcacgggca	gcggcgatag	13260
agaggccgag	tcctactttg	acgcggggcg	tgacctgcgc	tgggccccaa	gccgacgcgc	13320
cctggaggca	gctggggccg	gacctgggct	ggcggtggca	cccgcgcgcg	ctggcaacct	13380
cggcgcgctg	gagggaatgc	acgaggacga	tgagtagcag	ccagaggacg	gcgagtagta	13440
agcggtgatg	tttctgatca	gatgatgcaa	gcgcaaacgg	acccggcggt	gcgggcggcg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acggacgact	ggcgccaggt	catggaccgc	13560
atcatgtcgc	tgactgcgcg	caatcctgac	gcgttccggc	agcagccgca	ggccaaccgg	13620
ctctccgcaa	ttctggaagc	ggtgggtccc	gcgcgcgcaa	accccacgca	cgagaagggtg	13680
ctggcgagcg	ttaacgcgct	ggccgaaaac	agggccatcc	ggcccgcacg	ggccggcctg	13740
gtctacgacg	cgctgcttca	gcgcgtggct	cgttacaaca	gcggcaacgt	gcagaccaac	13800
ctggaccggc	tggtggggga	tgtgcgcgag	gcccgtggcg	agcgtgagcg	cgcgacgacg	13860
cagggcaacc	tgggtcccat	ggttgactaa	aacgccttcc	tgagtacaca	gcccgcaca	13920

gtgccgcggg	gacaggagga	ctacaccaac	tttgtgagcg	caactgcggct	aatggtgact	13980
gagacaccgc	aaagtggagg	gtaccagtct	gggccagact	atTTTTtcca	gaccagtaga	14040
caaggcctgc	agaccgtaaa	cctgagccag	gctttcaaaa	acttgcaggg	gctgtggggg	14100
gtgcgggctc	ccacaggcga	ccgcgcgacc	gtgtctagct	tgctgacgcc	caactcgcgc	14160
ctgttgctgc	tgctaataag	gcccttcacg	gacagtggca	gcgtgtcccg	ggacacatac	14220
ctaggtcact	tgctgacact	gtaccgcgag	gccataggtc	aggcgcagtg	ggacgagcat	14280
actttccagg	agattacaag	tgtcagccgc	gcgtgggggc	aggaggacac	gggcagcctg	14340
gaggcaaccc	taaaactacct	gctgaccaac	cggcggcaga	agatccctc	gttgacacagt	14400
ttaaaccagcg	aggaggagcg	cattttgctgc	tacgtgcagc	agagcgtgag	ccttaacctg	14460
atgcgcgacg	gggtaacgcc	cagcgtggcg	ctggacatga	ccgcgcgcaa	catggaaccg	14520
ggcatgtatg	cctcaaaccg	gccgtttatc	aaccgcctaa	tggactactt	gcatcgcgcg	14580
gccgccgtga	accccgagta	tttacccaat	gccatcctga	acccgcactg	gctaccgccc	14640
cctgggtttct	acaccggggg	attcgagggtg	cccaggggta	acgatggatt	cctctggggac	14700
gacatagacg	acagcgtggt	ttccccgcaa	ccgcagaccc	tgctagagtt	gcaacagcgc	14760
gagcaggcag	aggcggcgct	gcgaaaggaa	agcttccgca	ggccaagcag	cttgtccgat	14820
ctaggcgctg	cggccccgcg	gtcagatgct	agtagcccat	ttccaagctt	gatagggtct	14880
cttaccagca	ctcgcaccac	ccgccccgcg	ctgctggggc	aggaggagta	cctaaacaac	14940
tcgctgctgc	agccgcagcg	cgaaaaaac	ctgcctccgg	catttcccaa	caacgggata	15000
gagagcctag	tggacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	15060
ccaggccccg	gccccccac	ccgtcgtcaa	aggcacgacc	gtcagcgggg	tctgggtgtg	15120
gaggacgatg	actcggcaga	cgacagcagc	gtcctggatt	tgggaggagg	tggcaaccgc	15180
tttgcgccac	ttcgccccag	gctggggaga	atgttttaaa	aaaaaaaaag	catgatgcaa	15240
aataaaaaac	tcaccaaggc	catggcaccg	agcgttggtt	ttcttgatt	ccccttagta	15300
tgccggcgcg	ggcgatgtat	gaggaagggtc	ctcctccctc	ctacgagagt	gtgggtgagcg	15360
cggcgccagt	ggcggcgggc	ctgggttctc	ccttcgatgc	tcccttgagc	ccgcggtttg	15420
tgccctccgc	cctaccggcg	cctaccgggg	ggagaacacg	catccgttac	tctgagttgg	15480
cacccttatt	cgacaccacc	cgtgtgtacc	tggtggacaa	caagtcaacg	gatgtggcat	15540
ccctgaacta	ccagaacgac	cacagcaact	ttctgaccac	ggtcattcaa	aacaatgact	15600
acagccccgg	ggaggcaagc	acacagacca	tcaatcttga	cgaccgggtc	caactggggc	15660
gcgacctgaa	aaccatcctg	cataccaaca	tgccaaatgt	gaacgagttc	atgtttacca	15720
ataagtttaa	ggcgcggggt	atgggtgtcg	gcttgccctac	taaggacaat	caggtgggagc	15780
tgaaatacga	gtgggtggag	ttcacgctgc	ccgaggggcaa	ctactccgag	accatgacca	15840
tagaccttat	gaacaacgcg	atcgtggagc	actacttgaa	agtgggcaga	cagaacgggg	15900
ttctggaaag	cgacatcggg	gtaaagtttg	acaccgcaa	cttcagactg	gggtttgacc	15960
cogtcactgg	ctttgtcatg	cctggggtat	atacaaacga	agccttccat	ccagacatca	16020
ttttgctgcc	aggatgcggg	gtggacttca	cccacagccg	cctgagcaac	ttgttgggca	16080
tcgcaagcg	gcaacccttc	caggagggtc	ttaggatcac	ctacgatgat	ctggagggtg	16140
gtaacattcc	cgcactgttg	gatgtggacg	cctaccaggc	gagcttgaaa	gatgacaccg	16200
aacaggcgcg	gggtggcgca	ggcggcagca	acagcagtgg	cagcggcgcg	gaagagaact	16260
ccaacgcggc	atgcagcgca	atgcagcgcg	tggaggacat	gaacgatcat	gccattcgcg	16320
gcgacacctt	tgccacacgg	gctgaggaga	agcgcgtga	ggccgaagca	gcggccgaag	16380
ctgccgcccc	cgctgcgcaa	cccaggtcg	agaagcctca	gaagaaaccg	gtgatcaaac	16440
ccctgacaga	ggacagcaag	aaacgcagtt	acaaccta	aagcaatgac	agcaccttca	16500
cccagtaccg	cagctgggtac	cttgcataca	actacggcga	ccctcagacc	ggaatccgct	16560
catggaccct	gctttgcaact	cctgacgtaa	cctgcggctc	ggagcaggtc	tactggctcg	16620
tgccagacat	gatgcaagac	cccgtgacct	tccgctccac	gcgccagatc	agcaactttc	16680
cgggtgggtgg	cgccgagctg	ttgcccgtgc	actccaagag	cttctacaac	gaccaggccg	16740
tctactccca	actcatccgc	cagttttacct	ctctgaccca	cgtgttcaat	cgttttccc	16800
agaaccagat	tttggcgcg	ccgccagccc	ccaccatcac	caccgtcagt	gaaaacgttc	16860
ctgctctcac	agatcacggg	acgctaccgc	tgcgcaacag	catcggagga	gtccagcgag	16920
tgaccattac	tgacgccaga	cgccgcacct	gcccctacgt	ttacaaggcc	ctgggcatag	16980
tctcgccgcg	cgtcctatcg	agccgcactt	tttgagcaag	catgtccatc	cttatatcgc	17040
ccagcaataa	cacaggttgg	ggcctgcgct	tcccgaagcaa	gatgtttggc	ggggccaaga	17100
agcgctccga	ccaacaccca	gtgcgcgtgc	gcgggcacta	ccgcgcgcgc	tggggcgcg	17160
acaaacgcgg	ccgcaactgg	cgcaccaccg	tcgatgacgc	catcgacgcg	gtgggtggagg	17220
aggcgcgcaa	ctacacgccc	acgccgccac	cagtgtccac	agtggacgcg	gccattcaga	17280
ccgtggtgcg	cggagccccg	cgctatgcta	aaatgaagag	acggcggagg	cgcgtagcac	17340
gtcgccaccg	ccgcgcacc	ggcactggcg	cccaacgcgc	ggcggcgccc	ctgcttaacc	17400
gcgcacgtcg	caccggccga	cggggcgcca	tcggggcgcg	tcgaaggctg	gccgcgggta	17460
ttgtcactgt	gccccccagg	tccaggcgac	gagcggccgc	cgcagcagcc	gcggccatta	17520
gtgctatgac	tcagggtcgc	aggggcaacg	tgtattgggt	gcgcgactcg	gttagcggcc	17580
tgccgctgcc	cgtgcgcacc	cgccccccgc	gcaactagat	tgcaagaaaa	aactacttag	17640

actcgtactg	ttgtatgtat	ccagcggcgg	cggcgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga	agagatgctc	caggtcatcg	cgccggagat	ctatggcccc	ccgaagaagg	17760
aagagcagga	ttacaagccc	cgaaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact	tgacgacgag	gtggaactgc	tgcacgctac	cgcgcccagg	cgacgggtac	17880
agtggaaaagg	tgcagcgtga	aaacgtgttt	tgcgacccgg	caccaccgta	gtcttttacgc	17940
ccggtgagcg	ctccaccgcg	acctacaagc	gcgtgtatga	tgaggtgtac	ggcgacgagg	18000
acctgcttga	gcaggccaac	gagcgctcg	gggagtttgc	ctacggaaaag	cggcataagg	18060
acatgctggc	gttgccgctg	gacgagggca	acccaacacc	tagcctaaag	cccgtaacac	18120
tgcagcaggt	gctgcccgcg	cttgccaccgt	ccgaagaaaa	gcgcggccta	aagcgcgagt	18180
ctggtgactt	ggcaccacc	gtgcagctga	tggtaaccaa	gcgccagcga	ctggaagatg	18240
tcttgaaaaa	aatgaccgtg	gaacctgggc	tggagcccg	ggtccgcgtg	cggccaatca	18300
agcaggtggc	gcccggactg	ggcgtgcaga	ccgtggactg	tcagataccc	actaccagta	18360
gcaccagtat	tgccaccgcg	acagagggca	tggagacaca	aacgtccccg	gttgccctcag	18420
cgggtggcgg	tgccgcggtg	caggcggctg	ctgcggccgc	gtccaagacc	tctacggagg	18480
tgcaaacgga	cccgtggatg	tttcgcgttt	cagccccccg	gcgcccgcgc	ggttcgagga	18540
agtcaggcgc	cgccagcgcg	ctactgcccg	aatatgccct	acatccttcc	attgccccta	18600
cccccggtta	tctgtggctac	acctaccgcc	ccagaagacg	agcaactacc	cgacgccgaa	18660
ccaccactgg	aaccgcgcgc	cgccgtcgcc	gtcgccagcc	cgtgctggcc	ccgatttccg	18720
tgcgcagggg	ggctcgcgaa	ggaggcagga	ccctggtgct	gccaacagcg	cgctaccacc	18780
ccagcatcgt	ttaaaagccg	gtctttgtgg	ttcttgcaga	tatggccctc	acctgcccgc	18840
tccgtttccc	ggcgccggga	ttccgaggg	gaatgcaccg	taggaggggc	atggccggcc	18900
acggcctgac	ggcgccgcatg	cgctcgcgcc	accaaccggc	gcggcgcgcg	tcgcaccgtc	18960
gcatgcgcgg	cggatccctg	ccctccttta	ttccactgat	cgccgcggcg	attggcgccg	19020
tgcccgggaat	tgcattccgtg	gccttgcagg	cgcagagaca	ctgattaaaa	acaagttgca	19080
tgtggaaaaa	tcaaaaataaa	aagtctggac	tctcacgctc	gcttggctct	gtaactattt	19140
tgtagaatgg	aagacatcaa	ctttgcgtct	ctggccccgc	gacacggctc	gcgcccgttc	19200
atgggaaaact	ggcaagatat	cggcaccagc	aatatgagcg	gtggcgccct	cagctggggc	19260
tgcgtgtgga	gcggcattaa	aaatttcggt	tccaccgtta	agaactatgg	cagcaaggcc	19320
tggaaacagca	gcacaggcca	gatgctgagg	gataagttga	aagagcaaaa	tttccaacaa	19380
aaggtggtag	atggcctggc	ctctggcatt	agcggggtag	tggacctggc	caaccaggca	19440
gtgcaaaaata	agattaacag	taagcttgat	ccccgccctc	ccgtagagga	gcctccaccg	19500
gccgtggaga	cagtgtctcc	agaggggctg	ggcgaaaagc	gtccgcgccc	cgacagggaa	19560
gaaactctgg	tgacgcaaat	agacgagcct	ccctcgtagc	aggaggcact	aaagcaaggc	19620
ctgcccacca	cccgctcccat	cgcgcccctg	gctaccggag	tgtggggcca	gcacacaccc	19680
gtaacgctgg	acctgcctcc	ccccgcgcag	acccagcaga	aacctgtgct	gccagcccgc	19740
accgcccgtt	ttgtaaccgc	tcctagccgc	gcgtccctgc	gccgcgcccgc	cagcggctccg	19800
cgatcgttgc	ggcccgtagc	cagtggcaac	tggcaaagca	cactgaacag	catcgtgggt	19860
ctggggggtg	aatccctgaa	gcgcgcagca	tgcttctgaa	tagctaactg	gtcgtatgtg	19920
tgtcatgtat	gcgtccatgt	cgcgcgcaga	ggagctgctg	agccgcgcgc	cgccgcgctt	19980
ccaagatggc	tacccttctg	atgatgccgc	agtggctcta	catgcacatc	tcggccagg	20040
acgcctcgga	gtacctgagc	cccgggctgg	tgcagtttgc	ccgcgccacc	gagacgtact	20100
tcagcctgaa	taacaagttt	agaaacccca	cgggtggcgcc	tacgcacgac	gtgaccacag	20160
accgggtccca	gcgtttgacg	ctgcgggttca	tccctgtgga	ccgtgaggat	actgcgtact	20220
cgtacaaggc	gcggttcacc	ctagctgtgg	gtgataaccg	tgtgctggac	atggcttcca	20280
cgtacttttga	catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	20340
ctgcctacaa	cgccttggct	cccaagggtg	ccccaaatcc	ttgcgaatgg	gatgaagctg	20400
ctactgctct	tgaataaaac	ctagaagaag	aggacgatga	caacgaagac	gaagtagacg	20460
agcaagctga	gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	20520
ttacaagaag	gggtattcaa	ataggtgtcg	aaggtcaaac	acctaataat	gccgataaaa	20580
catttcaacc	tgaacctcaa	ataggagaat	ctcagtggta	cgaactgaa	attaatcatg	20640
cagctgggag	agtccttaaa	aagactaccc	caatgaaacc	atgttacggg	tcatatgcaa	20700
aaccacaaaa	tgaaaatgga	gggcaaggca	ttcttgtaaa	gcaacaaaat	ggaaagctag	20760
aaagtcaagt	ggaaatgcaa	ttttttctca	ctactgaggc	gaccgcaggc	aatgggtgata	20820
actttactcc	taaagtggta	ttgtacagtg	aatgtgtaga	tatagaaacc	ccagacatc	20880
atattttctta	catgcccact	attaaggaag	gtaactcacg	agaactaatg	ggccaacaat	20940
ctatgcccac	caggccta	tacattgctt	ttagggacaa	ttttattggg	ctaattgtatt	21000
acaacagcac	gggtaatatg	ggtgtttctg	cgggccaagc	atcgagttg	aatgctgttg	21060
tagatttccg	agacagaaac	acagagcttt	cataccagct	tttgcttgat	tccattgggt	21120
atagaatccg	gtacttttct	atgtgggaatc	aggctgttga	cagctatgat	ccagatgtta	21180
gaattatttga	aaatcatgga	actgaagatg	aacttccaaa	ttactgcttt	ccactgggag	21240
gtgtgatttaa	tacagagact	cttaccaagg	taaaacctaa	aacaggtcag	gaaaatggat	21300
gggaaaaaga	tgctacagaa	ttttcagata	aaaatgaaat	aagagttgga	aataattttg	21360

ccatggaaat	caatctaaat	gccaaacctgt	ggagaaat	cctgtactcc	aacatagcgc	21420
tgtatattgcc	cgacaagcta	aagtacagtc	cttccaacgt	aaaaatttct	gataacccaa	21480
acacctacga	ctacatgaac	aagcgagtgg	tggctcccgg	gttagtggac	tgctacatta	21540
accttggagc	acgctgggtcc	cttgactata	tggacaacgt	caaccatttt	aaccaccacc	21600
gcaatgctgg	cctgcgctac	cgctcaatgt	tgctgggcaa	tggtcgctat	gtgcccttcc	21660
acatccaggt	gcctcagaag	ttcttttgcca	ttaaaaacct	ccttctcctg	ccggggtcat	21720
acacctacga	gtggaacttc	aggaaggatg	ttaacatggt	tctgcagagc	tccttaggaa	21780
atgacctaa	ggttgacgga	gccagcatta	agtttgatag	catttgctt	tacgccacct	21840
tcttccccat	ggcccacaac	accgcctcca	cgcttgaggc	catgcttaga	aacgacacca	21900
acgaccagtc	ctttaacgac	tatctctccg	ccgccaacat	gctctaccct	ataccgcga	21960
acgctaccaa	cgtgcccata	tccatcccc	cccgcactg	ggcggcttcc	cgcggctggg	22020
ccttcacgcg	ccttaagact	aaggaaaccc	catcactggg	ctcgggtatc	gaccttatt	22080
acacctactc	tggctctata	ccctacctag	atggaacctt	ttacctcaac	cacaccttta	22140
agaaggtggc	cattaccttt	gactcttctg	tcagctggcc	tggcaatgac	cgctgctta	22200
cccccaacga	gtttgaaatt	aagcgctcag	ttgacgggga	gggttacaac	gttgcccagt	22260
gtaacatgac	caaagactgg	ttcctggtag	aaatgctagc	taactacaac	attggctacc	22320
agggcttcta	tatcccagag	agctacaagg	accgcatgta	ctccttcttt	agaaacttcc	22380
agcccatgag	cgtcaggtg	gtggatgata	ctaaatacaa	ggactaccaa	caggtgggca	22440
tcctacacca	acacaacaac	tctggatttg	ttggctacct	tgccccacc	atgcgcgaag	22500
gacaggccta	ccctgctaac	ttccctatc	cgcttatagg	caagaccgca	gttgacagca	22560
ttaccagaa	aaagtttctt	tgcgatcgca	ccctttggcg	catccattc	tccagtaact	22620
ttatgtccat	gggcgcactc	acagacctgg	gccaaaacct	tctctacgcc	aactccgcc	22680
acgcgctaga	catgactttt	gaggtggatc	ccatggacga	gcccaccctt	ctttatgttt	22740
tgtttgaagt	ctttgacgtg	gtccgtgtgc	accggccgca	ccgcggcgtc	atcgaaaccg	22800
tgtacctgcy	cacgccttcc	tcggccggca	acgccacaac	ataaagaagc	aagcaacatc	22860
aacaacagct	gccgccatgg	gctccagtga	gcaggaactg	aaagccattg	tcaaagatct	22920
tggttggtgg	ccatattttt	tgggcaacct	tgacaagcgc	tttccaggct	ttgtttctcc	22980
acacaagctc	gcctgcgcca	tagtcaatac	ggccggtcgc	gagactgggg	gcgtacactg	23040
gatggccttt	gcctggaacc	cgcactcaaa	aacatgctac	ctctttgagc	cctttggctt	23100
ttctgaccag	cgactcaagc	aggtttacca	gtttgagtac	gagtcactcc	tgcgccgtag	23160
cgccattgct	tcttcccccg	accgctgtat	aacgctggaa	aagtccacc	aaagcgtaca	23220
ggggcccaac	tggcgccct	gtggactatt	ctgctgcattg	tttctccacg	cctttgccaa	23280
ctggcccaaa	actcccattg	atcacaaccc	caccatgaac	cttattaccg	gggtacccaa	23340
ctccatgctc	aacagtcctc	aggtacagcc	caccctgcgt	cgcaaccagg	aacagctcta	23400
cagcttctctg	gagcgccact	cgccttactt	ccgcagccac	agtgcgcaga	ttaggagcgc	23460
cacttctttt	gtcactttga	aaaacatgta	aaaataatgt	actagagaca	ctttcaataa	23520
aggcaaatgc	ttttatttgt	acactctcgg	gtgattattt	acccccacc	ttgccgtctg	23580
cgccgtttaa	aaatcaaagg	ggttctgccc	cgcatcgcta	tgcgccactg	gcagggacac	23640
gttgcgatac	tggtgttttag	tgtccactt	aaactcaggc	acaaccatcc	gcggcagctc	23700
ggtgaagttt	tactccaca	ggctgcgcac	catcaccaac	gcgtttagca	ggtcgggcgc	23760
cgatatcttt	aagtcgcagt	tggggcctcc	gcctcgccgc	cgcgagttgc	gatacacagg	23820
gttgcagcac	tggaaacta	tcagcgccgg	gtggtgcacg	ctggccagca	cgctcttgct	23880
ggagatcaga	tccgcgtcca	ggtcctccgc	gttgctcagg	gcgaacggag	tcaactttgg	23940
tagctgcctt	cccaaaaagg	gcgcgtgccc	aggctttgag	ttgcactcgc	accgtagtgg	24000
catcaaaagg	tgaccgtgcc	cggctctgggc	gttaggatac	agcgcctgca	taaaagcctt	24060
gatctgctta	aaagccacct	gagcctttgc	gccttcagag	aagaacatgc	cgcaagactt	24120
gccggaaaac	tgattggccg	gacaggccgc	gtcgtgcacg	cagcaccttg	cgtcggtgtt	24180
ggagatctgc	accacatttc	ggccccaccg	gttcttcacg	atcttggcct	tgctagactg	24240
ctccttcagc	gcgcgtgccc	cgttttcgct	agtcacatcc	atttcaatca	cgtgctcctt	24300
atctatcata	atgcttccgt	gtagacactt	aagctcgctt	tcgatctcag	cgcagcgtg	24360
cagccacaac	gcgcagcccg	tgggctcggtg	atgctttag	gtcacctctg	caaacgactg	24420
caggtacgcc	tgcaggaatc	gccccatcat	cgtcacaaag	gtcttggtgc	tggtgaaggt	24480
cagctgcaac	ccgcgggtgct	cctcgttcag	ccaggctctg	catacgccg	ccagagcttc	24540
cacttggtca	ggcagtagtt	tgaagttcgc	ctttagatcg	ttatccacgt	ggtacttgct	24600
catcagcgcg	cgcgcagcct	ccatgccctt	ctcccacgca	gacacgatcg	gcacactcag	24660
cgggttcac	accgtaattt	cactttccgc	ttcgctgggc	tcttctctt	cctcttgctg	24720
ccgcatacca	cgcgccactg	ggtcgctctt	attcagccgc	cgcactgtgc	gcttacctcc	24780
tttgccatgc	ttgattagca	ccgggtgggtt	gctgaaaccc	accatttgta	gcgccacatc	24840
ttctctttct	tcctcgctgt	ccacgattac	ctctggtgat	ggcgggcgct	cgggcttggg	24900
agaagggcgc	ttctttttct	tcttgggcgc	aatggccaaa	tccgcgcgcg	aggtcgatgg	24960
ccgcgggctg	ggtgtgcgcg	gcaccagcgc	gtcttgtgat	gagtcctcct	cgtcctcgga	25020
ctcgatacgc	cgcctcatcc	gcttttttgg	gggcgcgcgcg	ggaggcggcg	gcgacgggga	25080

cggggacgac	acgtcctcca	tggttggggg	acgtcgcgcg	gcaccgcgct	cgcgctcggg	25140
ggtggtttcg	cgctgctcct	cttcccgcact	ggccattttcc	ttctcctata	ggcagaaaaa	25200
gatcatggag	tcagtgcaga	agaaggacag	cctaaccgccc	ccctctgagt	tcgccaccac	25260
cgctccacc	gatgccgcca	acgcgcctac	caccttcccc	gtcgaaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggtttttgta	agcgaagacg	acgaggaccg	25380
ctcagtagca	acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaaca	25440
agtccggcgg	ggggacgaaa	ggcatggcga	ctacctagat	gtggggagacg	acgtgctgtt	25500
gaagcatctg	cagcgccagt	gcgccattat	ctgcgacgcg	ttgcaagagc	gcagcgatgt	25560
gcccctcgcc	atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	25620
accccccaaa	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgtattttg	gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	25740
accctatcc	tgccgtgcca	accgcagccg	agcggacaag	cagctggcct	tcgcccagg	25800
cgctgtcata	cctgatatac	cctcgctcaa	cgaagtgcc	aaaatctttg	agggctcttg	25860
acgcgacgag	aagcgcgccg	caaacgctct	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaac	tcgaggtgta	caacgcgcgc	ctagccgtac	taaaacgcag	25980
catcgaggtc	acccactttg	cctacccggc	acttaacct	ccccccaagg	tcattgagcac	26040
agtcagtagt	gagctgatcg	tgccgcgtgc	gcagcccctg	gagaggggatg	caaatttgca	26100
agaacaaaca	gaggagggcc	tacccgcagt	tgccgacgag	cagctagcgc	gctggcttca	26160
aacgcgcgag	cctgccgact	tgaggaggcg	acgcaacta	atgatggccg	cagtgcctgt	26220
taccgtggag	cttgagtga	tgacgcggtt	ctttgctgac	ccggagatgc	agcgcaagct	26280
agaggaacaa	ttgcaactaca	cctttcgaca	gggctacgta	cgccaggcct	gcaagatctc	26340
caacgtggag	ctctgcaacc	tggtctccta	ccttggaatt	ttgcacgaaa	accgccttgg	26400
gcaaaacgtg	cttcattcca	cgctcaaggg	cgaggcgcg	cgcgactacg	tccgcgactg	26460
cgtttactta	tttctatgct	acacctggca	gacggccatg	ggcggtttgg	agcagtgtct	26520
ggaggagtgc	aacctcaagg	agctgcagaa	actgctaaag	caaaacttga	aggacctatg	26580
gacggccttc	aacgagcgct	ccgtggccgc	gcacctggcg	gacatcattt	tccccgaacg	26640
cctgcttaaa	accctgcaac	agggctctgcc	agacttcacc	agtcaaagca	tggtgcagaa	26700
ctttaggaac	tttatcctag	agcgctcagg	aatcttgccc	gccacctgct	gtgcacttcc	26760
tagcgacttt	gtgcccatta	agtaccgcga	atgccctccg	ccgctttggg	gccactgcta	26820
ccttctgca	ctagccaact	accttgcccta	ccactctgac	ataatggaag	acgtgagcgg	26880
tgacgggtcta	ctggagtgtc	actgtcgctg	caacctatgc	accccgcaac	gctccctggg	26940
ttgcaattcg	cagctgctta	acgaaagtca	aattatcggt	acctttgagc	tgagggttcc	27000
ctcgccctgac	gaaaagtccg	cggctccggg	gttgaaactc	actccggggc	tgtggacgtc	27060
ggcttacctt	cgcaaatttg	tacctgagga	ctaccacgcc	cacgagatta	ggttctacga	27120
agaccaatcc	cgcccgccaa	atcgcgagct	taccgcctgc	gtcattacct	agggccacat	27180
tcttgggccaa	ttgcaagcca	tcaacaaagc	ccgccaagag	tttctgctac	gaaagggacg	27240
gggggtttac	ttggaccccc	agtccggcga	ggagctcaac	ccaatcccc	cgccgcccga	27300
gcccctatcag	cagcagccgc	gggccccttg	ttcccaggat	ggcaccocaa	aagaagctgc	27360
agctgccgcc	gccacccacg	gacgaggagg	aatactggga	cagtcaggca	gaggaggttt	27420
tgagcgagga	ggaggaggac	atgatggaag	actgggagag	cctagacgag	gaagcttccg	27480
aggtcgaaga	ggtgtcagac	gaaacaccgt	caccctcggt	cgcattcccc	tcgccggcgc	27540
cccagaaatc	ggcaaccggg	tccagcatgg	ctacaacctc	cgctcctcag	gcgcccgcgg	27600
cactgcccgt	tcgccgaccc	aaccgtagat	gggacaccac	tggaaaccagg	gccggtaagt	27660
ccaagcagcc	gccgccgtta	gcccgaagag	aacaacagcg	ccaaggctac	cgctcatggc	27720
gcgggcacaa	gaacgccata	gttgcttgct	tgcaagactg	tggggggcaac	atctccttcg	27780
cccgccgctt	tcttctctac	catcacggcg	tgcccttccc	ccgtaacatc	ctgcattact	27840
accgtcatct	ctacagccca	tactgcaccg	gcggcagcgg	cagcggcagc	aacagcagcg	27900
gccacacaga	agcaaaggcg	accggatagc	aagactctga	caaagcccaa	gaaatccaca	27960
gcggcgccag	cagcaggagg	aggagcgctg	cgtctggcgc	ccaacgaacc	cgtatcgacc	28020
cgcgagctta	gaaacaggat	ttttcccact	ctgtatgcta	tatttcaaca	gagcaggggc	28080
caagaacaag	agctgaaaat	aaaaaacagg	tctctgcat	ccctcaccgc	cagctgcctg	28140
tatcacaaaa	gcgaagatca	gcttcggcgc	acgctggaag	acgcggaggc	tctcttcagt	28200
aaatactgcg	cgctgactct	taaggactag	tttcgcgccc	tttctcaaat	ttaagcgcga	28260
aaactacgtc	atctccaggg	cccacacccc	ggcgcagcac	ctatcctcag	ccgcattata	28320

ttcacgcctc	gtcaggcaat	cctaactctg	cagacctcgt	cctctgagcc	gcgctctgga	28860
ggcattggaa	ctctgcaatt	tattgaggag	tttgtgccat	cggctctactt	taaccccttc	28920
tcgggacctc	cgggccacta	tccggatcaa	tttattccta	actttgacgc	ggtaaaggac	28980
tcggcggacg	gctacgactg	aatgttaagt	ggagaggcag	agcaactgcg	cctgaaacac	29040
ctggtccact	gtcgcgcgca	caagtgcctt	gcccgcgact	cgggtgagtt	ttgctacttt	29100
gaattgcccc	aggatcatat	cgagggcccg	gcgcacggcg	tccggcttac	cgcccaggga	29160
gagcttgccc	gtagcctgat	tcgggagttt	acccagcgcc	ccttgctagt	tgagcgggac	29220
aggggacctt	gtgttctcac	tgtgatttgc	aactgtccta	accttggtat	acatcaagat	29280
ttaattaatt	gccacatcct	cttacacttt	ttcatacatt	gcccagaagt	aaagaatcgt	29340
ttgtgttatg	tttcaacgtg	tttatttttc	aattgcagaa	aatttcaagt	catttttcat	29400
tcagtagtat	agccccacca	ccacatagct	tatacagatc	accgtacctt	aatcaaaactc	29460
acagaacctt	agtattcaac	ctgccacctc	cctcccaaca	cacagagtac	acagtccttt	29520
ctccccggct	ggccttaaaa	agcatcatat	catgggtaac	agacataatc	ttaggtgtta	29580
tattccacac	ggtttcctgt	cgagccaaac	gctcatcagt	gatattaata	aactcccccg	29640
gcagctcact	taagtteatg	tcgctgtcca	gctgctgagc	cacaggctgc	tgtccaactt	29700
gcggttgctt	aacggggcgg	gaaggagaag	tccacgccta	catgggggta	gagtcataat	29760
cgtgcatcag	gataggcg	tgggtgctga	gcagcgcg	aataaactgc	tgccgcgcgc	29820
gctccgtcct	gcaggaatac	aacatggcag	tgggtctctc	agcgatgatt	cgaccgcgcc	29880
gcagcataag	gcgccttgtc	ctccgggcac	agcagcgcac	cctgatctca	cttaaatacag	29940
cacagtaact	gcagcacagc	accacaatat	tggtcaaaat	cccacagtgc	aaggcgctgt	30000
atccaaagct	accggcgggg	accacagaac	cagcgtggcc	atcataccac	aagcgagggt	30060
agattaagtg	gcgacccctc	ataaacacgc	tggacataaa	cattacctct	tttggcatgt	30120
tgtaattcac	cacctcccg	taccatataa	acctctgatt	aaacatggcg	ccatccacca	30180
ccatcctaaa	ccagctggcc	aaaacctgcc	cgccggctat	acactgcagg	gaaccgggac	30240
tggaacaatg	acagtggaga	gcccaggact	cgtaaccatg	gatcatcatg	ctcgtcatga	30300
tatcaatggt	ggcacacaac	aggcacacgt	gcatacactt	cctcaggatt	acaagctcct	30360
cccgcgtag	aaccatatcc	cagggaacaa	ccatttcctg	aatcagcgta	aatcccacac	30420
tgaggggaag	acctcgacag	taactcacgt	tgtgcattgt	caaagtgtta	cattcgggca	30480
gcagcggatg	atcctccagt	atggttagcgc	gggtttctgt	ctcaaaagga	ggtagacgat	30540
ccctactgta	cggagtgcgc	cgagacaacc	gagatcgtgt	tggtcgtagt	gtcatgccaa	30600
atggaacgcc	ggacgttagtc	atatttcctg	aagcaaaacc	aggtgcgggc	gtgacaaaca	30660
gatctgcgtc	tccggtctcg	ccgcttagat	cgctctgtgt	agtagttgta	gtatatccac	30720
tctctcaaag	catccaggcg	ccccctggct	tcgggttcta	tgtaaaactcc	ttcatgcgcc	30780
gctgccctga	taacatccac	caccgcagaa	taagccacac	ccagccaacc	tacacattcg	30840
ttctgcgagt	cacacacggg	aggagcggga	agagctggaa	gaaccatgtt	ttttttttta	30900
ttccaaaaga	ttatccaaaa	cctcaaaatg	aagatctatt	aagtgaacgc	gctccccctc	30960
ggtggcgtgg	tcaaactcta	cagccaaaga	acagataatg	gcatttgtaa	gatgttgac	31020
aatggcttcc	aaaaggcaaa	cggccctcac	gtccaagtgg	acgtaaaggc	taaacccttc	31080
agggatgaat	tcctctataa	acattccagc	accttcaacc	atgcccacaa	aattctcatc	31140
tcgccacact	ctcctatat	ctctaagcaa	atcccgaata	ttaagtccgg	ccattgtaaa	31200
aatctgctcc	agagcgccct	ccaccttcag	cctcaagcag	cgaatcatga	ttgcaaaaat	31260
tcaggttctt	cacagacctg	tataagattc	aaaagcggaa	cattaacaaa	aataccgcga	31320
tcccgtaggt	cccttcgcag	ggccagctga	acataatcgt	gcaggtctgc	acggaccagc	31380
gcggccactt	ccccgcagag	aaccttgaca	aaagaaccca	cactgattat	gacacgcata	31440
ctcggagcta	tgctaaccag	cgtagccccg	atgtaagctt	tggtgcatgg	gcggcgatat	31500
aaaatgcaag	gtgctgctca	aaaaatcagg	caaagcctcg	cgcaaaaaag	aaagcacatc	31560
gtagtcatgc	tcattgcagat	aaaggcagg	aagctccgga	accaccacag	aaaaagacac	31620
catttttctc	tcaaacatgt	ctgcgggttt	ctgcataaac	acaaaataaa	ataacaaaaa	31680
aacatttaaa	cattagaagc	ctgtcttaca	acaggaaaaa	caacccttat	aagcataaga	31740
cggactacgg	ccatgcccgc	gtgaccgtaa	aaaaactgg	cacogtgatt	aaaaagcacc	31800
accgacagct	cctcggtcat	gtccggagtc	ataatgtaag	actcggtaaa	cacatcaggt	31860
tgattcatcg	gtcagtgcta	aaaagcgacc	gaaatagccc	gggggaatac	ataccgcgag	31920
gcgtagagac	aacattacag	cccccatagg	aggtataaca	aaattaatag	gagagaaaaa	31980
cacataaaca	cctgaaaaac	cctcctgcct	aggcaaaaata	gcacctccc	gctccagata	32040
aacatacagc	gcttcacagc	ggcagcctaa	cagtcagcct	taccagtaaa	aaagaaaacc	32100
tattaaaaaa	acaccactcg	acacggcacc	agctcaatca	gtcacagtgt	aaaaaagggc	32160
caagtgcaga	gcgagtatat	ataggactaa	aaaatgacgt	aacgggtaaa	gtccacaaaa	32220
aacacccaga	aaaccgcacg	cgaacctacg	ccagaaaacg	aaagccaaaa	aaccacacac	32280
ttcctcaaat	cgtcacttcc	gttttcccac	gttacgtaac	ttccattttt	aagaaaaacta	32340
caattcccaa	cacatacaag	ttactccgcc	ctaaaaaccta	cgtcacccgc	cccgttccca	32400
cgccccgcgc	cacgtcacaa	actccacccc	ctcattatca	tattggcttc	aatccaaaaat	32460
aaggatattt	attgatgatg					32480

<210> 24
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 24
 ctcaacaatt gtggatccgt actcc 25

<210> 25
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 25
 gtgctcagca gatcttgcca ctgtg 25

<210> 26
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 26
 ggcgcgttcg gatccactct cttcc 25

<210> 27
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 27
 ctacatgcta ggcagatctc gttcggag 28

<210> 28
 <211> 1240
 <212> DNA
 <213> adenovirus

<400> 28
 ggatccactc tcttccgcat cgctgtctgc gagggccagc tgttgggggtg agtactccct 60
 ctgaaaagcg ggcattgactt ctgcgctaag attgtcagtt tccaaaaacg aggaggattt 120
 gatattcacc tggcccgcgg tgatgccttt gaggggtggcc gcatccatct ggtcagaaaa 180
 gacaatcttt ttgttgtaaa gcttggtggc aaacgacccg tagagggcgt tggacagcaa 240
 cttggcgatg gagcgcaggg tttgggtttt gtcgcgatcg gcgcgctcct tggccgcgat 300
 gtttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tgggtgcgctc 360
 gtcgggcacc aggtgcacgc gccaaaccgc gttgtgcagg gtgacaaggc caacgctggg 420
 ggctacctct ccgcgtaggc gctcgttggg ccagcagagg cggccgccct tgcgcgagca 480
 gaatggcggt agggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540
 cccgggcagc aggcgcgcgt cgaagtagtc tatcttgcatt ccttgcaagt ctagcgccctg 600

ctgccatgcg	cgggcgccaa	gcgcgcgctc	gtatgggttg	agtgggggac	cccatggcat	660
gggggtgggtg	agcgcgagg	cgtacatgcc	gcaaagtgcg	taaacgtaga	ggggctctct	720
gagtattcca	agatatgtag	ggtagcatct	tccaccgcgg	atgctggcgc	gcacgtaatc	780
gtatagttcg	tgcgagggag	cgaggaggtc	gggaccgagg	ttgctacggg	cgggctgctc	840
tgctcggaag	actatctgcc	tgaagatggc	atgtgagttg	gatgatatgg	ttggacgctg	900
gaagacgttg	aagctggcgt	ctgtgagacc	taccgcgtca	cgcacgaagg	aggcgtagga	960
gtcgcgacgc	ttgttgacca	gctcggcggt	gacctgcacg	tctagggcgc	agtagtccag	1020
ggtttccttg	atgatgtcat	acttatcctg	tccctttttt	ttccacagct	cgcggttgag	1080
gacaaactct	tccgggtcct	tccagtactc	ttggatcgga	aaccgcgcgc	cctccgaacg	1140
agatccgtac	tccgcgcgcg	agggacctga	gcgagtcgcg	atcgaccgga	tcggaatacc	1200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgcaagatct			1240

<210> 29

<211> 8383

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV60

<400> 29

gacggatcgg	gagatctccc	gatccccat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtggt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaataca	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcg	tggctgaccg	cccaacgacc	360
cccggccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tattttacgg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggactttc	ctacttgcca	gtacatctac	gtattagtoa	600
tgcgtattac	catggtgatg	cggtttttgg	agtacatcaa	tgggctgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ctgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	ccatttgacg	caaatgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcggat	ccactctctt	ccgcacgcgt	gtctgcgagg	gccagctgtt	gggggtgagta	960
ctccctctga	aaagcgggca	tgacttctgc	gctaagattg	tcagtttcca	aaaacgagga	1020
ggatttgata	ttcacctggc	ccgcgggtgat	gcctttgagg	gtggccgcat	ccatctgggtc	1080
agaaaagaca	atctttttgt	tgtcaagctt	gggtggcaaac	gacccgtaga	gggcgttgga	1140
cagcaacttg	gcgatggagc	gcagggtttg	gtttttgtcg	cgatcggcgc	gctccttggc	1200
cgcgatgttt	agctgcacgt	attcgcgcgc	aacgcaccgc	cattcgggaa	agacgggtgt	1260
gcgctcgtcg	ggcaccaggt	gcacgcgcga	accgcgggtg	tgacgggtga	caaggtcaac	1320
gctgggtggc	acctctccgc	gtaggcgctc	gttgggtccag	cagaggcggc	cgcccttgcg	1380
cgagcagaat	ggcggtaggg	ggtctagctg	cgtctcgtcc	ggggggtctg	cgtccacggt	1440
aaagaccccg	ggcagcaggc	gcgcgtcgaa	gtagtctatc	ttgcatcctt	gcaagtctag	1500
cgctctgctg	catgcgcggg	cggcaagcgc	gcgctcgtat	gggttgagtg	ggggacccca	1560
tggcatgggg	tgggtgagcg	cggaggcgta	catgccgcaa	atgtcgtaaa	cgtagagggg	1620
ctctctgagt	attccaagat	atgtagggtg	gcactttcca	ccgcggatgc	tggcgcgcac	1680
gtaatcgtat	agtctcgtcg	agggagcgag	gaggtcgggg	ccgaggttgc	tacgggcggg	1740
ctgctctgct	cggaagacta	tctgcctgaa	gatggcatgt	gagttggatg	atatggttgg	1800
acgctgggaag	acgttgaagc	tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	1860
gtaggagtcg	cgcagcttgt	tgaccagctc	ggcggtgacc	tgcacgtcta	gggcgcagta	1920
gtccagggtt	tccttgatga	tgtcatactt	atcctgtccc	ttttttttcc	acagctcgcg	1980
gttgaggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcggaatac	cgtcggcctc	2040
cgaacgagat	ccgtactccg	ccgcggaggg	acctgagcga	gtccgcacgc	accggatcgc	2100
aaaacctctc	gagaaaaggc	tctaaccagt	cacagtcgca	agatccaaga	tgaagcgcgc	2160
aagaccgtct	gaagatacct	tcaaccccg	gtatccatat	gacacggaaa	ccggtcctcc	2220
aactgtgcct	tttcttactc	ctccctttgt	atcccccaat	gggtttcaag	agagtcccc	2280
tgggggtactc	tctttgcgcc	tatccgaacc	tctagttacc	tccaatggca	tgcttgcgct	2340
caaaatgggc	aacggcctct	ctctggacga	ggcgggcaac	cttacctccc	aaaatgtaac	2400
cactgtgagc	ccacctctca	aaaaaaccaa	gtcaaacata	aacctggaaa	tatctgcacc	2460

cctcacagtt	acctcagaag	ccctaactgt	ggctgccgcc	gcacctctaa	tggtcgcggg	2520
caacacactc	accatgcaat	cacaggcccc	gctaaccgtg	cacgactcca	aacttagcat	2580
tgccacccaa	ggacccctca	cagtgtcaga	aggaaagcta	gccctgcaaa	catcaggccc	2640
cctcaccacc	accgatagca	gtacccttac	tatcactgcc	tcacccctc	taactactgc	2700
cactggtagc	ttgggcattg	acttgaaaga	gccctttat	acacaaaatg	gaaaaactag	2760
actaaagtac	ggggctcctt	tgcatgtaac	agacgaccta	aacactttga	ccgtagcaac	2820
tggtccaggt	gtgactatta	ataatacttc	cttgcaaaact	aaagtactg	gagccttggg	2880
ttttgattca	caaggcaata	tgcaacttaa	tgtagcagga	ggactaagga	ttgattctca	2940
aaacagacgc	cttatacttg	atgttagtta	tccgtttgat	gctcaaaacc	aactaaatct	3000
aagactagga	cagggccctc	tttttataaa	ctcagcccac	aacttggata	ttaactacaa	3060
caaaggcctt	tacttgttta	cagcttcaaa	caattccaaa	aagcttgagg	ttaacctaag	3120
cactgccaa	gggttgatgt	ttgacgctac	agccatagcc	attaatgcag	gagatgggct	3180
tgaattttgt	tcacctaata	caccaaacc	aaatcccctc	aaaacaaaaa	ttggccatgg	3240
cctagaattt	gattcaaa	aggctatggt	tcctaaacta	ggaactggcc	ttagttttga	3300
cagcacaggt	gccattacag	taggaaacaa	aaataatgat	aagctaactt	tgtaggaccac	3360
accagctcca	tctcctaact	gtagactaaa	tgcaagaaaa	gatgctaaac	tcactttggt	3420
cttaacaaaa	tgtggcagtc	aaatacttgc	tacagtttca	gttttggtcg	ttaaaggcag	3480
tttggtcca	atatctggaa	cagttcaaa	tgctcatctt	attataagat	ttgacgaaaa	3540
tgagagtcta	ctaaacaatt	ccttcttggg	cccagaatat	tggaacttta	gaaatggaga	3600
tcttactgaa	ggcacagcct	atacaaacgc	ttgttgattt	atgcctaacc	tatcagctta	3660
tccaaaatct	cacggtaaaa	ctgccccaa	taacattgtc	agtcaagttt	acttaaacgg	3720
agacaaaact	aaacctgtaa	cactaaccat	tacactaaac	ggtacacagg	aaacaggaga	3780
cacaactcca	agtgcatact	ctatgtcatt	ttcatgggac	tggtctggcc	acaactacat	3840
taatgaaata	ttggccacat	cctcttacac	ttttctatc	attgcccagg	aataaaagaa	3900
gcgggcgcct	gagcatgcat	ctagaggggc	ctattctata	gtgtcaccta	aatgctagag	3960
ctcgctgatc	agcctcgact	gtgccttcta	gttgccagcc	atctgttgtt	tgccctccc	4020
ccgtgccttc	cttgaccctg	gaaggtgcca	ctcccactgt	cctttcctaa	taaaatgagg	4080
aaattgcatc	gcattgtctg	agtagggtgc	attctattct	gggggggtgg	gtggggcagg	4140
acagcaaggg	ggaggattgg	gaagacaata	gcaggcatgc	tggggatgag	gtgggctcta	4200
tggtctctga	ggcggaagaa	accagctggg	gctctagggg	gtatccccc	gcgcctgta	4260
gcgggcgcat	aagcgcgggc	ggtgtgggtg	ttacgcgcag	cgtgaccgct	acacttgcca	4320
gcgccctagc	gcccgcctct	ttcgctttct	tcccttctct	tctcgccacg	ttcgccggct	4380
ttccccgtca	agctctaact	cggggcatcc	ctttagggtt	ccgatttagt	gctttacggc	4440
acctcgaccc	caaaaaactt	gattagggtg	attggtcacg	tagtggggcca	tcgcccgtgat	4500
agacggtttt	tcgccccttg	acgttggagt	ccacgttctt	taatagtggg	ctcttgttcc	4560
aaactggaac	aacactcaac	cctatctcgg	tctattcttt	tgatttataa	gggatttttg	4620
ggatttcggc	ctattgggtt	aaaaatgagc	tgattttaaca	aaaatttaac	gcgaattaat	4680
tctgtggaat	gtgtgtcagt	taggtgttgg	aaagtcccca	ggctccccag	gcaggcagaa	4740
gtatgcaaa	catgcatctc	aattagtcag	caaccagggtg	tggaagtcc	ccaggctccc	4800
cagcaggcag	aagtatgcaa	agcatgcatc	tcaattagtc	agcaaccata	gtcccgcgcc	4860
taactccgcc	catcccgcgc	ctaactccgc	ccagttccgc	ccattctccg	ccccatgggt	4920
gactaatttt	ttttatttat	gcagaggcgc	aggccgcctc	tgctctgag	ctattccaga	4980
agtagtaggg	aggctttttt	ggaggcctag	gcttttgcaa	aaagctcccg	ggagcttgta	5040
tatccatttt	cggatctgat	caagagacag	gatgaggatc	gtttcgcatg	attgaacaag	5100
atggattgca	cgcaggttct	ccggccgctt	gggtggagag	gctattcggc	tatgactggg	5160
cacaacagac	aatcggctgc	tctgatgcgc	ccgtgttccg	gctgtcagcg	caggggcgcc	5220
cggttctttt	tgtcaagacc	gacctgtccg	gtgccttgaa	tgaactgcag	gacgaggcag	5280
cgcggctatc	gtggctggcc	acgacggggc	ttccttgccg	agctgtgctc	gacgttgtca	5340
ctgaagcggg	aagggaactg	ctgctatttg	gcgaagtgcc	ggggcaggat	ctcctgtcat	5400
ctcaccttgc	tcctgcccag	aaagtatcca	tcatggctga	tgcaatgcgg	cggctgcata	5460
cgttgatcc	ggctacctgc	ccattcgacc	accaagcgaa	acatcgcatc	gagcgagcac	5520
gtactcggat	ggaagccggg	cttgtcgatc	aggatgatct	ggacgaagag	catcaggggc	5580
tcgcgcagc	gcaactgttc	gccaggctca	aggcgcgcag	gcccgcggc	gaggatctcg	5640
tcgtgaccca	tggcgatgcc	tgcttgccga	atatcatggt	ggaaaatggc	cgcttttctg	5700
gattcatcga	ctgtggccgg	ctgggtgtgg	cggaccgcta	tcaggacata	gcgttggtta	5760
cccgtgatcc	tgctgaagag	cttggcggcg	aatgggctga	ccgcttctc	gtgcttttac	5820
gtatgcagc	tcctgatccg	cagcgcacgc	ccttcttgac	ccttcttgac	gagttctct	5880
gagcgggact	ctgggggttcg	aaatgaccga	ccaagcgacg	cccaacctgc	catcacgaga	5940
tttcgattcc	accgccgcct	tctatgaaag	gttgggcttc	ggaatcgttt	tcggggacgc	6000
cggctggatg	atcctccagc	gcggggatct	catgctggag	ttcttcgccc	accccaactt	6060
gtttatttga	gcttataatg	gttacaataa	aagcaatagc	atcacaat	tcacaaataa	6120
agcatttttt	tcactgcatt	ctagttgtgg	tttgtccaaa	ctcatcaatg	tatcttatca	6180

```

tgtctgtata ccgctcgacct ctagctagag cttggcgtaa tcatgggtcat agctgtttcc 6240
tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg 6300
taaaagcctgg ggtgcctaata gagtgagcta actcacatta attgcgttgc gctcactgcc 6360
cgctttccag tcgggaaacc tgctcgtgcca gctgcattaa tgaatcggcc aacgcgcggg 6420
gagaggcgggt ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc 6480
ggtcgttcgg ctgcggcgag cggatcagc tcaactcaaag gcggtaatatc gggttatccac 6540
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa agggcaggaa 6600
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca 6660
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 6720
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 6780
cctgtccgcc tttctccctt cggaagcgt ggcgctttct caatgctcac gctgtaggta 6840
tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca 6900
gcccagaccgc tgcgccttat ccggtacta tcgtcttgag tccaacccgg taagacacga 6960
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgagggt atgtaggcgg 7020
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 7080
tatctgcgct ctgctgaagc cagttacctt cgaaaaaaga gttggtagct cttgaccggc 7140
caaacaaacc accgctggta gccgtgggtt ttttgtttgc aagcagcaga ttacgcgcag 7200
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtggaa 7260
cgaaaactca cgtaagggga ttttgggtcat gagattatca aaaaggatct tcacctagat 7320
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 7380
tgacagttac caatgcttaa tcagtgggc acctatctca gcgatctgtc tatttcggtc 7440
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 7500
tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 7560
aataaaccag ccagccggaa gggccgagcg cagaagtgggt cctgcaactt tatccgcctc 7620
catccagctc attaattggt gccgggaagc tagagtaagt agttcgccag ttaatagtgt 7680
gcgcaacggt gttgccattg ctacaggcat cgtgggtgtca cgctcgtcgt ttgggtatggc 7740
ttcattcagc tccggttccc aacgatcaag gtccctccgat cgttgtcaga tgatcccca 7800
aaaagcgggt agctccttcg gtccctccat ttctcttact gtcatgccat ccgtaagatg 7860
atcactcatg gttatggcag actcaaccaa gtcatcttga gaatagtgt tgcggcgacc 7920
cttttctgtg actggtgagt caatacggga taataccgcg ccacatagca gaactttaaa 8040
gagttgctct attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 8100
gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 8160
caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa aggggaataag 8220
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 8280
tcaggggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 8340
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 8383

```

<210> 30

<211> 7960

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV67

<400> 30

```

gacggatcgg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg agaactctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcg tggctgaccg cccaacgacc 360
cccgccatt agacgtata atgacgtatg ttcccatagt aacgccaaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcgggttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaaatcaac ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gctggctagc 900

```

gtttaaactt	aagcttggtg	ccgagctcgg	atccactctc	ttccgcacgc	ctgtctgcga	960
gggccagctg	ttgggggtgag	tactccctct	gaaaagcggg	catgacttct	gcgcctaagat	1020
tgtcagtttc	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgccttttga	1080
gggtggccgc	atccatcttg	tcagaaaaga	caatcttttt	gttgtcaagc	ttgggtggcaa	1140
acgacccgta	gagggcggtt	gacagcaact	tggcgatgga	gcgcagggtt	tgggtttttgt	1200
cgcgatcggc	gcgctccttg	gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	1260
gccattcggg	aaagacggtg	gtgcgcctcg	cgggcaccag	gtgcacgcgc	caaccgcggt	1320
tgtgcagggt	gacaagggtc	acgctgggtg	ctacctctcc	gcgtaggcgc	tcgttgggtcc	1380
agcagaggcg	gccgcccttg	cgcgagcaga	atggcggtag	ggggtctagc	tgcgtctcgt	1440
ccgggggggtc	tgcgtccacg	gtaaaagacc	cgggcagcag	gcgcgcgctg	aagtagtcta	1500
tcttgcacgc	ttgcaagtct	agcgccctgt	gccatgcgcg	ggcggcaagc	gcgcgctcgt	1560
atgggttgag	tgggggaccc	catggcatgg	ggtgggtgag	cgcgaggcg	tacatgccgc	1620
aaatgtcgta	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcg	acgtaatcgt	atagttcgtg	cgagggagcg	aggaggctcg	1740
gaccgagggt	gctacggg	ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatattggt	ggacgctgga	agacgttgaa	gctggcgctc	gtgagacctc	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcggtga	1920
cctgcacgtc	tagggcgag	tagtccagg	tttccctgat	gatgtcatac	ttatcctgtc	1980
cctttttttt	ccacagctcg	cggttgagga	caaactcttc	gcggtctttc	cagtactctt	2040
ggatcgga	cccgtcggcc	tcggaacgag	atccgtactc	cgccgcgcgag	ggacctgagc	2100
gagtcgcgat	cgaccggatc	ggaaaacctc	tcgagaagg	cgtctaacca	gtcacagtcg	2160
caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggctct	ccaactgtgc	cttttcttac	tcctcccttt	gtatcccca	2280
atgggtttca	agagagtccc	cctgggggtac	tctctttg	cctatccgaa	cctctagtta	2340
cctccaatgg	catgcttg	ctcaaatgg	gcaacggcct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgta	accactgtga	gccacctctc	caaaaaaacc	aagtcaaca	2460
taaacctgga	aatatctgca	ccctcacag	ttacctcaga	agccctaact	gtggctgccg	2520
ccgcacctct	aatggctcg	ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaccg	2580
tgcacgactc	caaacttagc	attgccaccc	aaggaccctc	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	ccctcacca	ccaccgatag	cagtaccctt	actatcactg	2700
cctcaacccc	tctaactact	gccactggta	gcttgggcat	tgacttgaaa	gagccacttt	2760
atacacaaaa	tggaaaacta	ggactaaagt	acggggctcc	tttgcagtga	acagacgacc	2820
taaacacttt	gaccgtagca	actgggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacagggcc	tctttttata	aactcagccc	3060
acaacttgg	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctc	agcactgcca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgcaccaaac	acaaactccc	3240
tcaaaacaaa	aattggccat	ggcctagatg	tgtattcaaa	caaggctatg	gttccctaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	acaccagctc	catctcctaa	ctgtagacta	aatgcagaga	3420
aagatgctaa	actcactttg	gtcttaacaa	aatgtggcag	tcaaataact	gctacagttt	3480
cagttttggc	tgttaaaggc	agtttggctc	caatactgg	aacagttcaa	agtgtcatc	3540
ttattataag	atgttgacga	aatggagtgc	tactaaacaa	ttccttcctg	gaccagaat	3600
attggaactt	tagaaatgga	gatcttactg	aaggcacagc	ctatacaaac	gctgttggat	3660
ttatgcctaa	cctatcagct	tatccaaaat	ctcacggtaa	aactgccaaa	agtaacattg	3720
tcagtcaagt	ttacttaaac	ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	3780
acggtagaca	ggaaacagga	gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	3840
actgggtctg	ccacaactac	attaatgaaa	tatttggcac	atcctcttac	actttttcat	3900
acattgcccc	agaataaaa	aagcggccgc	tcgagtctag	agggcccggt	taaacccgct	3960
gatcagcctc	gactgtgcct	tctagttgcc	agccatctgt	tgtttgcccc	ccccccgctg	4020
cttccttgac	cctggaagg	gccactccca	ctgtccttcc	ctaataaaa	gaggaaattg	4080
catcgcatgt	tgtcattagg	tgtcattcta	ttctgggggg	tgggggtggg	caggacagca	4140
agggggagga	ttgggaagac	aatagcaggc	atgctgggga	tgcggtgggc	tctatggctt	4200
ctgaggcgga	aagaaccagc	tggggctcta	gggggtatcc	ccacgcgcc	tgtagcggcg	4260
cattaagcgc	ggcgggtgtg	gtgggttacgc	gcagcgtgac	cgctacactt	gccagcgccc	4320
tagcgccgcg	tcctttcgct	ttcttccctt	cctttctcgc	cacgttcgcc	ggctttcccc	4380
gtcaagctct	aaatcggggc	atccctttag	ggttccgatt	tagtgcttta	cggcacctcg	4440
accccaaaaa	acttgattag	ggtgatgggt	cacgtagtgg	gccatcgccc	tgatagacgg	4500
tttttcgccc	tttgacgttg	gagtcacagt	tctttaatag	tggaactctg	ttccaaactg	4560
gaacaacact	caaccctatc	tcgggtctatt	cttttgattt	ataagggatt	ttgggggattt	4620

cggcctattg	gttaaaaaat	gagctgattt	aacaaaaaatt	taacgcgaat	taattctgtg	4680
gaatgtgtgt	cagttagggg	gtggaaagtc	cccaggctcc	ccaggcaggc	agaagtatgc	4740
aaagcatgca	tctcaattag	tcagcaacca	ggtgtgga	gtccccaggc	tccccagcag	4800
gcagaagtat	gcaaagcatg	catctcaatt	agtcagcaac	catagtcccg	cccctaactc	4860
cgcccatccc	gcccctaact	ccgcccagtt	ccgcccattc	tccgccccat	ggctgactaa	4920
ttttttttat	ttatgcagag	gccgaggccg	cctctgcctc	tgagctattc	cagaagtagt	4980
gaggaggctt	ttttggaggc	ctaggctttt	gcaaaaaagc	cccgggagct	tgtatatcca	5040
ttttcggatc	tgatcagcac	gtgttgacaa	ttaatcatcg	gcatagtata	tcggcatagt	5100
ataatacgac	aaggtgagga	actaaaccat	ggccaagtgt	accagtgcgc	ttccgggtgt	5160
caccgcgcgc	gacgtcgccg	gagcggtcga	ggtctggacc	gaccggctcg	ggttctcccc	5220
ggacttcgtg	gaggacgact	tcgccggtgt	ggtccgggac	gacgtgacct	tgttcatcag	5280
cgccgtccag	gaccagggtg	tgccggacaa	caccctggcc	tgggtgtggg	tgccgcggct	5340
ggacgagctg	tacgccgagt	ggtcggaggt	cgtgtccacg	aacttccggg	acgcctccgg	5400
gcccgcccat	accgagatcg	gcgagcagcc	gtgggggcgg	gagttcgccc	tgccgcgacc	5460
ggccggcaac	tgcgtgcact	tcgtggccga	ggagcaggac	tgacacgtgc	taccagattt	5520
cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	atcgttttcc	gggacgcggg	5580
ctggatgac	ctccagcgcg	gggatctcat	gctggagtcc	ttcgcccacc	ccaacttgtt	5640
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	5700
atttttttca	ctgcattcta	gttgtggttt	gtccaaactc	atcaatgtat	cttatcatgt	5760
ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatac	tggtcatagc	tgtttcttgt	5820
gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	taaagtgtaa	5880
agcctggggg	gcctaattgag	tgagctaact	cacattaatt	gcgttgcgct	cactgcccgc	5940
tttccagctg	ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	gcgcggggag	6000
aggcgggttg	cgtattgggc	gctcttccgc	ttcctcgctc	actgactcgc	tgcgctcggt	6060
cgttcggctg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	tatccacaga	6120
atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaagg	cagcaaaaagg	ccagggaaccg	6180
taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	agcatcacia	6240
aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccagacagga	ctataaagat	accaggcggt	6300
tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgcgcgtta	ccggatacct	6360
gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	gtaggatatc	6420
cagttcggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	6480
cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	aacccggtaa	gacacgactt	6540
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtg	6600
tacagagttc	tgtaagtggg	ggcctaacta	cggctacact	agaaggacag	tatttggtat	6660
ctgcgctctg	ctgaagccag	ttacotttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	6720
acaaaccacc	gctggtagcg	gtgggttttt	tggttgcaag	cagcagatta	cgcgagaaa	6780
aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	agtggaaacga	6840
aaactcacgt	taagggattt	tggtcatgag	attatcaaaa	aggatcttca	cctagatcct	6900
tttaatttaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtata	cttggtctga	6960
cagttacca	tgcttaatca	gtgaggcacc	tatctcagcg	atctgtctat	ttcgttcatc	7020
catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgggagggct	taccatctgg	7080
ccccagtgct	gcaatgatac	cgcgagaccc	acgctcaccg	gctccagatt	tatcagcaat	7140
aaaccagcca	gccggaaggg	ccgagcgcag	agtggtcctt	gcaactttat	ccgcctccat	7200
ccagtcctatt	aattggttgc	gggaagctag	agtaagtagt	tcgccagtta	atagtttgcg	7260
caacggttgt	gccattgcta	caggcatcgt	ggtgtcacgc	tcgtcgtttg	gtatggcttc	7320
attcagctcc	ggttcccaac	gatcaaggcg	agttacatga	tcccccatgt	tggtgcaaaa	7380
agcggtttag	tccttcggtc	ctccgatcgt	tgtcagaagt	aagttggccg	cagtgttatc	7440
actcatgggt	atggcagcac	tgcataatc	tcttactgtc	atgccatccg	taagatgctt	7500
ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	7560
ttgctcttgc	ccggcgctca	tacgggataa	taccgcgcca	catagcagaa	ctttaaaagt	7620
gctcatcatt	ggaaaacgtt	cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	7680
atccagttcg	atgtaaccca	ctcgtgcacc	caactgatct	tcagcatctt	ttactttcac	7740
cagcgtttct	gggtgagcaa	aaacaggaag	gcaaaaaagg	gcaaaaaagg	gaataagggg	7800
gacacggaaa	tggtgaatac	tcatactctt	cctttttcaa	tattattgaa	gcatttatca	7860
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	7920
ggttccgcgc	acatttcccc	gaaaagtgcc	acctgacgct			7960

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 31

atgggatcca agatgaagcg cgcaagaccg

30

<210> 32

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 32

cactatagcg gccgcattct cagtcattct

30

<210> 33

<211> 7989

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV69

<400> 33

gacggatcgg	gagatctccc	gatccccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttaggggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccggc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgccca	cttggcagta	catcaagtgt	480
atcatatgcc	aagtagcccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgccagta	catgacctta	tgggactttc	ctacttgcca	gtacatctac	gtattagtca	600
tgcgtattac	catggtgatg	cggttttggc	agtagcatca	tgggcgtgga	tagcgggttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagc	900
gttttaaactt	aagcttggtg	ccgagctcgg	atccactctc	ttccgcacgc	ctgtctgcga	960
ggggccagctg	tgggggtgag	tactccctct	gaaaagcggg	catgacttct	gcgctaagat	1020
tgtcagtttc	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	1080
gggtggccgc	atccatctgg	tcagaaaaga	caatcttttt	gttgtcaagc	ttggtggcaa	1140
acgacccgta	gagggcggtg	gacagcaact	tggcgatgga	gcgcagggtt	tgggttttgt	1200
cgcgatcggc	gcgctccttg	gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	1260
gccattcggg	aaagacggtg	gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggt	1320
tgtgcagggt	gacaagggtc	acgctggtgg	ctacctctcc	gcgtaggcgc	tcgttgggtcc	1380
agcagaggcg	gccgcccttg	cgcgagcaga	atggcggtag	ggggtctagc	tgctgtctcgt	1440
ccgggggggtc	tgcgtccacg	gtaaagaccc	cgggcagcag	gcgcgcgctg	aagtagtcta	1500
tcttgcatcc	ttgcaagtct	agcgccctgt	gccatgcgcg	ggcggcaagc	gcgcgctcgt	1560
atgggttgag	tgggggaccc	catggcatgg	ggtgggtgag	cgcggaggcg	tacatgccgc	1620
aaatgtcgta	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcgc	acgtaatcgt	atagttcgtg	cgaggagcgc	aggaggctcg	1740
gaccgagggt	gctacgggcg	ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatatggtt	ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctc	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcggtga	1920
cctgcacgtc	tagggcgcag	tagtccaggg	tttccttgat	gatgtcatac	ttatcctgtc	1980
cctttttttt	ccacagctcg	cggttgagga	caaactcttc	gcggtctttc	cagtactctt	2040
ggatcggaaa	cccgtcggcc	tccgaacgag	atccgtactc	cgcgcgcgag	ggacctgagc	2100
gagtcgcgat	cgaccggatc	ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtgc	2160

caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggtcct	ccaactgtgc	cttttcttac	tcctcccttt	gtatccccc	2280
atgggtttca	agagagtccc	cctggggtac	tctctttgcg	cctatccgaa	cctctagtta	2340
cctccaatgg	catgcttgcg	ctcaaaatgg	gcaacggcct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgta	accactgtga	gcccacctct	caaaaaaac	aagtcaaaca	2460
taaacctgga	aatatctgca	cccctcacag	ttaccctcaga	agccctaact	gtggctgccc	2520
ccgcacctct	aatggctcgcg	ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaccg	2580
tgcacgactc	caaacttagc	attgccaccc	aaggacccct	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	cccctcacca	ccaccgatag	cagtaccctt	actatcactg	2700
cctcaccccc	tctaactact	gccactggta	gcttgggcat	tgacttgaaa	gagcccatth	2760
atacacaaaa	tggaaaacta	ggactaaagt	acggggctcc	tttgcattga	acagacgacc	2820
taaacacttt	gaccgtagca	actgggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccggttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggggcc	tctttttata	aactcagccc	3060
acaacttgga	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaaccta	agcactgcca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcaccta	tgacccaac	acaaatcccc	3240
tcaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	gggtccaaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttta	tccttgtaaa	aatggagga	attgttaatg	3480
gatatgtaac	gctaattggga	gcctcagact	acgttaacac	cttattttaa	aacaaaaatg	3540
tctccattaa	tgtagaacta	tactttgatg	ccactgggtc	tatattacca	gactcatctt	3600
ctcttaaaac	agatctagaa	ctaaaataca	agcaaacccg	tgacttttagt	gcaagaggtt	3660
ttatgccaa	tactacagcg	tatccatttg	tccttcctaa	tgccgggaaca	cataatgaaa	3720
attatatatt	tggtcaatgc	tactacaaag	caagcgatgg	tgcccttttt	ccgttggaag	3780
ttactgttat	gcttaataaa	cgccctgccag	atagtcgcac	atcctatgtt	atgacttttt	3840
tatggctcct	gaatgctggt	ctagctccag	aaactactca	ggcaaccctc	ataacctccc	3900
catttacctt	ttcctatatt	agagaagatg	actgattttt	aagaagcggc	cgctcgagtc	3960
tagaggggcc	gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	4020
tggtgtttgc	ccctcccccg	tgccctccct	gaccctggaa	gggtgccactc	ccactgtcct	4080
ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgcttg	4200
ggatgcggtg	ggctctatgg	ctctctgagg	ggaaagaacc	sncntagct	ggggctctag	4260
ggggtatccc	cacgcgccct	gtagcggcgc	attaagcgcg	gcgggtgtgg	tggttacgcg	4320
cagcgtgacc	gctacacttg	ccagcgcctc	agcgcgcgct	cctttcgcct	tcttcccttc	4380
ctttctcgcc	acgttcgcgc	gctttccccc	tcaagctcta	aatcggggca	tccttttagg	4440
gttcgcgatt	agtgcctttac	ggcacctcga	ccccaaaaaa	cttgattagg	gtgatgggtc	4500
acgtagtggg	ccatgcctct	gatagacggg	ttttcgccct	ttgacgttgg	agtcacagtt	4560
ctttaatagt	ggactcttgt	tcctaaactg	aacaacactc	aaccctatct	cggtctattc	4620
ttttgattta	taagggtatt	tggggatttc	ggcctatttg	ttaaaaaatg	agctgattta	4680
acaaaaattt	aacgcgaatt	aattctgtgg	aatgtgtgtc	agttagggtg	tggaaggtcc	4740
ccaggctccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	4800
gtgtggaaag	tccccaggct	ccccagcagg	cagaagtatg	caaagcatgc	atctcaatta	4860
gtcagcaacc	atagtcccg	ccctaactcc	gcccaccccg	cccctaactc	cgcccagttc	4920
cgccatttct	ccgccccatg	gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	4980
ctctgcctct	gagctattcc	agaagtatgt	aggaggcttt	tttggaggcc	taggcttttg	5040
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcagcacg	tggtgacaat	5100
taatcatcgg	catagtatat	cggcatagta	taatacgaca	aggtgaggaa	ctaaaccatg	5160
gccaaagtga	ccagtgcctg	tcgggtgctc	accgcgcgcg	acgtcgccgg	agcgggtcgag	5220
ttctggaccg	accggctcgg	gttctcccg	gacttcgtgg	aggacgactt	cgccgggtgtg	5280
gtccgggacg	acgtgacctg	gttcatcagc	gcggtccagg	accaggtggg	gccggacaac	5340
accctggcct	gggtgtgggt	gcggcgccctg	cgcgagctgt	acgccgagtg	gtcggagggtc	5400
gtgtccacga	acttcgggga	cgccctccggg	ccggccatga	ccgagatcgg	cgagcagccg	5460
tgggggaggg	agttcgccct	gcgcgacccg	gccggcaact	gcgtgcactt	cggtggccgag	5520
gagcaggact	gacacgtgct	acgagatttc	gattccaccg	ccgccttcta	tgaaagggtg	5580
ggcttcggaa	tcggtttccg	ggacgcgggc	ttgatgatcc	tcacgcggcg	ggatctcatg	5640
ctggagtctt	tcgcccaccc	caacttggtt	attgcagctt	ataatgggtt	caaataaagc	5700
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatcttag	ttgtgggttg	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	cgacctctag	ctagagcttg	5820
gcgtaatcat	ggtcatagct	gtttccctgtg	tgaaattggt	atccgctcac	aattccacac	5880

aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	cctaatagagt	gagctaactc	5940
acattaattg	cgttgcgctc	actgcccgtc	ttccagtcgg	gaaacctgtc	gtgccagctg	6000
cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	gtattgggag	ctcttccgct	6060
tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	atcagctcac	6120
tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	6180
gcaaaaaggcc	agcaaaaaggc	caggaaccgt	aaaaaaggccg	cgttgctggc	gtttttccat	6240
aggctccgcc	cccctgacga	gcatacaaaa	aatcgacgct	caagtcagag	gtggcgaaac	6300
ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	gcgctctcct	6360
gttccgaccc	tgccgcttac	cggatacctg	tccgcctttc	tcccttcggg	aagcgtggcg	6420
ctttctcaat	gctcacgctg	taggtatctc	agttcggtgt	aggctcgttc	ctccaagctg	6480
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	6540
cttgagtcca	acccggtaag	acacgactta	tcgccactgg	cagcagccac	tggtaacagg	6600
attagcagag	cgagggtatgt	aggcggtgct	acagagttct	tgaagtgggtg	gcctaactac	6660
ggctacacta	gaaggacagt	atcttggtatc	tgcgctctgc	tgaagccagt	taccttcgga	6720
aaaagagttg	gtagctcttg	atccggcaaaa	caaacaccgc	ctggtagcgg	tgggtttttt	6780
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	6840
tctacgggggt	ctgacgctca	gtggaacgaa	aactcacggt	aagggttttt	gggtcatgaga	6900
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagttt	taaatcaatc	6960
taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggcacct	7020
atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	gactccccgt	cgtgtagata	7080
actacgatac	gggagggtct	accatctggc	cccagtgtcg	caatgatacc	gcgagaccca	7140
cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	ccggaagggc	cgagcgcgaga	7200
agtggctcctg	caacttttatc	cgccctccatc	cagtctatta	attggtgccc	ggaagctaga	7260
gtaagttagtt	cgccagttaa	tagtttgccg	aacgttggtg	ccattgctac	aggcatcgctg	7320
gtgtcacgct	cgtcgtttgg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	7380
gtttacatgat	cccccatggt	gtgcaaaaaa	gcggttagct	ccttcgggtcc	tccgatcggt	7440
gtcagaagta	agttagccgc	agtgttatca	ctcatgggtta	tggcagcact	gcataattct	7500
cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	aaccaagtca	7560
ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	cggcgctcaat	acgggataat	7620
accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	ttcggggcga	7680
aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaaccac	tcgtgcaccc	7740
aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	aacaggaagg	7800
caaaatgccg	caaaaaaggg	aataagggcg	acacggaaat	ggtgaatact	catactcttc	7860
ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	atacatattt	7920
gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	catttccccg	aaaagtgcc	7980
cctgacgtc						7989

<210> 34

<211> 7607

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid GRE5-E1-SV40-Hygro

<400> 34

tctagaagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	gtacaggatg	60
ttctagctac	tttattagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	120
gtacaggatg	ttctagctac	tttattagat	ccgtgtacag	gatgttctag	ctactttatt	180
agatcgatct	cctggccggt	cggggtcaaaa	aaccagggtt	ggctataaaa	gggggtgggg	240
gcgcgttcgt	cctcactctc	ttccgcacgc	ctgtctgcga	gggccaggat	cgatcctgag	300
aacttcaggg	tgagtttggg	gacccttgat	tgttctttct	ttttcgctat	tgtaaaattc	360
atgttatatg	gagggggcaa	agttttcagg	gtgttggtta	gaatgggaag	atgtcccttg	420
tatcaccatg	gacctcatg	ataattttgt	ttcttactct	ttctactctg	ttgacaacca	480
ttgtctcctc	ttattttctt	ttcattttct	gtaacttttt	cgtaaaactt	tagcttgcat	540
ttgtaacgaa	tttttaaat	cacttttggt	tatttgctag	attgtaagta	ctttctctaa	600
tcactttttt	ttcaaggcaa	tcagggtata	ttatattgta	cttcagcaca	gttttagaga	660
acaattgtta	taattaaatg	ataaggtaga	atatctctgc	atataaattc	tggctggcgt	720
ggaaatattc	ttattggtag	aaacaactac	atcctgggtca	tcacccctgc	tttctcttta	780
tggttacaat	gatatacact	gtttgagatg	aggataaaat	actctgagtc	caaaccgggc	840
ccctctgcta	accatgttca	tgcttctctc	tttttcctac	agctcctggg	caacgtgctg	900
gttattgtgc	tgtctcatca	ttttggcaaa	gaattagatc	taagcttctg	cagctcgagg	960

actcggtcga	ctgaaaatga	gacatattat	ctgccacgga	ggtgttatta	ccgaagaaat	1020
ggccgccagt	cttttggacc	agctgatcga	agaggtactg	gctgataatc	ttccacctcc	1080
tagccatttt	gaaccaccta	cccttcacga	actgtatgat	ttagacgtga	cggcccccga	1140
agatcccaac	gaggaggcgg	tttcgcagat	ttttcccgac	tctgtaatgt	tggcggtgca	1200
ggaagggatt	gacttactca	cttttccgcc	ggcgcccggt	tctccggagc	cgccctcacct	1260
ttcccggcag	cccagcagc	cggagcagag	agccttgggt	ccggtttcta	tgccaaacct	1320
tgtaccggag	gtgatcgatc	ttacctgcca	cgaggctggc	tttccaccca	gtgacgacga	1380
ggatgaagag	ggtgaggagt	ttgtgttaga	ttatgtggag	caccccgggc	acggttgca	1440
gtcttgtcat	tatcacccga	ggaatacggg	ggacccagat	attatgtgtt	cgctttgcta	1500
tatgaggacc	tgtggcatgt	ttgtctacag	taagtgaaaa	ttatgggcag	tgggtgatag	1560
agtgggtgggt	ttgggtgggt	aatTTTTTTT	ttaatTTTTT	cagttttgtg	gtttaaagaa	1620
ttttgtattg	tgattTTTTT	aaaaggctct	gtgtctgaac	ctgagcctga	gcccagagcca	1680
gaaccggagc	ctgcaagacc	taccgcgcgt	cctaaaatgg	cgctgtctat	cctgagacgc	1740
ccgacatcac	ctgtgtctag	agaatgcaat	agtagtacgg	atagctgtga	ctccggctct	1800
tctaacacac	ctcctgagat	acacccgggt	gtcccgctgt	gccccattaa	accagtggcc	1860
gtgagagtgt	gtgggcgtcg	ccaggctgtg	gaatgtatcg	aggacttgct	taacgagcct	1920
gggcaacctt	tggacttgag	ctgtaaacgc	cccaggccat	aagggtgtaa	cctgtgattg	1980
cgtgtgtgggt	taacgccttt	gtttgctgaa	tgagttgatg	taagtttaat	aaaggggtgag	2040
ataatgttta	acttgcattg	cgtgttaaat	ggggcggggc	ttaaagggta	tataatgcgc	2100
cgtgggctaa	tcttggttac	atctgacctc	atggaggctt	gggagtgttt	ggaagtgttt	2160
tctgctgtgc	gtaacttgct	ggaacagagc	tctaacagta	cctcttgggt	ttggagggtt	2220
ctgtggggct	catcccaggc	aaagttagtc	tgagaatta	aggaggatta	caagtgggaa	2280
tttgaagagc	ttttgaaatc	ctgtgggtgag	ctgtttgatt	ctttgaatct	gggtcaccag	2340
gcgcttttcc	aagagaaggt	catcaagact	ttggattttt	ccacaccggg	gcgcgctgcg	2400
gctgctgttg	cttttttgag	ttttataaag	gataaatgga	gcgaagaaac	ccatctgagc	2460
gggggggtacc	tgctggattt	tctggccatg	catctgtgga	gagcggttgt	gagacacaag	2520
aatcgccctgc	tactgtttgc	ttccgtccgc	ccggcgataa	taccgacgga	ggagcagcag	2580
cagcagcagg	aggaagccag	gcggcgccgc	caggagcaga	gccccatgga	cccagagacc	2640
ggcctggacc	ctcggaatg	aatggtgtac	aggtggctga	actgtatcca	gaactgagac	2700
gcatttttgac	aattacagag	gatgggcagg	ggctaaaggg	ggtaaagagg	gagcgggggg	2760
cttgtgaggc	tacagaggag	gctaggaatc	tagcttttag	cttaatgacc	agacaccgtc	2820
ctgagtgtat	tacttttcaa	cagatcaagg	ataattgcgc	taatgagctt	gatctgctgg	2880
cgcagaagta	ttccatagag	cagctgacca	cttactggct	gcagccaggg	gatgatattg	2940
aggaggctat	tagggtatat	gcaaagggtg	cacttaggcc	agattgcaag	tacaagtcca	3000
gcaaacttgt	aatatcagg	aattgttgct	acatttctgg	gaacgggggc	gaggtggaga	3060
tagatacggg	ggatagggtg	gccttttagat	gtagcatgat	aaatatgtgg	ccggggggtgc	3120
ttggcatgga	cggggtgggt	attatgaatg	taagggtttac	tggccccaat	tttagcgggt	3180
cggttttcct	ggccaatacc	aaccttatcc	tacacggtgt	aagcttctat	gggtttaaca	3240
atactgtgtg	ggaagcctcg	accgatgtcc	gggttcgggg	ctgtgccttt	tactgtgctc	3300
ggaagggggt	ggtgtgtcgc	ccaaaaagca	ggccttcaat	taagaaatgc	ctctttgaaa	3360
ggtgtacctt	gggtatcctg	tctgagggtg	actccagggt	gcgccacaat	gtggcctccg	3420
actgtggttg	cttcatgcta	gtgaaaagcg	tggctgtgat	taagcataac	atgggtatgtg	3480
gcaactgcga	ggacaggggc	tctcagatgc	tgacctgtc	ggacggcaac	tgtcacctgc	3540
tgaagaccat	tcacgtagcc	agccactctc	gcaaggcctg	gccagtgttt	gagcataaca	3600
tactgacccg	ctgttccttg	catttggtga	acaggagggg	ggtgttcccta	ccttaccaat	3660
gcaatttgag	tcacactaag	atattgcttg	agcccagag	catgtccaag	gtgaacctga	3720
acgggggtgtt	tgacatgacc	atgaagatct	ggaaggtgct	gaggtacgat	gagacccgca	3780
ccagggtgcag	accctgcgag	tgtggcggtg	aacatattag	gaaccagcct	gtgatgctgg	3840
atgtgaccga	ggagctgagg	ccgatcaact	tggtgctggc	ctgcaccgc	gctgagtttg	3900
gctctagcga	tgaagataca	gattgagggt	ctgaaatgtg	tggcgctggc	ttaagggtgg	3960
gaaagaatat	ataaggtggg	ggtcttatgt	agttttgtat	ctgttttgca	gcagccgccg	4020
ccgccatgag	caccaactcg	tttgatggaa	gcattgtgag	ctcatatttg	acaacgcgca	4080
tgcccccatg	ggccgggggtg	cgtcagaatg	tgatgggtc	cagcattgat	ggtcgccccg	4140
tctgccccgc	aaactctact	accttgacct	acgagaccgt	gtctggaacg	ccgttgagga	4200
ctgcagcctc	cgccgcgcgt	tcagccgctg	cagccaccgc	ccgcgggatt	gtgactgact	4260
ttgctttcct	gagcccgcct	gcaagcagtg	cagcttcccc	ttcatccgcc	cgcgatgaca	4320
agttgacggc	tcttttggca	caattggatt	ctttgaccgc	ggaacttaat	gtcgtttctc	4380
agcagctgtt	ggatctgcgc	cagcaggttt	ctgcctgaa	ggcttccctc	cctcccaatg	4440
cggtttaaaa	cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgtctt	4500
gctgtctcag	ctgactgctt	aagtcgcaag	ccgaattgga	tccaattcgg	atcgatctta	4560
ttaaagcaga	acttgtttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca	4620
aatttcacaa	ataaagcatt	tttttcaactg	cattctagtt	gtggtttgtc	caaactcatc	4680


```

aatgtatctt atcatgtctg gtcgactcta gactcttccg cttectcgct cactgactcg 4740
ctgcgctcgg tegtccggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc atagggtccg ccccccctgac 4920
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980
taccaggcgt tccccctgg aagctccctc ctgctcctc ctgttccgac cctgccgctt 5040
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 5100
ttaggtatc tcagttcggg taggttcgtt cgctccaagc tgggctgtgt gcacgaacc 5160
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggt 5220
agacacgact tatcgccact ggcagcagcc actggttaaca ggattagcag agcgagggt 5280
gtaggcgggt ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5340
gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5400
tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa gcagcagatt 5460
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 5520
cagtggaaacg aaaactcacg ttaagggtat ttggtcatga gattatcaaa aaggatcttc 5580
acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 5640
acttgggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5700
tttcgttcac ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc 5760
ttaccatctg gccccagtg tgaatgata ccgcgagacc cacgctcacc ggctccagat 5820
ttatcagcaa taaaccagcc agccggaagg gccagcgca gaagtgggtc tgcaacttta 5880
tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt 5940
aatagtttgc gcaacgttgt tgccattgct acaggcatcg tgggtgtcacg ctcgctgctt 6000
ggtatggctt cattcagctc cgttcccaa cgatcaaggc gagttacatg atcccccatg 6060
ttgtgcaaaa aagcgggttag ctccctcggg cctccgatcg ttgtcagaag taagttggcc 6120
gcagtgttat cactcatggg tatggcagca ctgcataatt ctcttactgt catgccatcc 6180
gtaagatgct tttctgtgac tggtagtac tcaaccaagt cattctgaga atagtgtatg 6240
cggcgaccga gttgtctctg cccggcgctc atacgggata ataccgcgcc acatagcaga 6300
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360
ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 6420
tttactttca ccagcgtttc tgggtgagca aaaaacaggaa ggcaaaaatgc cgcaaaaaaag 6480
ggaataaggg cgacacggaa atgttgaaata ctcatactct tcctttttca atattattga 6540
agcatttatc aggggtattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600
aaacaaatag ggggtcccg cacttttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaaat aggcgtatca cgaggccctc ttcgtctcgc 6720
gcgtttcggg gatgacgggtg aaaacctctg acacatgcag ctcccgaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgctcag ggcgcgtcag cgggtgttg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgacca 6900
tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgttaata ttttggtaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020
caataggccg aaatcgcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgttggtc cagtttgga caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
ggcgaaaaaa ccgtctatca gggcgatggc ccactacgtg aacctacacc ctaatcaagt 7200
tttttggggg cgagggtgccg taaagcacta aatcggaacc ctaaaaggag ccccgattt 7260
agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga 7320
gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc 7380
gcgcttaatg cgccgctaca gggcgctcc cattcgccat tcaggtgcg caactgttg 7440
gaagggcgat cgggtcgggc ctcttcgcta ttacgcagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttccagt cagcaggtt taaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcgaattaa ttcgggg 7607

```

<210> 35

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid MMTV-E2a-SV40-Neo

<400> 35

```

gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggg gtgcacctcc aagcttgggc agaaatgggt gaactcccg 120

```

gagtgtccta	cacctagggg	agaagcagcc	aaggggttgt	ttcccaccaa	ggacgacccg	180
tctgcgacaca	aacggatgag	cccatcagac	aaagacatat	tcattctctg	ctgcaaaactt	240
ggcatagctc	tgctttgcct	ggggctattg	ggggaagtgt	cgggttcgtgc	tcgcaggggct	300
ctcacccttg	actcttttaa	tagctcttct	gtgcaagatt	acaatctaaa	caattcggag	360
aactcgacct	tcctcctgag	gcaaggacca	cagccaactt	cctcttacia	gccgcacga	420
ttttgtcctt	cagaaataga	aataagaatg	cttgctaaaa	attataatctt	taccaataag	480
accaatccaa	taggtagatt	attagttact	atgttaagaa	atgaatcatt	atcttttagt	540
actattttta	ctcaaattca	gaagttagaa	atgggaatag	aaaatagaaa	gagacgctca	600
acctcaattg	aagaacaggt	gcaaggacta	ttgaccacag	gcctagaagt	aaaaaaggga	660
aaaaagagtg	tttttgtcaa	aataggagac	aggtggtggc	aaccagggac	ttatagggga	720
ccttacatct	acagaccaac	agatgcccc	ttaccatata	caggaagata	tgacttaaat	780
tgggataggt	gggttacagt	caatggctat	aaagtgttat	atagatccct	cccttttcgt	840
gaaagactcg	ccagagctag	acctccttgg	tgtatgttgt	ctcaagaaga	aaaagacgac	900
atgaaacaac	aggtacatga	ttatatattat	ctaggaacag	gaatgcactt	ttggggaaaag	960
attttccata	ccaaggaggg	gacagtggct	ggactaatag	aacattattc	tgcaaaaact	1020
catggcatga	gttattatga	atagccttta	ttggcccaac	cttgcggttc	ccagggctta	1080
agtaagtttt	tggttacaaa	ctgttcttaa	aacgaggatg	tgagacaagt	ggtttctctga	1140
cttggttttg	tatcaaaggt	tctgatctga	gctctgagtg	ttctatcttc	ctatgttctt	1200
ttggaattta	tccaaatctt	atgtaaatgc	ttatgtaaac	caagatataa	aagagtgtctg	1260
atttttttag	taaaacttga	acagtcctaa	cattcacctc	ttgtgtgttt	gtgtctgttc	1320
gccatcccg	ctccgctcgt	cacttatcct	tcactttcca	gaggggtccc	ccgcagaccc	1380
cgccgacctt	caggtcggcc	gactgcggca	gctggcgccc	gaacagggac	cctcggataa	1440
gtgacccttg	tctctatttc	tactatttgg	tgtttgtctt	gtattgtctc	tttcttgtct	1500
ggctatcatc	acaagagcgg	aacggactca	ccatagggac	caagctagcg	cttctcgtcg	1560
cgtccaagac	cctcaaagat	ttttggcact	tcgttgagcg	aggcgatatc	aggtatgaca	1620
gcgccttgcc	gcaaggccag	ctgcttgtcc	ctcggctgc	gggtggcagc	gcaggatagg	1680
ggtatcttgc	agttttggaa	aaagatgtga	taggtggcaa	gcacctctgg	cacggcaaat	1740
acggggtaga	agttgaggcg	cgggttgggc	tcgcatgtgc	cgttttcttg	gcgtttgggg	1800
ggtacgcgcg	gtgagaatag	gtggcggttcg	taggcaaggc	tgacatccgc	tatggcgagg	1860
ggcacatcgc	tgcgctcttg	caacgcgtcg	cagataatgg	cgcactggcg	ctgcagatgc	1920
ttcaacagca	cgtcgtctcc	cacatctagg	tagtcgccat	gcctttcgtc	ccccgcgccg	1980
acttgttcct	cgtttgccct	tgcgttgtcc	tggtcttgc	ttttatcctc	tggtggtagt	2040
gagcggctct	cgctcgtctc	gcttacaaaa	cctgggtcct	gctcgataat	cacttctctc	2100
tcctcaagcg	ggggtgcctc	gacggggaag	gtggtaggcg	cgttggcggc	atcggtggag	2160
gcggtggtgg	cgaactcaga	gggggcggtt	aggctgtcct	tcttctcgac	tgactccatg	2220
atctttttct	gcctatagga	gaaggaaatg	gccagtccgg	aagaggagca	gcgcgaaacc	2280
acccccgagc	gcggacgcgg	tgccggcgca	cgtcccccaa	ccatggagga	cgtgtcgtcc	2340
ccgtccccgt	cgccgcgcgc	tccccgggcg	cccccaaaaa	agcggatgag	gcggcgtatc	2400
gagtcaggag	accgaggaaga	ctcatcacia	gacgcgctgg	tgccgcgcac	acccagcccg	2460
cggccatcga	cctcggcgcc	ggatttggcc	attgcgccca	agaagaaaaa	gaagcgccct	2520
ttccccaagc	ccgagcgccc	gccatcacca	gaggtaatcg	tggacagcga	ggaagaaaga	2580
gaagatgtgg	cgctacaaat	ggtgggtttc	agcaaccac	cgggtgctaat	caagcatggc	2640
aaaggaggta	agcgcacagt	gcggcggctg	aatgaagacg	acccagtggc	gcgtggtagt	2700
cggacgcaag	aggaagagga	agagcccagc	gaagcggaag	gtgaaattac	ggtgatgaac	2760
ccgctgagtg	tgccgatcgt	gtctgcgtgg	gagaagggca	tggaggctgc	gcgcgcgctg	2820
atggacaagt	accacgtgga	taacgatcta	aaggcgaact	tcaaactact	gcctgaccaa	2880
gtggaagctc	tggcggccgt	atgcaagacc	tggctgaacg	aggagcaccg	cgggttgtag	2940
ctgaccttca	ccagcaacaa	gacctttgtg	acgatgatgg	ggcgattcct	gcaggcgtag	3000
ctgcagtcgt	ttgcagaggt	gacctacaag	catcacgagc	ccacgggctg	cgcgttgttg	3060
ctgcaccgct	gcgctgagat	cgaaggcgag	cttaagtgtc	tacacggaag	cattatgata	3120
aataaggagc	acgtgattga	aatggatgtg	acgagcgaaa	acgggcagcg	cgcgctgaag	3180
gagcagtcta	gcaaggccaa	gatcgtgaag	aaccgggtgg	gccgaaatgt	ggtgcagatc	3240
tccaacaccg	acgcaaggtg	ctgcgtgcac	gacgcggcct	gtccggccaa	tcagttttcc	3300
ggcaagtgtt	cgggcatgtt	cttctctgaa	ggcgcaaaag	ctcagggtggc	ttttaagcag	3360
atcaaggctt	ttatgcaggc	gctgtatcct	aacgcccaga	ccgggcacgg	tcaccttttg	3420
atgccactac	ggtgcgagtg	caactcaaag	cctgggcacg	cgcccttttt	gggaaggcag	3480
ctaccaaaagt	tgactccgtt	cgccctgagc	aacgcggagg	acctggacgc	ggatctgatc	3540
tccgacaaga	gcgtgctggc	cagcgtgcac	caccgcggcg	tgatagtgtt	ccagtgtctg	3600
aacctgtgtg	atcgcaactc	gcgcgcgcag	ggcgagggcc	ccaactgcga	cttcaagata	3660
tcggcgcccc	acctgctaaa	cgcggtgggtg	atgggtgcgca	gcctgtggag	tgaaaacttc	3720
accgagctgc	cgcggatggg	tgtgcctgag	tttaagtggg	gcactaaaca	ccagtatcgc	3780
aacgtgtccc	tgccagtggc	gcatagcgat	gcgcggcaga	acccctttga	tttttaaacg	3840

gcgcagacgg	caagggtggg	ggtaaataat	cacccgagag	tgtacaaata	aaagcatttg	3900
cctttattga	aagtgtctct	agtacattat	ttttacatgt	ttttcaagtg	acaaaaagaa	3960
gtggcgctcc	taatctgcgc	actgtggctg	cggaagtagg	gcgagtggcg	ctccagggaag	4020
ctgtagagct	gttcctgggt	gcgacgcagg	gtgggctgta	cctggggact	gttgagcatg	4080
gagttgggta	ccccggtaat	aagggttcag	gtggggttgt	gatccatggg	agtttggggc	4140
cagttggcaa	aggcgtggag	aaacatgcag	cagaatagtc	cacaggcggc	cgagttgggc	4200
ccctgtacgc	tttgggtgga	cttttccagc	gttatacagc	ggtcggggga	agaagcaatg	4260
gcgctacggc	gcaggagtga	ctcgtactca	aactggtaaa	cctgcttgag	tcgctggtca	4320
gaaaagccaa	agggtcctaaa	gaggtagcat	gttttttgagt	gcgggttcca	ggcaaaggcc	4380
atccagtgtg	cgccccagct	ctcgcgacgc	gccgtattga	ctatggcgca	ggcgagcttg	4440
tgtggagaaa	caaagcctgg	aaagcgcttg	tcataaggctg	ccaaaaaata	tggcccaaaa	4500
ccaagatctt	tgacaatggc	tttcagttcc	tgtctactgg	agcccatggc	ggcagctggt	4560
gttgatgttg	cttgcttctt	tatgtttgtg	cgttgcccgc	cgagaagggc	gtgcgcaggt	4620
acacggtttc	gatgacgcgc	cggtgcggcc	ggtgcacacg	gaccacgtca	aagacttcaa	4680
acaaaacata	aagaagggtg	ggctcgtcca	tgggatccat	atatagggcc	cgggttataa	4740
ttacctcagg	tcgacctcga	gggatctttg	tgaaggaaac	ttacttctgt	ggtgtgacat	4800
aattggacaa	actacctaca	gagattttaa	gctctaaggt	aaatataaaa	tttttaagtg	4860
tataatgtgt	taaactactg	attctaattg	tttgtgtatt	ttagattcca	acctatggaa	4920
ctgatgaatg	ggagcagtg	tggaatgcct	ttaatgagga	aaacctgttt	tgctcagaag	4980
aaatgccatc	tagtgatgat	gaggctactg	ctgactctca	acattctact	cctccaaaaa	5040
agaagagaaa	ggtagaagac	cccaaggact	ttccttcaga	attgctaagt	tttttgagtc	5100
atgctgtgtt	tagtaataga	actcttgctt	gctttgctat	ttacaccaca	aaggaaaaag	5160
ctgcactgct	atacaagaaa	attatggaaa	aatattctgt	aacctttata	agtaggcata	5220
acagttataa	tcataacata	ctgttttttc	ttactccaca	caggcataga	gtgtctgcta	5280
ttaataacta	tgtcctaaaa	ttgtgtacct	ttagcttttt	aattttgtaa	ggggtaataa	5340
aggaatat	gatgtatagt	gccttgacta	gagatcataa	tcagccatac	cacatttgta	5400
gaggttttac	ttgctttaaa	aaacctccca	cacctccccc	tgaacctgaa	acataaaatg	5460
aatgcaattg	ttgttggttaa	cttgttttat	gcagcttata	atggttacia	ataaagcaat	5520
agcatcacaa	atttcacaaa	taaagcattt	atctcactgc	attctagtgt	tgggtttgtcc	5580
aaactcatca	atgtatctta	tcattgtctg	ttccggctgt	ggaatgtgtg	tcagttagg	5640
tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	5700
tcagcaacca	ggtgtgga	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	5760
catctcaatt	agtcagcaac	catagttccg	cccctaactc	cgcccatccc	gcccctaact	5820
ccgcccagtt	ccgcccattc	tccgcccatt	ggctgactaa	ttttttttat	ttatgcagag	5880
gcccaggccg	cctcggcctc	tgagctat	cagaagtagt	gaggaggctt	ttttggaggc	5940
ctaggctttt	gcaaaaagct	tcacgctgcc	gcaagcactc	agggcgcaag	ggctgctaaa	6000
ggaagcggaa	cacgtagaaa	gccagtcgcg	agaaacgggt	ctgaccccg	atgaatgtca	6060
gctactgggc	tatctggaca	agggaaaaac	caagcgcaaa	gagaaagcag	gtagcttgca	6120
gtgggcttac	atggcgatag	ctagactggg	cgggttttatg	gacagcaagc	gaaccgggaat	6180
tgccagctgg	ggcgccctct	ggtaagggtg	ggaagccctg	caaagtaaac	tggatggctt	6240
tcttgccgcc	aaggatctga	tggcgagggg	gatcaagatc	tgatcaagag	acaggatgag	6300
gatcgtttgc	catgattgaa	caagatggat	tgacgcgagg	ttctccggcc	gcttgggtgg	6360
agaggctatt	cggctatgac	tgggcacaac	agacaatcgg	ctgctctgat	gccgcggtg	6420
tccggctgtc	agcgcagggg	cgcccggttc	tttttgtcaa	gaccgacctg	tccggtgccc	6480
tgaatgaact	gcaggacgag	gcagcgcggc	tatcgtggct	ggccacgacg	ggcggttccct	6540
gcgcagctgt	gctcgacgtt	gtcactgaag	cgggaaggga	ctggctgcta	ttgggcgaag	6600
tgccggggca	ggatctcctg	tcattctacc	ttgctcctgc	cgagaaagta	tccatcatgg	6660
ctgatgcaat	gcggcggctg	catacgcttg	atccggctac	ctgcccattc	gaccaccaag	6720
cgaaacatcg	catcgagcga	gcacgtactc	ggatgggaag	cggctcttgc	gatcaggatg	6780
atctggacga	agagcatcag	gggctcgcgc	cagccgaact	gttcgccagg	ctcaaggcgc	6840
gcatgcccga	cggcgaggat	ctcgtcgtga	cccatggcga	tgccctgctt	ccgaatatca	6900
tgggtgaaaa	tggccgcttt	tctggattca	ctgactgtgg	cgggtgggt	gtggcgggac	6960
gctatcagga	catagcgttg	gctaccgctg	atattgctga	agagcttggc	ggcggaatgg	7020
ctgaccgctt	cctcgtgctt	tacggtatcg	ccgctcccga	ttcgcagcgc	atcgccctct	7080
atcgccctct	tgacgagttc	ttctgagcgg	gactctgggg	ttcgaaatga	ccgaccaagc	7140
gacgcccac	ctgccatcac	gagatttcga	ttccaccgcc	gccttctatg	aaaggttggg	7200
cttcggaatg	gttttccggg	acgcggctg	gatgatcctc	cagcgcgggg	atctcatgct	7260
ggagttcttc	gcccaccccg	ggctcgatcc	cctcgcgagt	tggttcagct	gctgctgag	7320
gctggacgac	ctcgcggagt	tctaccggca	gtgcaaatcc	gtcggcatcc	aggaaaccag	7380
cagcggttat	ccgcgcaccc	atgccccga	actgcaggag	tggggaggca	cgatggccgc	7440
tttgggtccc	gatctttgtg	aaggaaacct	acttctgtgg	tgtgacataa	ttggacaaac	7500
tacctacaga	gatttaaagc	tctaaggtaa	atataaaatt	tttaagtgtg	taatgtgtta	7560

aactactgat	tctaattggt	tgtgtatttt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtggg	gaatgccttt	aatgaggaaa	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaaagg	7740
tagaagaccc	caaggacttt	ccttcagaat	tgctaagttt	tttgagtcac	gctgtgttta	7800
gtaatagaac	tcttgcttgc	tttgctattt	acaccacaaa	ggaaaaagct	gcactgctat	7860
acaagaaaa	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	ggcatagagt	gtctgctatt	aataactatg	7980
ctcaaaaatt	gtgtaccttt	agctttttta	tttgtaaagg	ggttaataag	gaatatattga	8040
tgtatagtgc	cttgactaga	gatcataatc	agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg	aacctgaaac	ataaaatgaa	tgcaattggt	8160
gttgttaact	tgtttattgc	agcttataat	ggttacaaat	aaagcaatag	catcacaaat	8220
ttcacaaata	aagcattttt	ttcactgcat	tctagtgtgt	gtttgtccaa	actcatcaat	8280
gtatcttatc	atgtctggat	ccccaggaag	ctcctctgtg	tcctcataaa	ccctaacctc	8340
ctctacttga	gaggacattc	caatcatagg	ctgcccattc	accctctgtg	tccctcctgt	8400
aattaggcca	cttaacaaaa	aggaaattgg	gtaggggttt	ttcacagacc	gctttctaag	8460
ggtaatttta	aaatatctgg	gaagtcctct	ccactgctgt	gttccagaag	tggtggtaaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccac	8580
acctgtctca	tcaagaagca	ctgtgggtgc	tgtgttagta	atgtgcaaaa	caggaggcac	8640
atttttccca	cctgtgtagg	ttccaaaata	tctagtgttt	tcatttttac	ttggatcagg	8700
aaccagcac	tccactggat	aagcattatc	cttatccaaa	acagccttgt	ggctcagtgt	8760
catctgctga	ctgtcaactg	tagcattttt	tgggggttaca	gtttgagcag	gatatttggt	8820
cctgtagttt	gctaacacac	cctgcagctc	caaagggtcc	ccaccaacag	caaaaaaatg	8880
aaaatttgac	ccttgaatgg	gttttccagc	accatttttca	tgagtttttt	gtgtccctga	8940
atgcaagttt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaaa	tttccacagg	tttaagtcct	atttaaatga	ggcaaaggaa	ttcttgaaga	9060
cgaaagggcc	tcgtgatacg	cctattttta	taggttaatg	tcatgataat	aatgggtttc	9120
tagacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9180
taaatacatt	caaatatgta	tcgcctcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	tccctttttt	9300
goggcatttt	gccttcctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	9360
gaagatcagt	tggtgtcacg	agtgggttac	atcgaactgg	atctcaacag	cggtaagatc	9420
cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	9480
tgtggcgctg	tattatcccg	tggtgacgcc	gggcaagagc	aactcggtcg	ccgcatacac	9540
tattctcaga	atgacttggg	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	9600
atgacagtaa	gagaattatg	cagtgtctgc	ataaccatga	gtgataaacac	tgcggccaac	9660
ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	caacatgggg	9720
gatcatgtaa	ctcgccttga	tcgttgggaa	ccggagctga	atgaagccat	accaaaccag	9780
gagcgtgaca	ccacgatgcc	tcgcagcaat	gcaacaacgt	tgcgcaaac	attaactggc	9840
gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagtt	9900
gcaggaccac	ttctgcgctc	ggcccttcgc	gctggctggg	ttattgctga	taaatctgga	9960
gocgggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	10020
cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	tggtgaacg	aaatagacag	10080
atcgctgaga	taggtgcctc	actgattaa	cattggtaac	tgtcagacca	agtttactca	10140
tatatacttt	agattgattt	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	10200
ctttttgata	atctcatgac	caaaatccct	taacgtgagt	tttcggtcca	ctgagcgtca	10260
gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	10320
tgcttgcaaa	caaaaaaacc	accgctacca	gcggtgggtt	gtttgcccga	tcaagagcta	10380
ccaactcttt	ttccgaaggt	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	10440
ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	tagcaccgoc	tacatacctc	10500
gctctgctaa	tctgtttacc	agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	10560
ttggactcaa	gacgatagtt	accggataag	gcgcagcggg	cgggctgaac	gggggggttcg	10620
tgcacacagc	ccagcttgga	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	10680
ctatgagaaa	gcgcacgct	tccggaagg	agaaaggcgg	acaggtatcc	ggtaagcggc	10740
agggtcggaa	caggagagcg	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	10800
agtctgtctg	ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	10860
gggctggagcc	tatggaaaaa	cgcacgaac	gcggcctttt	tacggttcct	ggccttttgc	10920
tggccttttg	ctcacatgtt	cttctctgcg	ttatcccctg	attctgtgga	taaccgtatt	10980
accgcctttg	agttagctga	taccgctcgc	ctcagccgaa	cgaccgagcg	cagcgagtca	11040
gtgagcgagg	aagcggaaga	gcgcctgatg	cggtattttc	tccttacgca	tctgtgcggg	11100
atttcacacc	gcatatgggt	cactctcagt	acaatctgct	ctgatgccgc	atagtttaagc	11160
cagtatctgc	tccttgcttg	tgtgttggag	gtcgcgtgag	agtgcgcgag	caaaatttaa	11220
gctacaacaa	ggcaaggctt	gaccgacaat	tgcatgaaga	atctgcttag	gggttaggcgt	11280

```

tttgcgctgc ttcgcgatgt acggggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aagcggggct tcggttgtag gcgggttagga gtcccctcag gatatagtag 11400
tttcgctttt gcatagggag ggggaaatgt agtccttatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattggtgga agtaagggtg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact                               11600

```

<210> 36
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 36
 gtcactcgag gactcggctg actgaaaatg agacatatta tctgccacgg acc 53

<210> 37
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 37
 cgagatcgat cacctccggt acaaggtttg gcatag 36

<210> 38
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 38
 catgaagatc tggaaggtgc tgaggtacga tgagacc 37

<210> 39
 <211> 51
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 39
 gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51

<210> 40
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 40
 cacgaattcg tcagcgcttc tcgtcgcgtc caagaccc 38

<210> 41
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 41
 caccgccggg aggcggcggc gacggggacg gg

32

<210> 42
 <211> 7231
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid pDV80

<400> 42
 ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60
 acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggtttag gcgttttgcg 120
 ctgcttcgcg atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180
 tagtaatacaa ttacgggggtc attagttcat agcccatata tggagttccg cgttacataa 240
 cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt gacgtcaata 300
 atgacgtatg ttcccatagt aacgccataa gggactttcc attgacgtca atgggtggac 360
 tatttacggg aaactgccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420
 cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta catgacctta 480
 tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540
 cggttttggc agtacatcaa tgggcgtgga tagcgggttg actcacgggg atttccaagt 600
 ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660
 aaatgtcgta acaactccgc cccattgacg caaatggcg gtaggcgtgt acggtgggag 720
 gtctatataa gcagagctct ctggctaact agagaaccca ctgcttactg gcttatcgaa 780
 attaatacga ctactatag ggagacccaa gctggctagc gtttaaactt aagcttggtta 840
 ccgagctcgg atccactctc ttccgcacgc ctgtctgcga gggccagctg ttgggggtgag 900
 tactccctct gaaaagcggg catgacttct gcgctaagat tgtcagtttc caaaaacgag 960
 gaggatttga tattcacctg gccgcgggtg atgcctttga gggtagccgc atccatctgg 1020
 tcagaaaaga caatcttttt gttgtcaagc acgaccgta gagggcggtt 1080
 gacagcaact tggcgatgga gcgcagggtt tgggttttgt cgcgatcggc gcgctccttg 1140
 gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc gccattcggg aaagacgggtg 1200
 gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggg tgtgcagggt gacaaggtca 1260
 acgctgggtg ctacctctcc gcgtaggcgc tcgttgggtc agcagaggcg gccgccttg 1320
 cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt ccgggggggtc tgcgtccacg 1380
 gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta tcttgcatcc ttgcaagtct 1440
 agcgcctgct gccatgcgcg ggccgcaagc gcgcgctcgt atgggttagg tgggggaccc 1500
 catggcatgg ggtgggtgag cgcggaggcg tacatgccgc aaatgtcgta aacgtagagg 1560
 ggctctctga gtattccaag atatgtaggg tagcatcttc caccgcggat gctggcgcg 1620
 acgtaatcgt atagtctctg cgaggagcg aggaggtcgg gaccgaggtt gctacggg 1680
 ggctgctctg ctccgaagac tatctgcctg aagatggcat gtgagttgga tgatatgg 1740
 ggacgctgga agacgttgaa gctggcgtct gtgagacctt ccgcgtcacg cacgaagg 1800
 gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga cctgcacgtc tagggcg 1860
 tagtccaggg tttccttgat gatgtcatac ttatcctgtc cttttttttt ccacagct 1920
 cggttgagga caaactcttc gcggtctttc cagtactctt ggatcggaac cccgtcgg 1980
 tccgaacgag atccgtactc cgcgcgcgag ggacctgagc gagtccgcac cgaccggat 2040
 ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg caagatccaa gatgaag 2100
 gccgcgcccc gcgaagatga cttcaacccc gtctaccctt atggctacgc gcggaatc 2160
 aatatccctt tctcactcc cccctttgtc tctcctgatg gattcaaaaa cttccccct 2220
 ggggtactgt cactcaaaact ggctgatcca atcaccatta ccaatgggga tgtatccct 2280
 aagggtgggag gtggtctcac tttgcaagat ggaagcctaa ctgtaaaccc taaggctcca 2340
 ctgcaagtta atactgataa aaaacttgag cttgcatatg ataatccatt tgaaagtag 2400
 gctaataaac ttagttttaa agtaggacat ggattaaaag tattagatga aaaaagtgct 2460

gcgggggttaa	aagattttaat	tggcaaaactt	gtgggttttaa	caggaaaagg	aataggcact	2520
gaaaatttag	aaaatacaga	tggttagcagc	agaggaattg	gtataaatgt	aagagcaaga	2580
gaagggttga	catttgacaa	tgatggatagc	ttggtagcat	ggaacccaaa	gtatgacagc	2640
cgcacacttt	ggacaacacc	agacacatct	ccaaactgca	caattgctca	agataaggagc	2700
tctaaactca	cttttggtact	tacaaagtgt	ggaagtcaaa	tattagctaa	tgtgtctttg	2760
atttgtgtcg	caggaaagta	ccacatcata	aataataaga	caaattccaaa	aataaaaaagt	2820
tttactatta	aactgctatt	taataagaac	ggagtgcctt	tagacaactc	aaatcttgga	2880
aaagcttatt	ggaacttttag	aagtggaaat	tccaatgttt	cgacagctta	tgaaaaagca	2940
attgggttta	tgctaattt	ggtagcgtat	ccaaaaccca	gtaattctaa	aaaatatgca	3000
agagacatag	tttatggaac	tatatatctt	ggtggaaaac	ctgatcagcc	agcagtcatt	3060
aaaactacct	ttaaccaaga	aactggatgt	gaatactcta	tcacatttaa	cttttagttgg	3120
tccaaaacct	atgaaaaatgt	tgaatttgaa	accacctctt	ttaccttctc	ctatatgtgc	3180
caagaatgaa	agagcggccg	ctcgagtcta	gagggcccg	ttaaaccgcg	tgatcagcct	3240
cgactgtgcc	ttctagttgc	cagccatctg	ttgtttgccc	ctcccccg	ccttccttga	3300
ccctggaagg	tgccactccc	actgtccttt	cctaataaaa	tgaggaaatt	gcacgcgatt	3360
gtctgagtag	gtgtcattct	attctggggg	gtgggggtggg	gcaggacagc	aagggggagg	3420
attgggaaga	caatagcagg	catgctgggg	atgcggtggg	ctctatgggt	tctgaggcgg	3480
aaagaaccag	ctggggctct	agggggatc	cccacgcgcc	ctgtagcggc	gcatttaagcg	3540
cggcggtgt	ggtggttacg	cgcagcgtga	ccgctacact	tgccagcggc	ctagcgcggc	3600
ctcctttcgc	tttcttccct	tcttttctcg	ccacgttcgc	cggttttccc	cgtcaagctc	3660
taaatcgggg	catcccttta	gggttcggat	ttagtgtctt	acggcacctc	gaccccaaaa	3720
aacttgatta	gggtgatggg	tcacgtagt	ggcctatcgc	ctgatagacg	gtttttcggc	3780
ctttgacgtt	ggagtcacg	ttctttaata	gtggactctt	gttccaaact	ggaacaacac	3840
tcaaccctat	ctcggctctat	tcttttgatt	tataagggat	tttggggatt	tcggcctatt	3900
ggttaaaaaa	tgagctgatt	taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	3960
tcagttaggg	tgtggaaaagt	cccagggtc	cccaggcagg	cagaagtatg	caaagcatgc	4020
atctcaatta	gtcagcaacc	aggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	4080
tgcaaacgat	gcattctcaat	tagtcagcaa	ccatagtcgc	gcccctaact	ccgcccattc	4140
cgccccctaac	tccgcccagt	tccgcccatt	ctccgcccc	tggttgacta	atttttttta	4200
tttatgcaga	ggccgaggcc	gcctctgcct	ctgagctatt	ccagaagtag	tgaggaggct	4260
tttttgagg	cctaggcttt	tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	4320
ctgatcagca	actgttgaca	attaatcatc	gcatatagat	atcggcatag	tataatacga	4380
caaggtgagg	aactaaacca	tggccaagtt	gaccagtgc	gttcgggtgc	tcaccgcgcg	4440
cgacgtcgcc	ggagcggctg	agttctggac	cgaccggctc	gggttctccc	gggacttcgt	4500
ggaggacgac	ttcgccgggtg	tggtcgggga	cgacgtgacc	ctgttcatca	gcgcgggtcca	4560
ggaccagggtg	gtgcccggaca	acaccctggc	ctgggtgtgg	gtgcccggcc	tgagcgggtc	4620
gtacgccgag	tggtcggagg	tcgtgtccac	gaacttcggg	gacgcctccg	ggccggccat	4680
gaccgagatc	ggcgagcagc	cgtggggggc	ggagttcgcc	ctgcccagac	cggccggcaa	4740
ctgcgtgcac	ttcgtggccg	aggagcagga	ctgacacgtg	ctacgagatt	tcgattccac	4800
cgcgccttcc	tatgaaaggt	tgggcttcgg	aatcgttttc	cgggacgcgg	gctggatgat	4860
cctccagcgc	ggggatctca	tgctggagtt	cttcgcccac	cccaacttgt	ttattgcagc	4920
ttataatggg	tacaaataaa	gcaatagcat	cacaaatttc	acaaataaag	cattttttttc	4980
actgcattct	agttgtggtt	tgtccaaact	catcaatgta	tcttatcatg	tctgtatacc	5040
gtcgacctct	agctagagct	tggcgtaatc	atgggtcatag	ctgtttctcg	tgtgaaattg	5100
ttatccgctc	acaattccac	acaacatacg	agccggaagc	ataaagtgtg	aagcctgggg	5160
tgccctaatga	gtgagctaac	tcacattaat	tgcggtgcgc	tcactgcccg	ctttccagtc	5220
gggaaacctg	tcgtgccagc	tgcattaatg	aatcggccaa	cgcgcgggga	gaggcgggtt	5280
gcgtattggg	cgctcttccg	cttcctcgct	caactgactc	ctgcgctcgg	tcgttcggct	5340
gcggcgagcg	gtatcagctc	actcaaaggc	ggtaatacgg	ttatccacag	aatcaggggga	5400
taacgcagga	aagaacatgt	gagcaaaagg	ccagcaaaag	gcccaggaacc	gtaaaaaaggc	5460
cgcgttgctg	cggtttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	5520
ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	5580
aagctocctc	gtgcgctctc	ctgttccgac	cctgcgcgtt	accggatacc	tgtccgcctt	5640
tctcccttcg	ggaagcgtgg	cgctttctca	atgctcacgc	tgtaggtatc	tcagttcggg	5700
gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaaccc	ccggttcagc	ccgaccgctg	5760
cgccttatcc	ggtaactatc	gtcttgagtc	caaccgggta	agacacgact	tatcgccact	5820
ggcagcagcc	actggtaaca	ggatttagcag	agcgagggtat	gtaggcgggtg	ctacagagtt	5880
cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	gtatttggtg	tctgcgctct	5940
gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	tgatccggca	aacaaaccac	6000
cgcgtggtagc	gggtggtttt	ttggttgcaa	gcagcagatt	acgcgcagaa	aaaaaggatc	6060
tcaagaagat	cctttgatct	ttctacggg	ctgtcagcgt	cagtggaacg	aaaactcacg	6120
ttaagggatt	ttggtcatga	gattatcaaa	aaggatcttc	acctagatcc	ttttaaatta	6180

```

aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 6240
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6300
ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc 6360
tgcaatgata ccgcgagacc cagctcacc ggctccagat ttatcagcaa taaaccagcc 6420
agccggaagg gccgagcgca gaagtgggcc tgcaacttta tccgcctcca tccagtctat 6480
taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 6540
tgccattgct acaggcatcg tgggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 6600
cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 6660
ctccttcggg cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 6720
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6780
tggtgagtag tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 6840
cccggcgcta atacgggata ataccgcgcc acatagcaga actttaaaaag tgctcatcat 6900
tggaatacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 6960
gatgtaacca actcgtgcac ccaactgac ttcagcatct tttactttca ccagcgtttc 7020
tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080
atgttgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 7140
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7200
cacatttccc cgaaaagtgc cacctgacgt c 7231

```

<210> 43
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 43
 tgtcttggat ccaagatgaa gcgcgcccgc cccagcgaag atgacttc 48

<210> 44
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 44
 aaacacggcg gccgctcttt cattcttg 28

<210> 45
 <211> 17
 <212> PRT
 <213> Ad 37 N-terminus

<400> 45
 Met Ser Lys Arg Leu Arg Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15

<210> 46
 <211> 6
 <212> PRT
 <213> artificial sequence

<400> 46
 Lys Arg Ala Arg Pro Ser
 1 5

<210> 47
 <211> 17

<212> PRT
 <213> Ad5 modified N-terminus

<400> 47
 Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15

<210> 48
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 48
 ggatccatgg gatacttggt agca 24

<210> 49
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 49
 gcaactcgag tcattcttgg gcaatatagg 30

<210> 50
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 50
 cgcgctgact cttaaggact agtttc 26

<210> 51
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 51
 gcgcttaatt aacatcatca ataatatacc ttattttt 37